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Singlet Oxygen Dosimetry For Pleural Photodynamic Therapy
Abstract
Photodynamic therapy (PDT) is a promising treatment modality that involves visible light and a
photosensitizer to form reactive cytotoxic species, such as singlet oxygen in the case of type II PDT.
Dosimetry of PDT has shown to be challenging due to the complex interactions between the key components
of PDT: light, photosensitizer, and oxygen. Existing methods of quantifying dose involve monitoring one or
two of these quantities. In conventional clinical settings, PDT is prescribed by the light fluence rate (mW/
cm^2) and total light fluence ( J/cm^2). However, many additional factors influence the effective ``dose'' that
is being delivered. Variations in photosensitizer uptake in tumors, tissue oxygenation, and light penetration in
tissues of varying tissue optical properties affect the photodynamic efficiency. Using explicit dosimetry,
reacted singlet oxygen is calculated based on the measured light fluence, photosensitizer concentration, and
oxygen concentration. A macroscopic singlet oxygen model is used for explicit dosimetry, which involves
various photochemical parameters.
Relevant photochemical parameters for in vivo explicit dosimetry for a type II photosensitizer
benzoporphyrin monoacid ring-A (BPD) were determined using a mouse model, and further validated using
a study evaluating long term treatment outcome. Phantom studies were also performed to model the
generation of singlet oxygen and compare it with direct measurements using singlet oxygen luminescence
dosimetry (SOLD). Fluorescence spectroscopy methods were used to measure the drug concentration.
Tissue optical properties were determined by measuring the light fluence and using the diffusion
approximation for a point source at a fixed distance. Oxygenation was measured by using a phosphorescence-
based probe to measure oxygen partial pressure. These in vivo and in-phantom models provide controlled
environments where extensive explicit measurements can be performed to validate the model and recognize
which aspects of explicit dosimetry are more critical to correctly correlate treatment outcome and the
calculated dosimetric quantity.
The light component of PDT dosimetry was investigated further in a clinical setting. Patients undergoing
surgery for malignant pleural mesothelioma are treated with intraoperative PDT. The current treatment
protocol for a clinical trial at the University of Pennsylvania involves monitoring light fluence at 8 discrete
locations within the pleural cavity. Quantifying and planning treatment can be greatly improved by
monitoring the light fluence throughout the entire treatment area in real-time.
This work aims to provide details for singlet oxygen explicit dosimetry (SOED) to quantify the reacted singlet
oxygen species during PDT in in vivo and in-phantom models. Furthermore, the light fluence modeling and
calculation aspect of PDT dosimetry was developed and improved for an ongoing pleural PDT study at the
University of Pennsylvania.
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ABSTRACT
SINGLET OXYGEN DOSIMETRY FOR PLEURAL PHOTODYNAMIC
THERAPY
Michele M. Kim
Dr. Timothy C. Zhu
Photodynamic therapy (PDT) is a promising treatment modality that involves
visible light and a photosensitizer to form reactive cytotoxic species, such as singlet
oxygen in the case of type II PDT. Dosimetry of PDT has shown to be challenging
due to the complex interactions between the key components of PDT: light, photo-
sensitizer, and oxygen. Existing methods of quantifying dose involve monitoring one
or two of these quantities. In conventional clinical settings, PDT is prescribed by
the light fluence rate (mW/cm2) and total light fluence (J/cm2). However, many
additional factors influence the effective “dose” that is being delivered. Variations
in photosensitizer uptake in tumors, tissue oxygenation, and light penetration in tis-
sues of varying tissue optical properties affect the photodynamic efficiency. Using
explicit dosimetry, reacted singlet oxygen is calculated based on the measured light
fluence, photosensitizer concentration, and oxygen concentration. A macroscopic sin-
glet oxygen model is used for explicit dosimetry, which involves various photochemical
parameters.
Relevant photochemical parameters for in vivo explicit dosimetry for a type II pho-
tosensitizer benzoporphyrin monoacid ring-A (BPD) were determined using a mouse
model, and further validated using a study evaluating long term treatment outcome.
Phantom studies were also performed to model the generation of singlet oxygen and
compare it with direct measurements using singlet oxygen luminescence dosimetry
(SOLD). Fluorescence spectroscopy methods were used to measure the drug concen-
tration. Tissue optical properties were determined by measuring the light fluence and
v
using the diffusion approximation for a point source at a fixed distance. Oxygenation
was measured by using a phosphorescence-based probe to measure oxygen partial
pressure. These in vivo and in-phantom models provide controlled environments
where extensive explicit measurements can be performed to validate the model and
recognize which aspects of explicit dosimetry are more critical to correctly correlate
treatment outcome and the calculated dosimetric quantity.
The light component of PDT dosimetry was investigated further in a clinical set-
ting. Patients undergoing surgery for malignant pleural mesothelioma are treated
with intraoperative PDT. The current treatment protocol for a clinical trial at the
University of Pennsylvania involves monitoring light fluence at 8 discrete locations
within the pleural cavity. Quantifying and planning treatment can be greatly im-
proved by monitoring the light fluence throughout the entire treatment area in real-
time.
This work aims to provide details for singlet oxygen explicit dosimetry (SOED)
to quantify the reacted singlet oxygen species during PDT in in vivo and in-phantom
models. Furthermore, the light fluence modeling and calculation aspect of PDT
dosimetry was developed and improved for an ongoing pleural PDT study at the
University of Pennsylvania.
vi
Table of Contents
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . iii
Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
Table of Contents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
List of Tables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
List of Figures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiv
1 Introduction 1
1.1 PDT Dosimetry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Malignant Pleural Mesothelioma (MPM) and PDT . . . . . . . . . . 4
1.3 Three-dimensional Light Dosimetry . . . . . . . . . . . . . . . . . . . 5
1.4 Project Aims and Outline of Thesis . . . . . . . . . . . . . . . . . . . 6
2 General Theory of Reactive Oxygen Species (ROS) Explicit Dosime-
try 8
2.1 Type I and II oxidation reactions . . . . . . . . . . . . . . . . . . . . 9
2.1.1 Photochemical reactions . . . . . . . . . . . . . . . . . . . . . 9
2.1.2 Kinetics of type I reactions . . . . . . . . . . . . . . . . . . . . 14
2.1.3 Kinetics of type II reactions . . . . . . . . . . . . . . . . . . . 15
2.1.4 Explicit model of type I and II photodynamic interactions . . 16
2.1.5 Relationship between rate parameters and the photochemical
parameters . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
vii
2.2 Experimental methods to determine the rate parameters . . . . . . . 25
2.2.1 Direct methods . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.2.2 Fluorescence spectroscopy . . . . . . . . . . . . . . . . . . . . 27
2.2.3 Phosphorescence spectroscopy . . . . . . . . . . . . . . . . . . 30
2.2.4 Indirect methods . . . . . . . . . . . . . . . . . . . . . . . . . 32
2.2.5 Other methods . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.3 A review of existing values of photochemical parameters . . . . . . . 35
2.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3 Explicit Dosimetry Techniques 43
3.1 Light Transport and Optical Properties . . . . . . . . . . . . . . . . . 43
3.1.1 Measurement of light fluence . . . . . . . . . . . . . . . . . . . 43
3.1.2 Diffusion theory for spherical geometry . . . . . . . . . . . . . 44
3.1.3 Measurement of tissue optical properties . . . . . . . . . . . . 46
3.2 Tumor Model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.3 Measurement of Photosensitizer Concentration . . . . . . . . . . . . . 49
3.3.1 Interstitial photosensitizer measurements . . . . . . . . . . . . 51
3.3.2 Surface photosensitizer measurements . . . . . . . . . . . . . . 55
3.3.3 Verification of in vivo BPD concentration . . . . . . . . . . . 58
3.4 Treatment Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.5 Macroscopic Singlet Oxygen Model in vivo . . . . . . . . . . . . . . . 60
4 Determination of In-Phantom Photochemical Parameters 62
4.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.1.1 SOED model in phantoms . . . . . . . . . . . . . . . . . . . . 63
4.1.2 SOLD instrumentation . . . . . . . . . . . . . . . . . . . . . . 70
4.1.3 Measurements in tissue-simulating phantoms . . . . . . . . . . 72
viii
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.2.1 SOED photophysical parameters . . . . . . . . . . . . . . . . 73
4.2.2 SOED in phantom . . . . . . . . . . . . . . . . . . . . . . . . 75
4.2.3 SOED/SOLD comparison in solution . . . . . . . . . . . . . . 80
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.3.1 SOED and SOLD intercomparison . . . . . . . . . . . . . . . 81
4.3.2 Feasibility of using SOLD at 523 nm for predicting [1O2]rx at
630 nm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
4.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
5 Determination of in vivo Photochemical Parameters 91
5.1 Theory and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
5.1.1 Macroscopic model for in vivo studies . . . . . . . . . . . . . . 91
5.1.2 Treatment delivery . . . . . . . . . . . . . . . . . . . . . . . . 92
5.1.3 RIF tumor necrosis measurement and analysis . . . . . . . . . 93
5.1.4 Macroscopic singlet oxygen model to fit necrosis . . . . . . . . 94
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
5.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
6 In vivo Outcome Study 109
6.1 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . 110
6.1.1 Photodynamic therapy treatment . . . . . . . . . . . . . . . . 110
6.1.2 Tissue oxygen concentration and photosensitizer concentration
measurements . . . . . . . . . . . . . . . . . . . . . . . . . . . 112
6.1.3 Tumor regrowth rate analysis . . . . . . . . . . . . . . . . . . 114
6.1.4 Monte Carlo simulation of φ distribution in tumors . . . . . . 115
ix
6.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
6.2.1 Parameter verification . . . . . . . . . . . . . . . . . . . . . . 116
6.2.2 Explicit dosimetry and treatment outcome evaluation . . . . . 117
6.2.3 Long term local tumor control . . . . . . . . . . . . . . . . . . 121
6.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
6.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
7 IR Navigation System 130
7.1 Pleural Photodynamic Therapy . . . . . . . . . . . . . . . . . . . . . 131
7.2 Optical Infrared (IR) Navigation System . . . . . . . . . . . . . . . . 132
7.2.1 Modified treatment delivery wand . . . . . . . . . . . . . . . . 133
7.2.2 Pleural cavity geometry reconstruction . . . . . . . . . . . . . 136
7.2.3 Light fluence calculations . . . . . . . . . . . . . . . . . . . . . 138
7.2.4 Anisotropy modeling . . . . . . . . . . . . . . . . . . . . . . . 139
7.2.5 Light fluence dosimetry in lung shaped cavities . . . . . . . . 144
7.3 Extrapolation of Detector Locations . . . . . . . . . . . . . . . . . . . 146
7.4 Clinical Photofrin Pleural PDT Results . . . . . . . . . . . . . . . . . 156
7.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
8 Conclusions and Future Work 169
A Chlorophyll Products 172
B P3 Approximation in an Infinite Medium 177
B.1 Light Transport and Optical Properties . . . . . . . . . . . . . . . . . 177
B.1.1 Diffusion Approximation for Light Transport . . . . . . . . . . 177
C List of Publications 186
x
C.1 Peer Reviewed Publications . . . . . . . . . . . . . . . . . . . . . . . 186
C.2 Invited Book Chapter . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
C.3 Conference Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . 187
References 190
xi
List of Tables
2.1 Definition of photochemical reaction rate constants . . . . . . . . . . 13
2.2 Reduced photochemical parameters for PDT modeling . . . . . . . . 22
2.3 Selected photosensitizers and their in vivo photophysical parameters . 39
2.4 Selected photosensitizers and their in-phantom photophysical parameters 41
4.1 Measured lifetimes for Photofrin and Rose Bengal . . . . . . . . . . . 73
5.1 BPD-mediated necrosis study treatment conditions . . . . . . . . . . 94
5.2 Photochemical parameters obtained for BPD . . . . . . . . . . . . . . 99
5.3 BPD-mediated Necrosis Study Calculated Dosimetric Metrics . . . . 102
6.1 Refined photochemical parameters . . . . . . . . . . . . . . . . . . . . 116
6.2 PDT parameters for four mice with individual fitting . . . . . . . . . 117
6.3 BPD outcome study treatment conditions . . . . . . . . . . . . . . . 120
6.4 Summary of treated mice for long term tumor control . . . . . . . . . 122
7.1 Light source point shift from calibration point . . . . . . . . . . . . . 134
7.2 φscattered/s in phantoms with µ
′
s = 6.7 cm
−1 . . . . . . . . . . . . . . 145
7.3 Calculated φscattered/s with µ
′
s = 6.7 cm
−1 (% error between calculated
and measured mean) . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
7.4 Measured and extrapolated detector position comparison . . . . . . . 151
xii
7.5 Calculated and measured fluence comparison in patients using extrap-
olated detector positions . . . . . . . . . . . . . . . . . . . . . . . . . 153
7.6 Measured and extrapolated detector position comparison averaged over
patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
7.7 Calculated and measured fluence with shifted extrapolated detector
positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155
7.8 Calculated and measured fluence comparison in patients . . . . . . . 159
7.9 Pleural cavity area, absorption, diffuse reflectance, and scattering . . 164
7.10 Summary of uniformity of treatment in the pleural cavity . . . . . . . 167
xiii
List of Figures
1.1 Schematic diagram of the light-sensitizer-tissue interactions . . . . . . 2
1.2 PDT of the Pleural Cavity . . . . . . . . . . . . . . . . . . . . . . . . 6
2.1 Photodynamic process Jablonski diagram . . . . . . . . . . . . . . . . 9
2.2 Secondary (photochemical) reactions for type I photosensitizers . . . 14
2.3 Fluorescence and absorption spectra of BPD . . . . . . . . . . . . . . 28
2.4 Fluorescence and absorption spectra of Photofrin . . . . . . . . . . . 29
3.1 Dosimetry system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.2 Treatment set-up of interstitial PDT . . . . . . . . . . . . . . . . . . 48
3.3 SVD component analysis . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.4 Optical property correction factor for interstitial measurements . . . . 54
3.5 Optical property correction factor for semi-infinite geometry . . . . . 57
3.6 BPD fluorescence excited by treatment light . . . . . . . . . . . . . . 58
4.1 Singlet oxygen luminescence photon counts for Rose Bengal phantoms 65
4.2 Photofrin in-phantom data modeled with hypoxic interactions . . . . 66
4.3 Rose Bengal in-phantom data modeled with hypoxic interactions . . . 67
4.4 SOLD Instrumentation . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.5 Singlet oxygen quenching due to NaN3 . . . . . . . . . . . . . . . . . 74
4.6 SOED for Photofrin Phantoms . . . . . . . . . . . . . . . . . . . . . . 77
4.7 SOED for Rose Bengal Phantoms . . . . . . . . . . . . . . . . . . . . 78
xiv
4.8 Oxygen changes due to NaN3 . . . . . . . . . . . . . . . . . . . . . . 79
4.9 SOED/SOLD comparison in solution . . . . . . . . . . . . . . . . . . 80
4.10 SOED/SOLD comparison in solution . . . . . . . . . . . . . . . . . . 81
4.11 MC simulation of fluence rate distribution by a circular beam . . . . 83
4.12 Tissue µa and µ
′
s in patients . . . . . . . . . . . . . . . . . . . . . . . 85
4.13 Ratio of φ and φair . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4.14 Calculated [1O2]rx at 630 nm and 523 nm for different fluences . . . . 88
5.1 Fluence rate distribution in a tumor with a linear source model . . . 96
5.2 Calculated [1O2]rx profile for RIF tumors treated with CDF . . . . . 100
5.3 PDT-induced necrosis radius versus different dosimetric quantities . . 101
6.1 Collimated beam treatment of mice . . . . . . . . . . . . . . . . . . . 111
6.2 Real-time in vivo measurements of BPD concentration and [3O3] . . . 113
6.3 Tumor volumes over days after collimated beam PDT treatment . . . 114
6.4 Photosensitizer and [1O2]rx profiles . . . . . . . . . . . . . . . . . . . 119
6.5 CI plotted against various dose metrics . . . . . . . . . . . . . . . . . 121
6.6 Survival curves for long term local tumor control rate . . . . . . . . . 123
6.7 Temporal dependence of [3O2](t) calculated for various φair . . . . . . 126
7.1 Treatment delivery wand and the surgical setting . . . . . . . . . . . 134
7.2 Light source positioning tool . . . . . . . . . . . . . . . . . . . . . . . 136
7.3 Reconstructed Pleural Cavity . . . . . . . . . . . . . . . . . . . . . . 137
7.4 Treatment wand anisotropy schematic . . . . . . . . . . . . . . . . . . 140
7.5 Treatment wand anisotropy measurement and fit . . . . . . . . . . . . 141
7.6 Fluence calculation comparison using anisotropy modeling . . . . . . 143
7.7 Scattering experiment setup . . . . . . . . . . . . . . . . . . . . . . . 145
xv
7.8 Regions with features in measured cumulative fluence during light de-
livery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
7.9 Measured and extrapolated detector locations plotted . . . . . . . . . 150
7.10 Measured and calculated fluence data with no scattering . . . . . . . 158
7.11 Measured and calculated fluence data with constant scattering . . . . 162
7.12 Measured and calculated fluence data with constant scattering and
dual correction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
7.13 Fluence distribution map for a representative patient . . . . . . . . . 165
7.14 Fluence distribution profiles for patient cases . . . . . . . . . . . . . . 166
A.1 Fluorescence spectra of mouse on standard diet . . . . . . . . . . . . 173
A.2 Small multi-fiber contact probe . . . . . . . . . . . . . . . . . . . . . 174
A.3 Chlorophyll signal normalized by autofluorescence observed over 9 days 175
Chapter 0 Michele M. Kim xvi
Chapter 1
Introduction
Photodynamic therapy (PDT) is a treatment modality that uses a photosensitizing
drug, light, and oxygen to cause local cell damage [1]. The FDA has approved PDT for
use with esophageal cancers [2], non-small cell lung cancer [3,4], actinic keratosis [5],
and age-related macular degeneration [6, 7]. There are also numerous off-label uses
and pre-clinical, as well as clinical trials using PDT to treat other cancers including
skin cancers [8], bladder cancers [9], prostate cancers [10], head and neck cancers [11],
and malignant mesothelioma [12,13]. Unlike chemotherapy, PDT is a highly localized
treatment method that can spare healthy cells. Furthermore, conventional radiation
therapy uses ionizing radiation that causes DNA damage. PDT uses non-ionizing
light and since most PDT photosensitizers do not accumulate in cell nuclei, PDT has
a low potential of causing DNA damage, mutations, and carcinogenesis [3, 14].
1
Figure 1.1: Schematic diagram of the light-
sensitizer-tissue interactions
Figure 1.1 shows a schematic of the PDT process. The photosensitizer is admin-
istered either intravenously, orally, or topically. After the proper drug-light interval
(DLI), which depends on the sensitizer, light is delivered to the treatment area. De-
spite the clear advantages of PDT, much work needs to be done in optimizing treat-
ment doses, PDT delivery methods, and PDT dosimetry. While PDT is the standard
care of treatment for certain skin lesions and esophageal cancers in certain areas of the
world, improvements in PDT dosimetry are necessary before it is used as a standard
in conjunction with existing treatment modalities.
1.1 PDT Dosimetry
Four different dosimetric methodologies can be used for PDT dosimetry: implicit
dosimetry, biophysical/biological tissue response monitoring, explicit dosimetry, and
direct dosimetry [15]. Two or more of the treatment parameters can be incorpo-
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rated into a single metric. Such a metric is PDT dose, the product of light fluence
(J/cm2) and the sensitizer concentration. Other metrics include implicit dosimetry
with photosensitizer photobleaching through monitoring the photosensitizer fluores-
cence. Photobleaching during PDT is the irreversible destruction of ground state
sensitizer. This has the advantage of being relatively simple and practical to imple-
ment. Fluorescence spectroscopic measurements of photoproducts associated with
photobleaching have also been used as a metric; however, this is not applicable to all
photosensitizers. Biophysical and biological tissue response monitoring can also be
used as a dosimetric method. This includes monitoring vascular shut down, treatment
induced necrosis, and blood flow monitoring by laser Doppler or diffuse correlation
spectroscopy. It is not yet clear whether any of these specific techniques could be
used to predict the biological response and hence, outcome.
In conventional clinical settings, PDT is prescribed by the light fluence (mW/cm2)
rate and total light fluence (or “light dose,” J/cm2). However, there are many ad-
ditional factors which may influence the effective “dose” actually delivered to any
particular lesion [16]. Variation in photosensitizer uptake in tumors is present both
in humans and in mice [17]. Different tissues show a large range of wavelength de-
pendent optical absorption and scattering coefficients of different tissues, which will
affect the light penetration and distribution of light in the target volume [18, 19].
Variability in tissue oxygenation will affect the photodynamic efficiency [20]. Photo-
sensitizers with higher extinction coefficients can significantly increase the absorption
to affect the light penetration and cause “self shielding” [21]. Furthermore, faster tis-
sue oxygen depletion with high fluence rate treatment leads to reduced photodynamic
effect [22–25].
Explicit dosimetry involves the measurement of the main components involved in
the photodynamic reaction (light, drug, and oxygen) and incorporation of these mea-
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surements into a dose model. Sections 3 and 4 will discuss explicit and direct methods
(singlet oxygen luminescence dosimetry) in detail, as well as a plan to implement both
dosimetry methods concurrently in vivo.
Development of photosensitzers that are appropriate for PDT is ongoing, with
optical absorption designed to be in the “therapeutic window” (650-850 nm) where
the absorption spectrum of hemoglobin permits deeper penetration. Furthermore,
treatment light in this region penetrates deeper into the tissue since optical absorption
is lower than in other parts of the spectrum [1]. For this work, the photosensitizers
considered were benzoporphyrin derivative monoacid ring A (BPD), porfimer sodium
(Photofrin), and 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH). These
have already been used in a clinical setting. Another photosensitizer, Rose Bengal
(4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein) was also investigated in phantoms
(liquid solution models to simulate in vivo settings) for certain studies.
1.2 Malignant Pleural Mesothelioma (MPM) and
PDT
At the University of Pennsylvania, PDT is used as an adjuvant surgically-based treat-
ment modality for patients with malignant pleural mesothelioma. The source of ma-
lignant mesothelioma is in the cells lining the pleura and peritoneal cavities, and
while naturally occurring mesothelioma is rare, risk is increased with exposure to
asbestos [12]. The incidence of mesothelioma in the United States is estimated to be
2500-3000 cases per year, and the most commonly affected patients have a median
age of onset of 60 years. Regardless of treatment, median survival is reported to be
6-15 months [12]. Part of the difficulty in treatment of mesothelioma comes from
eradicating all of the cancerous cells from the pleural cavity during surgical resec-
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tion. In surgical debulking of the cancerous tissue, cells are left behind in the cavity
leading to further disease propagation [26]. Several treatment modalities are being
investigated that combine surgery with follow-up treatments to kill these remaining
cells including chemotherapy, radiation therapy, and PDT [12].
PDT is a promising treatment modality for patients with mesothelioma as it
presents only minor toxicities to affect the original treatment course [26]. For this
treatment, the patient is administered with the photosensitizer systematically at the
appropriate time before surgery and light application. During surgery, the pleural
cavity is opened, and light can be delivered using a modified endotracheal (ET) tube
that contains the fiber optic light source and is filled with scattering media. Currently
at the Hospital of the University of Pennsylvania, the pleural PDT treatment protocol
monitors light fluence (measured in J/cm2) with eight isotropic detectors sutured at
different locations in the pleural cavity of a patient, without consideration of the
unique qualities of the patient’s thoracic cavity. This protocol monitors light at
discrete locations, but does not provide information of fluence for the cavity as a
whole. It has been shown that the light fluence on the entire pleural surface can be
determined for assessing the light fluence uniformity using an infrared (IR) navigation
system to track the treatment light [27]. The clinical protocol is approved by the IRB
of the University of Pennsylvania.
1.3 Three-dimensional Light Dosimetry
A commercial IR navigation system (Polaris Spectra, NDI, Waterloo, Canada) was
introduced to monitor the light source during treatment and to provide real-time
treatment guidance. The camera has a pair of stereo cameras that measures the
light reflection from a modulated laser source (λ = 850 nm). This device tracks 9
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reflectors that are in a fixed geometry and attached to the light delivery ET tube.
The 9 reflectors make up 3 faces with 3 reflectors each and are used to determine the
3D Cartesian coordinates and orientation of the light source with 2 mm accuracy.
Figure 1.2: PDT of the pleural cavity. (a) The physician delivers
the light via a modified endotracheal tube filled with scattering me-
dia. The light source is being tracked by an IR camera mounted
above the patient (upper right corner). (b) The treatment area is
an irregularly-shaped cavity.
1.4 Project Aims and Outline of Thesis
This work aims to provide in vivo singlet oxygen-based dosimetry for patients un-
dergoing PDT in the pleural cavity. This involves monitoring the delivered light in
real-time during treatment, quantifying the sensitizer concentration throughout the
cavity, and determining the reacted singlet oxygen.
Chapter 2 describes the theory behind explicit dosimetry and its requirements.
A review of existing photochemical parameters necessary for explicit dosimetry was
done to investigate which parameters are already present and studied for in in vitro
models, such as cell spheroid models, and which need further study. Chapter 3 ad-
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dresses the experimental techniques, instrumentation, and algorithms used to perform
in vivo studies in mouse models and phantom studies. Using these methods, chapter
4 investigates the explicit dosimetry model in liquid phantoms. In addition, explicit
dosimetry is compared with singlet oxygen luminescence dosimetry (SOLD) meth-
ods. Chapter 5 discusses the parameters determined in in vivo environments for the
photosensitizer BPD using a mouse model. Chapter 6 expands on verification of
the model as well as the parameters by looking at tumor re-growth rates of treated
mice. Chapter 7 discusses a translational application, looking deeper into the light
dosimetry aspect of clinical PDT dosimetry. Data collected from the Photofrin phase
II/III randomized clinical trial is presented in chapter 7. By providing a way to deter-
mine the dose being delivered to areas lacking isotropic detectors to directly measure
the light fluence, the physician can adjust the treatment to ensure that treatment
is uniform. Finally, chapter 8 concludes this work by summarizing the findings and
discussing future applications and expansions of the work presented.
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Chapter 2
General Theory of Reactive
Oxygen Species (ROS) Explicit
Dosimetry
Photosensitizer photochemical parameters are crucial data in accurate dosimetry for
PDT based on photochemical modeling. Progress has been made in the last few
decades in determining the photochemical properties of commonly used photosensi-
tizers, mostly in solution or in vitro. Recent developments allow for the estimation
of some of these photochemical parameters in vivo. Furthermore, photochemical pa-
rameters that are independent of environmental factors or are universal for different
photosensitizers are examined. Most photosensitizers discussed in this chapter are of
the type II (singlet oxygen) photooxidation category, although type I photosensitiz-
ers that involve other reactive oxygen species (ROS) will be discussed as well. The
compilation of these parameters will be essential for ROS modeling of PDT.
8
2.1 Type I and II oxidation reactions
2.1.1 Photochemical reactions
The PDT kinetics process was described using rate equations in the literature for
microscopic and macroscopic models [22, 28–30]. Figure 2.1 shows the energy dia-
gram for the process. The PDT process is started by the absorption of light by the
photosensitizer in the ground state, S0. It is excited into the singlet state, S1. The
S1 state can spontaneously decay to the ground state with the emission of a photon
or heat [30].
Figure 2.1: Jablonski diagram for the photoactivation of photosensitizer in the
presence of oxygen and biomolecules. The photosensitizer in its ground state
(S0) absorps a photon and is excited to its first singlet state (S1). It converts
to its excited triplet state (T1) via intersystem crossing (ISC). From T1, energy
is transferred to ground state molecular oxygen (3O2), creating reactive singlet
oxygen (1O2) for a typical type II reaction. In type I reactions, the triplet photo-
sensitizer will transfer an electron to 3O2 which will react with molecular targets
to produce radical species, or alternatively, interact directly with the acceptor
[A], without oxygen mediation.
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[S0]
k0
k3
[S1] (2.1)
This is a reversible process. The monomolecular absorption rate, k0 (s
−1), is pro-
portional to the light fluence, φ, and the extinction coefficient, ε. The monomolecular
decay rate, k3(s
−1) is the rate from S1 to S0. The decay rate due to fluorescence (ra-
diative) is k3R (s
−1) and the internal conversion (non-radiative) decay rate is k3NR
(s−1), so that k3 = k3NR + k3R [31]. The photosensitizer in its ground state can
interact with singlet oxygen and ROS to form a photoproduct [SO2]. This can be
described by the decay rate constant, k1 = k11 + k12 (µM
−1s−1).
[S0] + [
1O2]
k12
[SO2] (type II) (2.2a)
[S0] + [O
·–
2 ]
k11
[SO2] (type I) (2.2b)
Similarly, the bimolecular decay rate, k2 (µM
−1s−1), describes the rate of inter-
actions by collisions between the triplet state photosensitizer [T1] and ground state
oxygen [3O2]. A fraction (S∆) of the interactions yields singlet oxygen (2.3), while
another fraction (SI) yields the superoxide anion (O –·2 ) as in (2.4).
[T1] + [
3O2]
S∆k2
[S0] + [
1O2] (type II) (2.3)
[T1] + [
3O2]
SIk2
[S +·0 ] + [O
–·
2 ] (type I) (2.4)
[T1] + [
3O2]
SNLk2
[S0] + [
3O2] (2.5)
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The last equation shows the fraction (SNL = 1−S∆SI) of the interactions between
the triplet state photosensitizer and ground state oxygen to produce non-luminescent
decay of [T1] and do not yield singlet oxygen and/or superoxide anion. Physical
quenching can also occur where singlet oxygen is converted back to triplet oxygen
(1O2
3O2).
Triplet decay rate and intersystem crossing of the photosensitizer are described
by the monomolecular reaction rates k4 and k5 (s
−1), respectively. The triplet decay
rate includes both the radiative (k4R) and non-radiative (k4NR) decay rate constants.
[T1]
k4
[S0] (2.6)
[S1]
k5
[T1] (2.7)
The phosphorescence (or luminescence) of singlet oxygen is described by the
monomolecular decay rate k6 (s
−1).
[1O2]
k6
[3O2] (2.8)
This reaction produces the signature luminescence at 1270 nm. However, there are
also non-luminescent reactions of 1O2, such as solvent quenching or physical quenching
of 1O2, mentioned above [32].
The oxidation of biomolecular acceptors, [A], is described by the decay rate k7 =
k71 + k72 (µM
−1s−1).
[1O2] + [A]
k72
[AO2] (type II) (2.9a)
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and
[O –·2 ] + [A]
k71
[AO2] (type I) (2.9b)
Triplet state photosensitizer can also react with the biological substrate [A] with
the bimolecular rate constant, k8 (µM
−1s−1). For typical type II reactions, however,
this term is considered to be small since singlet oxygen is much more reactive than
triplet state photosensitizer.
[T1] + [A]
k8
[T1A] (2.10)
In in vivo settings, the concentration of biomolecular acceptors is very large,
resulting in a dominant k7[A] term. However, there can be singlet oxygen quenchers
([Q]) that convert 1O2 back to ground state
3O2. This can be described by the
bimolecular reaction rate constant k9 (µM
−1s−1).
[1O2] + [Q]
k9
[3O2] + [Q] (2.11)
Table 2.1 summarizes the definition of all rate constants used here along with their
conventional names.
Chapter 2 Michele M. Kim 12
Table 2.1: Definition of photochemical reaction rate con-
stants
Symbol∗ Definition
k0, ka (s
−1)
Photon absorption rate of photosensitizer as a
function of photosensitizer concentration (in µM),
k0 = εφ/hν, for φ =100 mW/cm
2.
k1, kos (µM
−1s−1)
Bimolecular decay rate for 1O2 (k12) and ROS (k11)
reactions with ground-state photosensitizer
k2, kot (µM
−1s−1)
Bimolecular rate of triplet photosensitizer quench-
ing by 3O2
SIk2 Reactions involving triplet state and
electron transfer to 3O2 (type I)
S∆k2 Reactions involving triplet state and en-
ergy transfer to 3O2 (type II)
k3, kf (s
−1)
Fluorescence decay rate of first excited singlet
state photosensitizer to ground state photosensi-
tizer including internal conversion (non-radiative,
k3NR) and fluorescent (radiative, k3R) terms
k4, kp (s
−1)
Phosphorescence decay of the photosensitizer
triplet state to ground state photosensitizer, in-
cluding radiative (k4R) and non-radiative (k4NR)
components
k5, kisc (s
−1)
Intersystem crossing (ISC) decay rate from first
excited photosensitizer to triplet state photosensi-
tizer
k6, kd (s
−1) Phosphorescence (or luminescence) decay rate of
1O2 to
3O2
k7, koa (µM
−1s−1)
Bimolecular decay rate of reaction of type II 1O2
(k72) and type I ROS (k71) with biological sub-
strate [A]
k8, kta (µM
−1s−1)
Bimolecular decay rate constant for reaction of
triplet photosensitizer with substrate [A]
k9, koq (µM
−1s−1)
Bimolecular decay rate constant for the quenching
reaction of 1O2 by a quencher [Q]
∗ The first symbol is used in this thesis. The second symbol is also
commonly found in the literature
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2.1.2 Kinetics of type I reactions
Type I photooxidation reactions are described by the bimolecular reaction rate SIk2
(µM−1s−1) with the fraction of triplet interactions that lead to type I reactions, de-
scribed in Eq. (2.4). In a type I reaction, the photosensitizer can undergo electron
transfer with oxygen to generate a superoxide anion (O –·2 ). Superoxide anion, its
protonated form HO ·2, and other radicals such as hydroxyl radicals (HO
·) cause cell
damage to different degrees. Notice that even though all ROSs are generated by the
superoxide anion (O –·2 ) for type I photosensitizer, there are many additional path-
ways to generate ROS that are not all included in Fig. 2.2, details of which can be
found elsewhere [33]. For simplicity, we have combined these interactions as a direct
interaction with superoxide anion (2.9b). Other reactions involve the reaction of the
triplet state [T1] with the molecular substrate directly, described by the reaction rate
k8 (µM
−1s−1) and Eq. (2.10).
Figure 2.2: Secondary (photochemical) reactions for type I photosensitizers to
generate the resulting reactive oxygen species (HO·, H2O2, O
–·
2 ). Other redox
active metals are also pertinent for generation of ROS and should be included as
part of secondary reactions in “. . . ” . ROS will in turn oxidate acceptors in cells
to cause cellular damage [33,34].
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2.1.3 Kinetics of type II reactions
Diatomic Oxgen Energy States
The electronic behavior of molecular oxygen results from the arrangement of two
electrons in the outer pig shell (it has a total of 16 electrons since Z = 8 for each O
atom) [35, 36]. Molecular oxygen has an electron configuration in which orbitals are
designated as even parity (g = gerade) or odd parity (u = ungerade) [34]:
(1σg)
2(2σu)
2(2σg)
2(2σu)
2(3σg)
2(1piu)
4(1pig)
2
where the pig orbital (formally an open shell) has three possible electron spin arrange-
ments giving rise to three energetically different species: Ground state molecular
oxygen (3Σ−g ), and two singlet states(
1Σ+g and
1∆g). Because
1∆g oxygen lifetimes
are in the microsecond range, they can undergo bimolecular reactions whereas the
1Σ+g oxygen lifetime is short (due to its fast interconversion to
1∆g oxygen) and is
therefore chemically unreactive [37].
Photosensitization routes to 1∆g and
1Σ+g are of interest; however, the longer
lifetime of the former relates to its reactivity. Chemical reactivity has been generated
for 1∆g oxygen with biomolecules. Consequently, the bimolecular reaction rates have
been investigated for the disappearance of and oxidation by 1∆g oxygen (labeled as
1O2 in this thesis).
The reactions of singlet oxygen with substrates can be defined by the rate con-
stants (k72, k6). k72 (also commonly referred to as koa in the literature) is the the
chemical reaction rate constant of 1O2 which accounts for the rate of formation of
oxygenated products and gives the rate of disappearance of 1O2 induced by the sub-
strate, [A]. This is related to how readily the product is consumed and can depend
on the reaction environment. k6 (also commonly referred to as kd in the literature) is
the rate constant for the natural decay of 1O2 back to
3O2 (also called solvent quench-
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ing). For example, amines efficiently deactivate 1O2 back to
3O2 by charge-transfer
quenching, and carotenoids efficiently deactivate 1O2 back to
3O2 by energy-transfer
quenching [38–41].
2.1.4 Explicit model of type I and II photodynamic interac-
tions
For both type I and II primary photochemical reactions, a set of coupled differential
equations can be used to describe the PDT process [30, 34,42–46]
d[S0]
dt
= −k0[S0]− k12[1O2]([S0] + δ)− k11[O –·2 ]([S0] + δ) + k2[T1][3O2] + k3[S1] + k4[T1]
(2.12)
d[S1]
dt
= −(k3 + k5)[S1] + k0[S0] (2.13)
d[T1]
dt
= −k2[T1][3O2]− k4[T1] + k5[S1]− k8[T1][A] (2.14)
d[3O2]
dt
= −S∆k2[T1][3O2]− SIk2[T1][3O2] + k6[1O2] + k9[Q][1O2] + Γ (2.15)
d[1O2]
dt
= −k12[1O2]([S0]+δ)+S∆k2[T1][3O2]−k6[1O2]−k72[A][1O2]−k9[Q][1O2] (2.16)
d[O –·2 ]
dt
= −k11[O –·2 ]([S0] + δ) + SIk2[T1][3O2]− k71[A][O –·2 ] (2.17)
d[A]
dt
= −k72[A][1O2]− k71[A][O –·2 ]− k8[T1][A] (2.18)
These equations are based on the kinetic equations of the photochemical reac-
tions using their rate constants, k0, ..., k9 (see their definitions in table 2.1). Here,
[S0], [S1], and [T1] are the ground, first excited singlet, and triplet photosensitizer
concentrations respectively. [3O2] and [
1O2] are the ground triplet and excited state
oxygen concentrations. [O−·2 ] is the concentration of superoxide anion and represents
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the amounts of ROS in a type I mechanism. Γ and [A] are the oxygen supply rate and
the concentration of (1O2 and ROS) acceptors excluding the photosensitizer molecule.
[Q] is the concentration of 1O2 quenchers present that will quench
1O2 and convert
it back to 3O2. Depending on the methods used to determine the oxygen supply
rate in (2.15), the model is divided into microscopic and macroscopic models. In the
microscopic model, oxygen diffusion into capillaries, from capillaries into tissue, and
diffusion within tissue are used to calculate the Γ term [43]. More details can be
found in Ref. [47]. Based on the kinetic equations of the photochemical reactions, the
oxygen supply term in a macroscopic theory can be expressed as [28,30,44]:
Γ = g
(
1− [
3O2]
[3O2]0
)
, (2.19)
where g is the macroscopic maximum oxygen supply rate and [3O2]0 is the initial
tissue oxygen concentration. This term ensures that the oxygen level does not exceed
the initial value. In the macroscopic model, the Γ term is assumed to be uniformly
distributed everywhere without consideration of oxygen diffusion through the vascu-
lature. The functional form of Eq. (2.19) was validated using forward calculations
with standard vascular parameters [48]. Since the spatial scale of light transport is
much larger than the spatial scale of oxygen diffusion (∼1 mm versus ∼65 µm), the
light fluence rate was also set to be a constant within the vasculature model [48,49].
Due to the short lifetime and diffusion distance of 1O2 in biological media, the
term for photobleaching kinetics for ground state photosensitizer undergoing 1O2-
mediated bleaching has the low concentration correction constant, δ [50, 51]. 1O2
is generated at the site of the parent photosensitizer molecule. Due to the short
diffusion distance (10-100 nm [51, 52]), it has a higher probability of reacting with
the parent photosensitizer molecule than with adjacent photosensitizer molecules.
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For low photosensitizer concentrations, the rate of photobleaching depends only on
the rate of 1O2 generation because the volume through which each
1O2 can diffuse
before reacting will contain exactly one photosensitizer molecule, independent of the
total photosensitizer concentration. In other words, δ is the concentration of [S0]
where intermolecular distance is equal to the 1O2 diffusion distance [53].The value of
this critical low photosensitizer concentration is estimated to be between 3 and 3000
µM [54]. δ can be expressed as
δ =
1
d3NA
. (2.20)
Here, d is the diffusion distance of 1O2 in the environment of interest, which can be
related to the singlet oxygen lifetime, τ∆, by d = (6Dτ∆)
1/2, where D is the diffusion
coefficient for 1O2 and NA is Avogadro’s number [53].
If one only cares about the dynamic processes of PDT in the time scale of a few
seconds to hours, then the time derivative on the right hand sides of equations (2.13),
(2.14), (2.16), and (2.17) can be set to zero because these processes are known to be
very fast (∼µs or less) and converge to equilibrium states. Solving for this equilibrium
state, the equations become
[S1] =
1
k3 + k5
ε
hν
φ[S0], (2.21)
[T1] =
k5
k3 + k5
1
k2
1
[3O2] + β
ε
hν
φ[S0], (2.22)
[1O2] =
1
k12([S0] + δ) + k6 + k72[A] + k9[Q]
ξII
[3O2]
[3O2] + β
φ[S0], (2.23)
[O−·2 ] =
1
k11([S0] + δ) + k71[A]
ξI
[3O2]
[3O2] + β
φ[S0], (2.24)
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d[S0]
dt
= − (ξIIσII + ξIσI) [
3O2]
[3O2] + β
([S0] + δ)φ[S0]− η 1
[3O2] + β
φ[S0], (2.25)
d[3O2]
dt
= [− (ξII + ξI) + ξIIτ∆(k6 + k9[Q])] [
3O2]
[3O2] + β
φ[S0] + Γ, (2.26)
d[A]
dt
= −(k72ξIIτ∆ + k71ξIτS)[A] [
3O2]
[3O2] + β
φ[S0]− η 1
[3O2] + β
φ[S0]. (2.27)
All of the parameters (ξ, ξI , ξII , σ, σI , σII , τf , τ∆, τS) have been defined in table 2.2.
σ = (σIIξII + σIξI)/ξ where ξ = ξI + ξII . For the in vivo scenario, it is assumed that
the concentration of biological acceptors is large, so k72[A]τ∆ ≈ 1 and k71[A]τS ≈ 1.
Furthermore, σII([S0] + δ) 1, and it is assumed that k9[Q] k7[A]. The simplified
model to describe the in vivo environment is described in section 3.5. For the in-
phantom scenario, while there are no biomolecular singlet oxygen acceptors, Intralipid
that was added can react with singlet oxygen to form oxygenated products, so the
k7[A] term was calculated by using a reduced singlet oxygen lifetime in phantoms.
Without the addition of a quencher, the k9[Q] term can be set to 0. When type II
reactions dominate, it can be assumed that ξ ≈ ξII .
Utilizing equation (2.27), the amount of biological acceptor that has reacted with
a reactive oxygen species ([ROS]rx) can be defined by the following
d[ROS]rx
dt
= −fξ [
3O2]
[3O2] + β
φ[S0]− η 1
[3O2] + β
φ[S0], (2.28)
where f is the fraction of ROS interacting with [A]. Here, the first term relates
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to the fraction of acceptors that reacted due to ROS-mediated reactions, and the
second term relates to the fraction that reacts under hypoxic conditions or any other
non-oxygen-mediated reactions, such as triplet interactions. In cases where type II
reactions dominate (S∆  SI and η = 0), the reacted singlet oxygen ([1O2]rx) can be
described by
d[1O2]rx
dt
= −fξ [
3O2]
[3O2] + β
φ[S0], (2.29)
The required photochemical parameters can be reduced from 12 (δ, g, k0, . . . , k9)
to 6 (δ, β, ξ, σ, η, g), with some of the latter expressed as ratios of the former, if
one is not interested in modeling [S1], [T1], [
1O2], and [O
−·
2 ]. The definitions for the
photochemical parameters, ξ, β, η, δ, σ, and g, are shown in table 2.2, along with
their relationships to the reaction rate constants.
The specific oxygen consumption rate, ξ, is the PDT oxygen consumption rate per
light fluence rate and photosensitizer concentration under the condition that there is
an infinite 3O2 supply. σ, the specific photobleaching ratio, is the probability ratio of
a ROS (including 1O2 molecule) to react with ground state photosensitizer compared
to the ROS (including 1O2 molecule) reacting with a cellular target, [A]. Notice
that ξ and σ consider interactions of both type I and type II nature. β represents
the ratio of the monomolecular decay rate of the triplet state photosensitizer to the
bimolecular rate of the triplet photosensitizer quenching by 3O2 [44] and is called the
oxygen quenching threshold concentration, meaning the oxygen concentration where
the quantum efficiency of singlet oxygen generation is reduced by half [27]. η is
the hypoxic consumption rate that describes interactions between the triplet state
photosensitizer and the cellular target. It is considered to be “hypoxic” as there is
no oxygen involved in the reaction.
Table 2.2 also provides the definitions of several other important photochemi-
Chapter 2 Michele M. Kim 20
cal parameters for a specific photosensitizer. Fluorescence quantum yield (Φf ) of
a compound is defined as the fraction of molecules that emit a photon after direct
excitation [55]. The triplet quantum yield (Φt) describes the crossover efficiency for
photosensitizer to go from the singlet state to the triplet state via intersystem cross-
ing [56]. Similarly, the singlet oxygen quantum yield (Φ∆) is given as the efficiency
to produce singlet oxygen from the triplet state of a photosensitizer [32]. We have
introduced a quantity of superoxide anion quantum yield (ΦROS) as the efficiency of
producing superoxide anion from the triplet state of a photosensitizer. In addition
to the quantum yields, the fluorescence lifetime (τf ), triplet lifetime (τt), and singlet
oxygen lifetime (τ∆) represent mean lifetime of each state (i.e. of the fluorescence
state, the triplet state, and of singlet oxygen) [57]. ε is the extinction coefficient (cm−1
µM−1) defined as the absorption coefficient of the photosensitizer per concentration.
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Table 2.2: Definition of some key parameters used in PDT modeling [34]
Symbol Definition
β (µM) Oxygen quenching threshold concentration k4+k8[A]
k2
δ (µM) Low concentration correction
η (cm2 mW−1 s−1 µM) Hypoxic reaction consumption rate Φt εhν
k8[A]
k2
ξ (cm2 mW−1 s−1)
Specific oxygen consumption rate
ξ = ξII + ξI = S∆Φt
ε
hν
+ SIΦt
ε
hν
σ (µM−1)
Specific photobleaching ratio σ = (ξIIσII+ξIσI)/ξ
where σII = k12τ∆ and σI = k11τS
g (µM s−1) Macroscopic maximum oxygen supply rate
ε (cm−1 µM−1) Photosensitizer extinction coefficient
τf (s) Fluorescence lifetime
1
k3+k5
τ∆ (s) Singlet oxygen lifetime
1
k12([S0]+δ)+k6+k72[A]+k9[Q]
τS (s)
Superoxide anion lifetime 1
k11([S0]+δ)+k71[A]
τt (s) Triplet state lifetime
1
k4+k2[3O2]+k8[A]
[A] (µM)
Singlet oxygen receptors, considered a constant
during PDT because it is too large to be
changed during PDT.
S∆
Fraction of triplet state photosensitizer-3O2 reac-
tions to produce 1O2
SI
Fraction of triplet state photosensitizer reactions
involved in type I reactions
SNL
Fraction of triplet state photosensitizer reactions
that are non-luminescent S∆ + SI + SNL = 1
Φ∆ Singlet oxygen quantum yield S∆
k5
k3+k5
ΦROS
Reactive oxygen species/superoxide anion quan-
tum yield SI
k5
k3+k5
Φf
Fluorescence quantum yield k5
k3+k5
k3R
k3
, where k3R is
fluorescence radiative decay rate between SI
and S0
Φt Triplet quantum yield
k5
k3+k5
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2.1.5 Relationship between rate parameters and the photo-
chemical parameters
The rate constants for each of the reactions described previously can be determined
by knowing some of the basic photochemical parameters mentioned before including
the singlet oxygen lifetime (τ∆), the fluorescence lifetime (τf ), the triplet lifetime
(τt), and the triplet quantum yield (Φt), all of which are measurable quantities with
existing technologies.
The photon absorption rate of the photosensitizer is given by knowing the ex-
tinction coefficient (ε) of the photosensitizer, the fluence rate (φ = 100 mW cm−1),
Plank’s constant (h), and the frequency of light used for treatment (ν)
k0 =
ε
hν
(2.30)
The reaction rates involving 1O2 (k12, k6, k72) can be determined by measuring
the singlet oxygen lifetime using SOLD. The relationship between τ∆ and the rate
constants is the following
τ−1∆ = k12([S0] + δ) + k6 + k72[A] + k9[Q] (2.31)
By varying the concentration of [S0] in water in the absence of any singlet oxygen
acceptors, ([A] = 0), the plot of τ−1∆ versus [S0] will yield a slope which will be k12
with a low concentration correction (δ) [53, 58]. Furthermore the extrapolation to
[S0] = 0 will yield the value of k6, provided that the values of δ and k12 are known.
Adding known concentrations of acceptors will allow for extrapolation of the value
k72. The value of δ can be found by investigating photobleaching kinetics and the
steady-state singlet oxygen concentration approximation [54].
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Similarly, the reactive oxygen species lifetime can be written as
τ−1S = k11([S0] + δ) + k71[A] (2.32)
Triplet quantum yield (Φt) and fluorescence decay time (τf ) can be used to cal-
culate k3 and k5 with the following equations [31]
τf =
1
k3 + k5
(2.33)
k3 =
1− Φt
τf
(2.34)
k5 =
Φt
1− Φtk3 =
Φt
τf
(2.35)
Rate reactions involving the triplet state photosensitizer (k2, k4, k8) are related to
the triplet state lifetime by
τ−1t = k4 + k2[
3O2] + k8[A] (2.36)
Triplet state lifetime can also be measured by SOLD. Measurement of the ground state
oxygen in a phantom will enable extrapolation of k2 and k4 in a linear fit of τ
−1
t versus
[3O2] with the slope gives k2 and extrapoliation to [
3O2] = 0 gives k4 + k8[A]. The
oxygen quenching threshold concentration β (= (k4 + k8[A])/k2) in the macroscopic
model can be calculated with the ratio of the two. k8 can be determined as the slope
between τ−1t and [A]. All other photophysical parameters (ξ, σ, η) can be determined
using the rate constants and expressions in table 2.2.
The quantum yield for generation of singlet oxygen (Φ∆) and reactive oxygen
species or superoxide anion (ΦROS) are important quantities in determining the con-
centrations of the cytotoxic oxygen species. Both are related to the photosensitizer
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triplet quantum yield by
Φ∆ = S∆Φt (2.37)
ΦROS = SIΦt (2.38)
Using SOLD techniques, values of Φ∆, Φt, and ΦROS can be measured so that S∆
and SI can be calculated.
2.2 Experimental methods to determine the rate
parameters
The advent of spectroscopic techniques to measure rate constants of photosensitiza-
tion and oxygenation has opened the way to the determination of their photochemical
and photophysical parameters. This section describes a sampling of methods to deter-
mine experimental rate parameters and other key photochemical factors. The scope
of this review is focused mainly on photochemical parameters in vivo. At present, this
is only achievable through indirect methods (section 2.2.4) — namely, extrapolation
of the parameters in table 2.2 by applying the macroscopic model directly in in vivo
systems or in phantoms. The potential for direct methods to be applied to in vivo
systems will be pointed out whenever possible.
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2.2.1 Direct methods
Absorption spectroscopy
Absorption spectroscopy refers to a technique that measures the absorption of ra-
diation by a sample. By using a spectrophotometer and a white light source, the
extinction coefficient (ε; units cm−1 µM−1) of a photosensitizer can be determined by
the Beer-Lambert law [59,60]
A = − ln I
I0
= εlc (2.39)
where I is the output light intensity, I0 is the input light intensity, l is the path length
of the measured sample, and c is the concentration of the sample (in µM). Typically,
absorbance, A, is defined for l = 1 cm. Notice the definition of extinction coefficient
is loge based rather than log10 based. The latter is often the case in chemistry
literature and causes ε to be decreased by a factor of 2.30 (ln 10). Figure 2.3 and 2.4
shows an example of the wavelength dependence of ε, also called absorption spectra
for photosensitizers BPD and Photofrin from both the literature and experimentally
measured methods. Using equation (2.30), the value of k0 can easily be determined
from the measured ε and knowing the measured wavelength, λ, of the light (hν =
hcλ−1).
Transient absorption spectroscopy
Transient absorption spectroscopy is an extension of absorption spectroscopy. Also
called pump-probe spectroscopy, the absorbance of a sample is measured as a function
of time after excitation by a flash of light, usually a pulsed laser, mainly to determine
the triplet lifetime of the sensitizer, τt [61]. This technique can be used to measure the
singlet oxygen quantum yield (Φ∆) for a photosensitizer utilizing another chemical
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with known singlet oxygen quantum yields [62,63].
2.2.2 Fluorescence spectroscopy
Photosensitizer fluorescence can be used to determine the concentration ([S0]) of pho-
tosensitizer present both in vivo and in vitro [64, 65]. However, fluorescence signal
in vivo is affected by the tissue optical properties of scattering and absorption. The
reduction of fluorescence signal due to absorption can be accounted for by incorpo-
rating an empirical correction factor based on tissue optical properties [10]. Many
commonly used photosensitizers produce unique fluorescence spectra when excited at
a certain wavelength. Figure 2.3 and 2.4 shows an example of two photosensitizers
(BPD and Photofrin) and their fluorescence spectra from both the literature and the
basis spectra used for in vitro measurements. Fluorescence basis spectra were ob-
tained by excitation of samples with photosensitizer in water by 405 nm laser light.
Such emission spectra, corrected for instrument response and tissue optical prop-
erties, can be analyzed as a linear combination of fluorescence basis spectra using
a singular value decomposition (SVD) fitting algorithm [42]. Fluorescence spectra
from phantoms with known photosensitizer concentrations can be used to determine
the correction factor for fluorescence due to tissue optical properties as well as the
absolute value of [S0] in an in vivo environment [10].
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Figure 2.3: Our own experimentally measured fluorescence and ab-
sorption spectra (solid black and grey lines) of BPD in water, and
fluorescence and absorption spectra (dashed red and light red lines)
of BPD in PBS solution from [66–68]. Measured fluorescence was of
BPD in water excited by 405 nm laser light, and measured absorp-
tion was of BPD in water excited by a white light source.
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Figure 2.4: Our own experimentally measured fluorescence and ab-
sorption spectra (solid black and grey lines) of Photofrin in Intralipid
solution, and fluorescence and absorption spectra (dashed red and
light red lines) of Photofrin in PBS solution from [68]. The litera-
ture absorption curve for Photofrin above 480 nm has been multi-
plied by 10× for clarity. Measured fluorescence was of Photofrin in
water excited by 405 nm laser light, and measured absorption was
of Photofrin in water excited by a white light source. Solvent differ-
ences account for variations in fluorescence and absorption intensity
between measured and literature spectra.
Fluorescence lifetime spectroscopy and imaging (FLI)
Time-resolved fluorescence decay measurements can be used to study details about
the structure and dynamics of macromolecules. These measurements are commonly
performed with microsecond to picosecond laser sources with high-speed photodetec-
tors [69].
The fluorescence lifetime, τf , of photosensitizer can be determined from time-gated
spectra along with single photon counting, using a picosecond to microsecond pulsed
diode laser for fluorescence excitation. Specific wavelength ranges can be selected to
plot the fluorescence exponential decay curve (e−(k3+k5)t) to yield the decay constant
(k3 + k5), which can be used to calculate τt = 1/(k3 + k5) [70].
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2.2.3 Phosphorescence spectroscopy
Phosphorescence is similar to fluorescence in that absorbed energy by a substance is
released in the form of light. However, phosphorescence occurs on a longer time scale
than fluorescence. Besides the decays from monomol 1O2 to
3O2 +hν at 1270 nm (22
kcal mol−1), dimol singlet oxygen molecules (2 1O2) can also decay to 2 moles 1O2 to
3O2 + hν at 634 nm (44 kcal mol
−1) and 701 nm [71–75]. The latter (634 nm and/or
701 nm) is readily observed in the gas phase but is often not detected in solution due
to other optical signals at these wavelengths. The detection of 1O2 luminescence at
1270 nm is potentially difficult in vivo because of the short lifetime of 1O2.
Singlet oxygen luminescence (SOL) detection (or laser flash photolysis)
SOLD (or laser flash photolysis) is a standard technique for identification of short-
lived, excited states of photosensitizers and characterization of their reactions [76–78].
It is a popular and precise technique used to directly measure k6 and k72, where the
photosensitizer solution of the substrate is saturated with O2 and irradiated with
a laser at a specific absorption wavelength. The resulting phosphorescence of 1O2
at 1270 nm as a function of time is measured with a time-correlated detector [79].
With the time-correlated singlet photon counting (TCSPC) module, phosphorescence
decay characteristics can be measured with a time resolution of ≤ 100 ps and a
spatial resolution in the subcellular region. With a high pulse repetition rate (40
MHz), the total acquisition time is short (less than 1 s) for each fluorescence decay
curve [70]. Production of 1O2 by laser excitation occurs in less than 2 µs, its decay
is approximated by a first order exponential decay model (derived from Eq. (2.31)).
A Stern-Volmer plot of concentration of substrate [A] versus 1/τ∆ (where τ∆ is the
experimentally measured singlet oxygen lifetime), gives a straight line with the slope
equal to k72 and the y-intercept is equal to k6
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The rate constants for oxidized product formation, k7, are obtained by competition
technique reported by Higgins et al. [80] where the substrate solution containing
photosensitizer and an alkene for comparative trapping to deduce the contribution
from physical quenching, k9, can be obtained by difference using equation (2.31),
which can also be written as k6+k7[A]+k9[Q] [81,82]. Unlike unsaturated compounds
such as alkenes, amines and polyenes are effective singlet oxygen physical quenchers
and protect against photooxygenation [83].
Singlet oxygen quantum yields (Φ∆) can be determined from the phosphorescence
intensity at 1270 nm from singlet oxygen. Intensity can be recorded as a function of
excitation laser energy and of the concentration of the photosensitizer. The slope of
this linear plot is proportional to Φ∆ and is compared to the slope of the same plot
for a reference photosensitizer with a known value of Φ∆ [84].
Measurements of this near-infrared (NIR) luminescence of singlet oxygen in bio-
logical environments is difficult due to the short 1O2 lifetime (which can be less than
the triplet state photosensitizer lifetime) and its low quantum yield for phosphores-
cence. However, this can be achieved using a NIR-sensitive photomultiplier tube.
Time-resolved analysis shows that 1O2 lifetime is reduced in vivo (τ∆ = 0.03 − 0.18
µs) compared to lifetime in vitro (τ∆ = 3.0 ± 0.3 µs). This may be due to the
protein binding to 1O2 in cellular environments [52]. The detector must be suffi-
ciently fast (with a rise time of ∼3 ns) for phosphorescence single-photon counting,
and it must have a broad, flat spectral response that enables spectral resolution
of the 1O2 signal [15]. Examples of detectors used for this purpose include photo-
multiplier tubes, superconducting nanowire single-photon detectors (SNSPDs) and
semiconductor-based single-photon avalanche diodes (SPADs) [85].
The shorter lifetime has been attributed to the rapid quenching of 1O2 by biomolecules
combined with a lack of adequately sensitive detectors at NIR wavelengths, since the
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luminescence emission is proportional to the lifetime. When exchanging the H2O
solvent for D2O, the lifetime of singlet oxygen increases by 20-fold. The τ∆ in D2O
is 69 µs at 20◦C and in H2O 3.5 µs at 20◦C [32,86,87].
The triplet state lifetime is highly dependent on the molecular oxygen concen-
tration according to a Stern-Volmer relationship described by Eq. (2.36). k4 can be
written as the sum of k4R and k4NR, which are the radiative and non-radiative photo-
sensitizer triplet state decay rate constants. The changes in triplet state lifetime (τt)
can be used to determine changes in [3O2], given k2 and k4 are known. In biological
systems, τt  τ∆ so that the exponential decay of the singlet oxygen luminescence
curves are govered by τt [15, 88,89].
Most singlet oxygen luminescence dosimetry (SOLD) studies have been done on
microspheres of cells. Detection of SOL from a murine tumor using Photofrin and
ATX-S10NAa(II) has been reported [90]. The full luminescence spectrum can be
measured by placing a monochromator in front of the detector.
The great impact of SOLD techniques comes with reports that show detection of
1O2 in complex biological systems directly. The integrated detected
1O2 luminescence
counts is proportional to the total amount of 1O2 created in the target during PDT
and thus is predictive of PDT response [15]. Ultimately it is the cumulative 1O2 dose
that determines the biological effect. Furthermore, changes in the effective PDT dose
due to oxygen depletion or due to photosensitizer photobleaching can be evaluated
with time-resolved SOLD measurements.
2.2.4 Indirect methods
Singlet oxygen explicit dosimetry (SOED) methods have been developed to calculate
the reacted singlet oxygen, [1O2]rx, in vivo and in vitro for type II photosensitizers.
The main cytotoxic agent in type II PDT has been attributed to 1O2 [91]. PDT
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efficacy can be correlated to the calculated [1O2]rx, thus making SOED an effective
method of dosimetry for in vivo studies as well as in clinical settings. The methodol-
ogy for SOED for type II photosensitizer can be expanded for reactive oxygen species
involving type I photosensitizers, even though it has not been used in existing stud-
ies. However, the parameters obtained should include photodynamic action from
both type I and type II even though singlet oxygen is predominant for the type II
photosensitizers studied. These methods are discussed in more detail in following
chapters.
2.2.5 Other methods
In addition to the experimental methods mentioned in this section, there are other
techniques that can be used to investigate the presence of the reactive oxygen species.
These methods have been mostly used in vitro; however, some may be applicable in
in vivo systems as well. These methods involve fluorescent markers and analytical
methods.
Several methods are developed to detect the presence of singlet oxygen and/or
HO·. Singlet oxygen can be detected from dioxetanes from [2 + 2] cycloadditions,
endoperoxides from [2 + 4] cycloadditions, and allylic hydroperoxides from ‘ene’ reac-
tions [92,93]. Simple alkenes often take up 1 equivalent of 1O2. Tandem
1O2 reactions
can take place in polyunsaturated compounds, and there are also instances where
bisperoxides rearrange to spiro compounds. Peroxides can also be generated through
type I reactions that do not involve singlet oxygen. For example, there are electron
transfer photooxidation reactions with 9-mesityl-10-methylacridinium ion [94, 95]. It
may be noted that ene-derived hydroperoxides and cycloaddition-derived endoperox-
ides have a toxicity of their own that is separate of singlet oxygen’s toxicity [96,97].
Aromatic compounds such as 9,10-disubstituted anthracenes can trap 1O2 and
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be detected by UV-vis spectroscopy [98–100]. Another trapping reaction is 9,10-
anthracene-9,10-endoperoxide dipropionate dianion that arises from a [2 + 4] cy-
cloaddition of 1O2 with 9,10-anthracene dipropionate dianion at pH = 10 in water
dtected by UV-vis spectroscopy.
Analytical methods such as low-temperature NMR spectroscopy can be used to
detect unstable peroxide compounds in reaction mixtures. For example, dioxetane
13C NMR signals are fairly characteristic [101]. Electron-rich olefins such as alkoxy-
substituted alkenes react with singlet oxygen and form dioxetanes. Decomposition of
dioxetanes is often accompanied by chemiluminescence due to a fragmented excited
carbonyl compound [102,103].
Singlet oxygen sensor green (SOSG) is a 1O2-specific fluorescent probe reagent that
has been used to quantitatively measure 1O2 that has been produced by determining
the reaction rate of SOSG with 1O2. SOSG is a fluorescein-anthracene dye that
fluoresces after its initial reaction with 1O2. The endoperoxide product from a [2 +
4] cycloaddition of 1O2 closes off the FRET quenching channel of precursor SOSG
[98, 104]. SOSG reacts with 1O2 to produce SOSG endoperosides, which emits a
strong fluorescence signal at 531 nm. Φ∆ has also been determined using SOSG for
a porphyrin-based photosensitizer, hematoporphyrin monomethyl ether [105].
Fluorescence probes can also be used to detect highly reactive singlet oxygen
species such as hydroxyl radical (HO·) and reactive intermediates of peroxidase.
2-[6-(4?-hydroxy)phenoxy-3H-xanthen-3-on-9-yl] benzoic acid (HPF) and 2-[6-(4?-
amino)phenoxy-3H-xanthen-3-on-9-yl] benzoic acid (APF) are two examples of such
fluorescent probes [106]. Both probes are reported to be cell-permeable, relatively
insensitive to superoxide anion, nitric oxide, 1O2, and alkyl peroxides [107, 108].
APF is ∼5 times more fluorescent during HO· than HPF [107]. Other fluorescent
probes of hydroxyl radical include coumarin- and rhodamine nitroxide-based com-
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pounds [109–111].
The methods mentioned in this section can be useful tools to determine in vivo
and in vitro photochemical parameters as well as characteristics of reactive species
relevant for a specific photosensitizer.
2.3 A review of existing values of photochemical
parameters
Photosensitizers are typically delivered systemically or topically for PDT. The sys-
temic administration involves either oral administration or intravenous injection so
that the drug will circulate through the whole body system, and preferentially there
will be more drug localized in the target site than in others. An ideal photosensi-
tizer should have low or no toxicities and a fast clearance process. Some systemi-
cally delivered photosensitizer are benzoporphyrin derivative (BPD), Photofrin, and
2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH), which were also used for
pre-clinical studies in this work. In contrast with the systemic administration, ALA
a pro-drug that reacts with heme to generate the photosensitizer protoporphyrin IX
(PpIX), can also be applied topically to perform more localized delivery, which is
commonly used for skin treatment.
There are several photosensitizers that have been approved for standard clinical
use by the US Food and Drug Administration (FDA) or the European Medicines
Agency (EMA) [112, 113]. ALA (a pro-drug that produces PpIX) was approved
for the treatment of actinic keratoses in 1999 by the FDA under the trade name
Levulan [114] and in 2009 and 2011 by the EMA under the trade name Alacare
and Ameluz, respectively. Similar photosensitizer derivatives were developed to also
produce PpIX: methyl-ALA was approved by the FDA in 2004 for the treatment of
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non-hyperkeratotic actinic keratoses, and hexyl-ALA was approved in Europe in 2006
for the diagnosis of bladder cancer under the trade name Hexvix [115]. In 2000 the
FDA approved use of BPD in the treatment of age-related macular degeneration [116].
mTHPC was approved by the EMA for the treatment of head and neck squamous cell
carcinomas. Photofrin was approved by the FDA for multiple treatment sites. It was
approved for treatment of microinvasive endobronchial non-small cell lung cancer in
1998 and high-grade dysplasia in Barrett’s esophagus in 2003.
The photochemical parameters, β, δ, ξ, σ, and g, can be determined using indirect
methods that will be described in detail for BPD in chapter 5. Other studies for HPPH
and Photofrin have been performed as well [44,117]. The fundamental photophysical
parameters are fairly well-established for most photosensitizers (e.g. ε, τf , τt) and
they can be used to determine some parameters, such as ξ. However, indirect methods
in vivo can only be used to determine the ratios of rate constants (ki’s, where i =
1− 8), thus additional measurements are necessary to determine individual reaction
rate constants.
The photochemical parameters were determined mostly for in vitro systems; how-
ever, it is reasonable to expect that they will largely remain the same in in vitro
systems (such as ε, k0 k3, and k5). Some parameters (k6, and k72) are photosensitizer
independent since they are properties of either 1O2 or other reactive oxygen species
and they should behave the same. Assumptions can be made that they are the same
for all type II photosensitizers.
For BPD, the extinction coefficient (ε) was found to be 0.0783 cm−1 µM−1 using
absorption spectroscopy [66, 118]. The value of k0 was found at a fluence rate of 100
mW cm−2 using equation (2.30) and ε. k21 was found by using the approximation
k12 ≈ σII · k71[A], where σII is the specific photobleaching ratio determined in vivo
using SOED described in section 5. k2 was found to be 3 × 103 µM−1 s−1 using the
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observed triplet lifetime (τt) in the presence and abscence of
3O2 (equation (2.36))
[66]. Using this value and the measured value for β in vivo, k4 can be found to be
k4 = β×k2 = (11.9µM)×(3×103µM−1 s−1) = 3.6×104 s−1. The values for k3 and k5
were found by using the fluorescence lifetime (εf ) and the triplet quantum yield (Φt)
and equations (2.33)-(2.35). The value of τf was taken from literature using a time-
correlated single photon counting method [66]. The value of Φt was obtained from
literature using laser-induced opto-acustic calorimetry (LIOAC) [66]. The resulting
values were k3 = (1 − Φt)/τf = (1 − 0.79)/(5.2 × 10−9 s) = 4.04 × 107 s−1 and k5 =
Φt/τf = 0.79/(5.2×10−9 s) = 1.52×107 s−1. The singlet oxygen lifetime (τ∆) in water
with no acceptors to react with 1O2 can be used with equation (2.31) to obtain the
value of k6, which is only a property of singlet oxygen and should be photosensitizer
independent. Therefore, for all type II photosensitizers, k6 = τ
−1
∆ = (3µs)
−1 =
3.3×105 s−1 [27]. The value of k72[A] in vivo is only a property of singlet oxygen and
is thus assumed to be the same for all type II photosensitizers. By using the value
of τ∆ in tissue (0.1 µs) and the known value for k6, k72 = τ
−1
∆ − k6 = (0.1µs)−1 =
(3.3× 105 s−1) = 1× 107 s−1 [53]. Since BPD is a type II photosensitizer, there is no
significant contribution of type I reactions between [T1] and [A] so k8[A] and η were
assumed to be 0. The values of ξ, σ, and g were found in vivo using the SOED method
described in more detail in chapter 5 [119–121]. The low concentration correction, δ,
was assumed to be the same for BPD as that of Photofrin. Further experiments are
needed to confirm this value for BPD. The fraction of 1O2 producing reactions between
[T1] and
3O2 was determined using the definition of ξ: S∆ = ξ/Φt/ε × (hν) = (51 ×
10−3 cm2mW−1s−1)/(0.79)/(0.0312µM−1cm−1) × (6.022 × 1014 cm3µM−1) × (2.72 ×
10−16 mW s) = 0.144.
For Photofrin, the extinction coefficient (ε) was found to be 0.0035 cm−1 µM−1
using absorption spectroscopy [118, 122]. The value of k0 was found at a fluence
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rate of 100 mW cm−2 using equation (2.30) and ε. k21 was found by using the
approximation k12 ≈ σII · k71[A], where σII is the specific photobleaching ratio de-
termined in vivo using SOED [44]. k2 was found to be 1.4 × 103 µM−1 s−1 us-
ing the observed triplet lifetime (τt) in the presence and abscence of
3O2 (equation
(2.36)) [31]. Using this value and the measured value for β in vivo, k4 can be found
to be k4 = β× k2 = (11.9µM)× (1.4× 103µM−1 s−1) = 1.67× 104 s−1. The values for
k3 and k5 were found by using the fluorescence lifetime (εf ) and the triplet quantum
yield (Φt) and equations (2.33)-(2.35). The value of τf was taken from literature
using a time-correlated single photon counting method [123]. The value of Φt was
obtained from literature [22, 124]. The resulting values were k3 = 2.9 × 107 s−1 [31]
and k5 = Φtk3/(1 − Φt) = (0.63) × (2.9 × 107 s−1)/(1 − 0.63) = 4.94 × 107 s−1.
Values of k6 and k7 were found for Photofrin in the same method described above
for BPD. Since Photofrin is a type II photosensitizer, there is no significant con-
tribution of type I reactions between [T1] and [A] so k8[A] and η were assumed to
be 0. The values of ξ, σ, and g were found in vivo using the SOED methods de-
scribed in more detail in chapter 5 [34, 44]. The low concentration correction, δ,
was found from the literature to be 33 µM [53]. The fraction of 1O2 producing
reactions between [T1] and
3O2 was determined using the definition of ξ: S∆ =
(3.7 × 10−3 cm2mW−1s−1)/(0.63)/(0.0035 µM−1cm−1) × (6.022 × 1014 cm3µM−1) ×
(3.16× 10−16 mW s) = 0.319.
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Table 2.3: Selected photosensitizers and their in vivo photophysical parameters
Parameter Photofrin BPD
ε 0.0035 0.0783
(cm−1µM−1) @630 nm [122] @690 nm [27,66]
k0 (s
−1)
1.84a 45.13a
@100 mWcm−2
k1 7.6× 102b[125] 1.7× 10
2 b
(µM−1s−1) (150-550) [119,121]
k2 1.4× 103 [31] 3× 103 [66]
(µM−1s−1)
k3 (s
−1) 2.9× 107 [31] 4.04× 107c[66]
k4 (s
−1) 1.67× 104d 3.6× 104d
k5 (s
−1) 4.94× 107e 1.52× 107e
k6 (s
−1) 3.3× 105f 3.3× 105f
k7[A] (s
−1)
1× 107h 1× 107h
(3× 106 (3× 106
−3× 107) −3× 107)
k8[A] (s
−1) (0)h (0)h
β (µM) 11.9 [125] (11.9)i
δ (µM)
33 [53] 33i
(33-150) (33-260) [45]
ξ 3.7× 10−3 [27, 124,125] (55± 15)× 10−3
(cm2mW−1s−1) (2.9− 3.7)× 10−3 [119,120,126]
σ (µM−1) 7.6× 10−5 [125] (1.8± 0.3)× 10
−5
((1− 5)× 10−5) [119,120,126]
η (cm2mW−1
(0)h (0)h
s−1µM)
g
0.76 [44] 1.7± 0.4 [119,120,126]
(µM−1 s−1)
S∆ 0.319
j 0.144j
Φt
0.63
0.79 [66]
(0.63-0.80) [22,27,124]
Φ∆
0.20k 0.11k
(0.12-0.56) [124,127] (0.11-0.84) [128,129]
Φf 0.16 [129] 0.05 [66]
τf (s) (5.5± 1.2)× 10−9 [123] 5.2× 10−9 [66]
a Calculated based on the value of ε and φ = 100 mW cm−2:
k0 = εφ/(hν). Photofrin: k0 = (0.0035 µM
−1cm−1)/(6.022 ×
1014 cm2µM−1)×(100 mW cm−2)/(3.16×10−16 mW s) = 1.84 s−1.
BPD: k0 = (0.0783 µM
−1cm−1)/(6.022 × 1014 cm2µM−1) ×
(100 mW cm−2)/(2.88× 10−16 mW s) = 45.13 s−1.
b Calculated based on the value of σ and k7: k1 = σ×k7[A]. Photofrin:
k1 = (7.6× 10−5 µM−1)× (1× 107 s−1) = 7.6× 102 µM−1s−1.
c Calculated based on the value of Φt and τf : k3 = (1−Φt)/τf . BPD:
k3 = (1− 0.79)/(5.2× 10−9) = 4.04× 107 s−1
d Calculated based on the value of β and k2: k4 = β × k2. Photofrin:
k4 = (11.9 µM) × (1.4 × 103 µM−1s−1) = 1.67 × 104 s−1. BPD:
k4 = (11.9 µM)× (3× 103 µM−1s−1) = 3.6× 104 s−1.
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e Calculated based on the value of k3 and Φt: k5 = Φtk3/(1 − Φt).
Photofrin: k5 = (0.63)× (2.9× 107 s−1)/(1− 0.63) = 4.94× 107 s−1.
BPD: k5 = (0.79)× (4.04× 107 s−1)/(1− 0.79) = 1.52× 107 s−1.
f τ∆ = 3 µs in water and 0.16 µs in tissue [53]. k6 = τ
−1
∆ − k7[A] =
(3 µs)−1 = 3.3× 105 s−1.
g k7[A] = τ
−1
∆ − k6 = (0.1µs)−1 − (3.3× 105 s−1) = 1× 107 s−1, taken
from Zhu et al. [47]. The value of [A] is unknown but can be es-
timated from the value of k7 = 235 µM
−1s−1 for a well-known sin-
glet oxygen quencher, NaN3 [130]: [A] = 10
7 s−1/235 µM−1s−1 =
42 mM. The magnitude of [A] is reasonable considering the singlet
oxygen threshold dose can be up to 12 mM [27], without causing
any effect on singlet oxygen lifetime. k7 = k71 + k72. k7 is assumed
to be k7 = k72 for type II photosensitizers and k7 = k71 for type I
photosensitizers.
h Assuming no hypoxic interactions.
i Assumed to be similar to the values for Photofrin.
j In vivo values calculated based on the values of ξ, Φt,
and ε: S∆ = ξ/Φtε × (hν). Photofrin: S∆ =
(3.7 × 10−3 cm2mW−1s−1)/(0.63)/(0.0035 µM−1cm−1) × (6.022 ×
1014 cm3µM−1) × (3.16 × 10−16 mW s) = 0.319. BPD: S∆ =
(51 × 10−3 cm2mW−1s−1)/(0.79)/(0.0312 µM−1cm−1) × (6.022 ×
1014 cm3µM−1)× (2.72× 10−16 mW s) = 0.144.
k In vivo values calculated based on the values of S∆ and Φt: Φ∆ =
S∆ × Φt. Photofrin: Φ∆ = (0.319) × (0.63) = 0.20. BPD: Φ∆ =
(0.144)× (0.79) = 0.11.
Photochemical parameters in phantoms were also investigated using in phantom ex-
periments (described further in chapter 4). The two photosensitizers utilized for these
studies were Photofrin (for its clinical relevance) and Rose Bengal (for its availabil-
ity and higher quantum yield to produce singlet oxygen). The parameters used for
calculations in phantom studies are summarized in table 2.4.
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Table 2.4: Selected photosensitizers and their in-phantom photophysical parameters
Parameter Photofrin Rose Bengal
ε 0.0035 @ 632 nma 0.095 @ 549 nma
(cm−1µM−1) 0.0089 @ 523 nma 0.059 @ 523 nma
k0 (s
−1)
1.84b 25.69b
@100 mWcm−2
k1 (µM
−1s−1) 6.6× 102c 50 [131]
k2 (µM
−1s−1) 1.4× 103 [31] 1.6× 103 [132]
k3 (s
−1) 2.9× 107 [31] 1.89× 107 [133]
k4 (s
−1) 1.67× 104d 1.90× 104d
k5 (s
−1) 4.9× 107e 5.7× 108e
k6 (s
−1) 2.2× 105f 2.7× 105f
k7[A] (s
−1) 1.9× 106g 1.7× 106g
k8[A] (s
−1) (0)h (0)h
k9[Q] (s
−1) 1.17× 106f 1.15× 105f
β (µM) 11.9 [125] 11.9 [124]i
δ (µM) 26± 5j 25± 9j
ξ (cm2mW−1s−1) (10.0± 2.6)× 10−3 @ 632 nmk (169± 38)× 10−3 @ 523 nmk
σ (µM−1) (6.8± 5)× 10−5l (9.4± 1.2)× 10−6l
η (cm2mW−1) (0)h (0)h
τ∆ (s) 0.5× 10−6m 0.5× 10−6m
τf (s) (5.5± 1.2)× 10−9 [123] 1.18× 10−10 [134]
τt (s) (0.43± 0.03)× 10−6m (2.1± 0.2)× 10−6m
Φ∆ 0.56 [124,127] 0.76 [135]
Φt 0.63 [22,27] 0.75 [129,136]
a Measured from absorption spectroscopy
b Calculated based on the value of ε and φ = 100 mW cm−2:
k0 = εφ/(hν). Photofrin: k0 = (0.0035 µM
−1cm−1)/(6.022 ×
1014 cm2µM−1) × (100 mW cm−2)/(3.16 × 10−16 mW s) = 1.84 s−1.
Rose Bengal: k0 = (0.059 µM
−1cm−1)/(6.022 × 1014 cm2µM−1) ×
(100 mW cm−2)/(3.8× 10−16 mW s) = 25.69 s−1.
c Calculated based on the value of σ and k7: k1 = σ × k7[A]. Photofrin:
k1 = (6.6× 10−5 µM−1)× (1× 107 s−1) = 6.6× 102 µM−1s−1.
d Calculated based on the value of β and k2: k4 = β × k2. Photofrin:
k4 = (11.9 µM)× (1.4× 103 µM−1s−1) = 1.67× 104 s−1. Rose Bengal:
k4 = (11.9 µM)× (1.6× 103 µM−1s−1) = 1.90× 104 s−1.
e Calculated based on the value of k3 and Φt: k5 = Φt/(1− Φt) · k3.
Photofrin: k5 = (0.63)/(1 − 0.63) × (2.9 × 107 s−1) = 4.94 × 107 s−1.
Rose Bengal: k5 = (0.75)/(1−0.75)×(1.89×108 s−1) = 5.67×108 s−1.
f Determined from measurements described in chapter 4 and figure 4.5,
for Photofrin phantoms with Intralipid and Rose Bengal in water. For
k9[Q], [Q] assumed to be 5 mM of NaN3 as per the experiment settings,
resulting in k9 = 234 µM
−1s−1 for Photofrin and 23 µM−1s−1 for Rose
Bengal.
g Calculated for phantom studies with Intralipid using τ−1∆ = k1([S0] +
δ)+k6 +k7[A] for [S0] = 50 µM and the values of k1, k6, and δ provided
in the table.
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h Assuming no hypoxic or type I interactions. Fig. 4.2 and 4.3 show
contributions from η do not model the measured data and require ξ to
be larger than possible.
i Assumed to be similar to the value for Photofrin and mTHPC [124].
j Obtained from fitting shown in figure 4.6c (for Photofrin) and 4.7c (for
Rose Bengal) using equation (4.3). δ = b/m where b is the intercept
and m is the slope of the linear fit .
k Values were determined from fit to in-phantom experiments de-
scribed in section 4.1.1 and shown in figure 4.6 and 4.7. Ini-
tial guesses were calculated from ξ = Φ∆ε/hν. Photofrin: ξ =
(0.56)(0.0035 cm−1µM−1)/(3.2×10−16 mWs)/(6.022×1014 cm−3µM−1
= 10.3×10−3 cm2 mW−1s−1 @ 632 nm. Rose Bengal: ξ = (0.76)(0.059
cm−1µM−1)/(3.8×10−16 mWs)/(6.022×1014 cm−3µM−1 = 195×10−3
cm2 mW−1s−1 @ 523 nm.
l Obtained from fitting shown in figure 4.6c (for Photofrin) and 4.7c (for
Rose Bengal) using equation (4.3). σ = m/ξ where m is the slope of
the linear fit.
m Assumed values to simulate short singlet oxygen lifetime with Intralipid
(at 0.2%) acting as a singlet oxygen acceptor (see Fig. 4.1). Measured
values from SOLD experiment when [A] = 0 and [Q] = 0 (i.e. without
Intralipid or NaN3) were found to be 9.4±0.2 µs for Photofrin and
3.8±0.3 µs for Rose Bengal (see Fig. 4.5).
2.4 Conclusions
This chapter reviews the photochemical parameters for the photosensitizers BPD,
Photofrin, and Rose Bengal. These parameters are needed for explicit dosimetry and
modeling the kinetic processes during PDT. Parameters for several other commonly
used photosensitizers are summarized in a review elsewhere [34]. Many fundamental
rate constant values are unavailable for many photosensitizers, and experimental ef-
forts to determine these parameters are required in order to perform explicit dosimetry
of reactive oxygen species.
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Chapter 3
Explicit Dosimetry Techniques
Much of the pre-clinical studies to investigate singlet oxygen explicit dosimetry were
performed using methods summarized in this chapter. The key components of explicit
dosimetry involved measurement of the light fluence, photosensitizer concentration,
and oxygen concentration.
3.1 Light Transport and Optical Properties
The amount of light that reaches the targeted tissue accounts for the treatment effi-
cacy in PDT. Light transport in biological matter is characterized by the absorption
and scattering of photons. These qualities are characterized by the optical proper-
ties of that tissue, namely, the absorption coefficient (µa) and the reduced scattering
coefficient (µ′s).
3.1.1 Measurement of light fluence
Light fluence was measured in various geometries depending on the treatment geom-
etry not only to determine the fluence delivered, but also for measurement of optical
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properties using a point source placed interstitially. Isotropic detectors (IP85 probe,
Medlight SA, Ecublens, Switzerland) were used to monitor fluence measured by an
in-house made dosimetry system, shown in Fig. 3.1.
Figure 3.1: In-house made dosimetry system. Fiber
optic probes are connected via SMA connector to
channels on the dosimetry system to measure light
fluence rate and cumulative fluence.
3.1.2 Diffusion theory for spherical geometry
For accurate dosimetry during pleural PDT, it is important to understand the effects
of light scattering in a cavity surrounded by tissue. The total fluence at the boundary
is larger than the non-scattered irradiance from a point source due to multiple light
scattering [9]. The diffusion theory can be used to derive an equation to calculate
the photon flux for tissue with a spherical cavity and an isotropic point source in the
center [137]. In an integrating sphere, the light does not penetrate deeply into the wall
and is back scattered close to the point where the light initially hit the wall, which
leads to the condition that the effective optical penetration depth is small compared
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to the dimension of the model. So 1/µeff  r, where r is the radius of the cavity, and
at the boundary, the total fluence can be written as [137]
φt(r)
S
≈ 1
4pir2
[
µeff
µa
− 2
]
. (3.1)
where S is the source power. The primary component of the light fluence (or the non-
scattered component) is calculated by φp(r)
S
= 1
4pir2
. When the refractive indices of the
tissue and non-scattering and non-absorbing material in the cavity do not match, the
fluence rate in the tissue is the same as with matched indices. The fluence rate in the
cavity does, however, depend on the difference in refractive index. On the boundary,
the total fluence can be calculated using Eq. (3.1). The scattered component of
fluence in the tissue is then written as
φs(r)
S
≈ 1
4pir2
[
µeff
µa
− 3
]
. (3.2)
The scattered fluence rate in the cavity is the same in the inward and outward direc-
tions. The scattered fluence rate in the cavity is [137]
φs(r)
S
≈ 1
4pir2
(1− r21)
(
µeff
µa
− 3
)
(3.3)
where the reflection factor, r21 is calculated from
r21 =2
∫ θ2=θc
θ2=0
[
1 + A2
(
exp(b2
√
cos θ2 − cos θc)− 1
)]
cos θ2
× sin θ2dθ2 +
∫ θ2=pi/2
θ2=θc
cos θ2 sin θ2dθ2. (3.4)
Here, θc is the critical angle, and θ2 is the angle between the incident ray in the medium
(tissue) with the normal to the surface. Using an air-water interface with nair = 1
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and nwater = 1.33, r21 = 0.4476. The term 1 + A2
(
exp(b2
√
cos θ2 − cos θc)− 1
)
is
equal to Rfresnel.
Using the diffusion theory, the scattered light fluence per power can be calculated
in two ways for arbitrary geometries. In particular, experiments were conducted in
ellipsoid shapes
φs
S
=
4
SA
Rd
1−Rd (3.5)
φs
S
=
(µeff/µa − 3) (1− r21)
SA
(3.6)
Here, SA is the surface area of the cavity volume. Rd is the diffuse reflectance and is
calculated using the following formula [138,139]:
Rd =
a′
2
(
1 + e−4/3A
√
3(1−a′)
)
e−
√
3(1−a′) (3.7)
where the transport albedo is given by a′ = µ′s/(µa + µ′s) and A is the internal reflection
parameter. This is a function of the ratio of the index of refraction of the two
media: nrel = ntissue/nnon−scattering and A = (1 + rd)/(1− rd, where rd = −1.44n−2rel +
0.710n−1rel + 0.668 + 0.0636nrel [140]. For an air-tissue interface, a good approximation
is A = 3.25 [139]. Experiments were conducted in phantoms to validate the scattered
light components, and results are shown in chapter 7.
3.1.3 Measurement of tissue optical properties
Optical properties of the tumor tissue was measured by using a two-catheter method
(shown in figure 3.2) described in detail elsewhere [141, 142]. Treatment wavelength
light was delivered through an isotropic 2 mm point source. The point source was
inserted into one of two parallel cathethers with a 3 mm separation. An isotropic
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detector was placed in the other catheter. This detector was connected to a light
dosimetry system and the position of the detector was controlled by a computer-
controlled step motor system to obtain a scanned profile of the light fluence from the
point source along the catheter. Using the diffusion approximation, the light fluence
rate per source power at a distance r from a point source can be expressed as
φ
S
=
µ2eff
4pirµa
e−µeff r =
3µ′s
4pir
e−µeff r (3.8)
where S is the source power of the point source in mW, φ(r) is the fluence rate in
mW/cm2 at a distance r, and µeff =
√
3µaµ′s. The point source was moved along
the catheter inside the tumor at 1 mm steps to obtain multiple fluence profiles inside
the tumor. The optical properties were determined by fitting the measured data to
the equation using a Matlab-based program.
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Figure 3.2: (a) Treatment set-up of interstitial PDT in a mouse RIF
tumor. (b) Schematic of parallel catheters in a tumor. One catheter
is inserted in the center of the tumor to contain the cylindrically
diffusing fiber to deliver the treatment light or the point source to
measure the optical properties, and a second catheter is inserted 3
mm away to contain the isotropic detector for light fluence profile
measurements for the optical properties or the side-firing fiber to
obtain fluorescence spectra. (c) Sample tumor section stained with
H & E to determine necrosis radius.
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3.2 Tumor Model
Radioactively induced fibrosarcoma (RIF) cells were cultured and 30 µl were injected
at 1 × 107 cells/ml in the right shoulders of 6-8 week old female C3H mice (NCI -
Frederick, Frederick, MD, USA). All animals were under the care of the University
of Pennsylvania Laboratory Animal Resources. All studies were approved by the
University of Pennsylvania Institutional Animal Care and Use committee. Tumors
were treated when they were ∼8-10 mm in diameter. The fur of the tumor region was
clipped prior to cell inoculation. After the appearance of a visible tumor (∼3 mm in
diameter), the treatment area was depilated with a topical hair remover, Nair (Church
& Dwight Co., Inc., Ewing, NJ, USA). Mice were provided with a chlorophyll-free
(alfalfa-free) rodent diet (Harlan Laboratories Inc., Indianapolis, IN, USA) starting at
least 10 days prior to treatment to eliminate the fluorescence signal from chlorophyll
breakdown products, which have a similar emission range to the BPD fluorescence
spectra (details are described in Appendix A).
3.3 Measurement of Photosensitizer Concentration
Photosensitizer concentration was determined using the characteristic fluorescence
spectra for each photosensitizer. Changes in photosensitizer concentration can be
observed by measuring the fluorescence spectra before, after, and during PDT. For
different studies, different techniques were used to obtain the fluorescence spectra.
Methods included interstitial fluorescence excited by 405 nm, surface fluorescence ob-
tained via a contact probe excited by 405 nm, and surface fluorescence obtained with
excitation by the treatment light. Obtained spectra were then analyzed by a fitting
algorithm described by Finlay et al. [42]. The spectra were fit as a linear combination
of fluorescence basis spectra using a single value decomposition (SVD) algorithm in
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Matlab. The components for a representative spectra with BPD is shown in figure
3.3. Basis spectra included those for the photosensitizer and the autofluorescence
(background) of the mouse. The algorithm employed also includes a 61-term Fourier
series to account for fluorescence of unknown origin. Spectra were corrected for CCD
integration time and background was also subtracted before analysis. SVD analy-
sis reduces the measured spectrum to a set of amplitudes of the components. To
account for variations in lamp intensity, the photosensitizer amplitude was divided
by the background amplitude from the same spectrum, to result in a normalized
BPD amplitude. Due differences in solvent between in-phantom and in vivo cases as
well as differences in absorption and scattering at both the excitation and emission
wavelengths of BPD, the measured BPD amplitude was multiplied by an empirically
determined correction factor described in the following sections.
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Figure 3.3: BPD fluorescence spectra analyzed using SVD. The raw
data (circles) are fit (solid line) using a linear combination of basis
spectra of BPD (dot-dashed line) and autofluorescence (dashed line)
components. Spectra was obtained from interstitial fluorescence ex-
cited by 405 nm light.
3.3.1 Interstitial photosensitizer measurements
Interstitial fluorescence measurements were made by inserting a side-cut fiber into
one of the two catheters that were inserted into the tumor. The side-cut fiberwas
connected to a 405 nm laser (Power Technology Inc., Little Rock, AR, USA), a
dichroic beam splitter, and a multichannel CCD spectrograph (InSpectrum, Prince-
ton Instruments, Trenton, NJ, USA). Collected spectra were analyzed using single
value decomposition (SVD) fitting [42]. Spectra were measured both before and after
treatment to investigate the effects of and relationship between photobleaching and
outcome. The in vivo photosensitizer concentration was obtained by comparing the
in vivo BPD fluorescence with that of phantoms with known BPD concentrations.
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An empirical correction factor was obtained from phantom experiments with known
constant BPD concentrations and varying absorption and scattering coefficients (µa
and µ′s). A set of experiments in tissue-simulating phantoms containing Intralipid
(Fresenius Kabi, Uppsala, Sweden) as a scatterer and Parker Quink (Parker Pen
Company, New Haven, East Sussex, England) as an absorber were designed. µa and
µ′s were varied for a fixed BPD concentration (0.25 mg/kg), and fluorescence spec-
tra were analyzed with SVD [42] to determine the spectral component magnitudes
for BPD and the autofluorescence from the 690 nm excitation laser light. The data
was then used to determine the empirical optical property correction factor for the
fluorescence method used to determine the PS concentration (Fig. 2 (a) ). A more
accurate method would involve knowledge of the optical properties at the excitation
wavelength (405 nm) as well as the emission wavelength (690 nm) [10], the former
is beyond the current fluorescence spectroscopy range. The effects of absorption and
scattering on measured fluorescence in semi-infinite media can be modeled using a
forward-adjoint fluorescence scheme proposed by Crilly et al.. [143]. This models
the forward propagation of excitation light from the source and the time reversed
propagation of positional importance from the detector. The positional importance
is defined as the probability that a photon emitted at a point is eventually caught by
a detector. The measured signal is proportional to the volume integral of the product
of the excitation fluence rate and the positional importance. An analytical solution
to this model has been derived by Finlay and Foster for the case of an isotropic point
source and an isotropic detector in an infinite homogeneous medium for the diffu-
sion approximation [10, 144]. To account for the actual measurement situation, it is
assumed that the light beam exiting or entering the probe is a pencil beam.
An empirical correction factor was introduced to account for differences in optical
properties between the phantom studies and in vivo measurements that depends on
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measured optical properties at 690 nm. Ideally, the measured optical properties could
be used as inputs for the full theoretical expression, however, the calculation would
require accurate knowledge of the optical properties at the excitation wavelength as
well as te emission wavelength, which is beyond the measurement system capabilities.
A multiplicative empirical correction factor of the following form can be determined,
which is an approximate inverse of the solution to the analytical solution described
by Finlay and Foster [144]. This is for the case of high albedo and unchanging optical
properties at the excitation wavelength.
CF = a
eb·µeff
µ′s
(3.9)
The raw SV D amplitude obtained from the in vivo fluorescence spectra was corrected
by multiplying it with CF to get corrected SV D (SV Dcorr). The values of a and b
were optimized so that SV Dcorr for phantoms with the same concentration of BPD
were matched (Fig. 3.4 (a)). Upon optimization using fminsearch in Matlab, it
was found that a = 1.2 cm−1 and b = 0.5016 cm. A separate tissue-simulating
phantom with fixed optical properties (µa = 0.7 cm
−1 and µ′s = 10.1 cm
−1) and
varying concentrations of BPD (µM) were used to determine a calibration curve for
SV Dcorr (Fig. 5.2 (b)). The correction factor for motexafin lutetium fluorescence
emission with optical properties measured using 732 nm from Finlay et al. had
values of a = 3.1 cm−1 and b = 0.97 cm [10]. The value of a is dependent on the
measurement set-up and the intensity of the incident excitation light. For the same
geometry, the value of b should not vary greatly depending on the photosensitizer and
wavelength used for optical property measurements. From these measurements, the
range of values of b is from 0.50 to 0.97 cm.
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Figure 3.4: Optical property correc-
tion of fluorescence signal for in-
terstitial measurements. (a) Flu-
orescence single value decomposi-
tion (SV D) amplitude for BPD in
tissue-simulating phantom experi-
ments with different optical prop-
erties but constant BPD concentra-
tion.An empirical correction factor
(CF ) of the form described in Eq.
(3.9) was obtained so that the cor-
rected SV Dcorr amplitudes were the
same. (b) A calibration curve of
BPD concentration (in µM) versus
SV Dcorr. (c) Interstitially measured
in vivo BPD concentration versus
ex vivo measured BPD concentra-
tion. Each data point represents
the average of three in vivo and ex
vivo measurements performed in the
same RIF tumor. The solid line rep-
resents the best linear fit (y = 0.99x)
to the data with R2 = 0.99. The
dashed line represents y = x.
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3.3.2 Surface photosensitizer measurements
Fluorescence measurements were made by a custom-made multi-fiber spectroscopic
contact probe (Fig. 6.1 (b)) described elsewhere [145]. The probe is placed in physical
contact with the tumor tissue both pre- and post-PDT to obtain fluorescence spectra
of BPD. The probe is comprised of two source optical fibers and a series of detection
fibers spaced between 0,14 and 0.88 cm away from the first source fiber. The source
fibers are connected to (i) a white light source to collect diffuse reflectance (Avalight;
Avantes, Broomfield, CO, USA) and (ii) a 405 nm laser source (Power Technologies,
Inc., Little Rock, AK, USA) for fluorescence excitation. The detection fibers were con-
nected to a multi-channel CCD spectroscopy system (InSpectrum; Roper Scientific,
Trenton, NJ). Fluorescence spectra were collected both before and after treatment
and analyzed using single value decomposition (SV D) fitting to obtain fluorescence
intensity due to BPD. An empirical optical property correction factor (CF ) that is
different than that of the interstitial geometry used in section 3.3.1 was determined.
CF was defined as the ratio of SV D between fluorescence with tissue optical proper-
ties of interest (µa, µ
′
s) and the corresponding fluorescence SVD for a reference system
with optical properties of µa = 0.69 cm
−1 and µ′s = 11 cm
−1, with BPD as the pho-
tosensitizer and optical properties measured at 690 nm. A multiplicative CF of the
following form was used to multiply raw SV D to obtain corrected SV D (SV Dcorr):
CF =
C1(1 + C2µ
′
s)
µ′s
· exp [(b1 + b2µ′s)µeff ] (3.10)
The input optical properties are those measured at 690 nm. This formulation for the
correction factor is an expansion of the expression in equation (3.9). Raw SV D was
multiplied by CF to get SV Dcorr. The values were optimized so that SV Dcorr for
phantoms with the same concentration of BPD were matched (Fig. 3.5 (a)). Upon
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optimization, it was found that C1 = 0.41 ± 0.16 cm−1, C2 = 0.142 ± 0.013 cm,
b1 = 0.85 ± 0.16 cm, and b2 = −0.032 ± 0.014 cm2. A separate tissue-simulating
phantom with constant scattering and absorption and varying amounts of BPD were
used as a calibration curve to correlate SV Dcorr to actual concentration in µM (Fig.
3.5 (b)). The line of best fit (shown as a solid line in Fig. 3.5 (b)) is [BPD] =
(0.0301±0.0009)×SV Dcorr is used to convert SV Dcorr to [BPD] in units of µM. The
values for CF for Photofrin studies were found to be C1 = 3.881 cm
−1, C2 = 0.00265
cm, b1 = 0.5043 cm, and b2 = −0.01622 cm2 [146]. Using a Monte Carlo simulation
for a tissue-air interface, the resulting values were C1 = 2.4258 cm
−1, C2 = −0.0033
cm, b1 = 0.4879 cm, and b2 = −0.01559 cm2. The values of C1 and C2 are dependent
on the measurement set-up and the intensity of the excitation light. The values for
b1 and b2 provide the range for the fit parameters for CF .
Fluorescence spectra were also obtained via surface illumination of tumors with the
treatment light at 690 nm. A bare fiber was placed next to the collimated beam source
facing the tumor. Between the fiber and the spectrometer, a long-pass filter (FF01-
715/LP-25, Semrock Inc., Rochester, NY, USA) was used eliminate the treatment
light. An example of spectra obtained using this method is shown in Fig. 3.6.
Intensity from the fluorescence signal obtained using this method was used to do
continuous monitoring of photosensitizer concentration during treatment for a set of
mice described in chapter 6. Initial photosensitizer concentration was measured using
contact probe methods described earlier.
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Figure 3.5: Optical property correction of
fluorescence signal for surface fluorescence
measurements. Fluorescence optical prop-
erty correction phantoms and verification
with in vivo and ex vivo comparison. (a)
Fluorescence SV D amplitude for phantom
experiments with varying optical proper-
ties and the same BPD concentration (0.25
mg/kg). The best-fit (shown as dashed
lines) is of the form a/CF , where CF
is given by Eq. (3.10) and a = 7.645.
(Note, CF = 1 is normalized for mean op-
tical properties of µa = 0.69 cm
−1, µ′s =
11 cm−1) (b) BPD concentration (in µM)
versus the corrected SV D (SV Dcorr). The
line of best fit [BPD] = (0.0301±0.0009)×
SV Dcorr with R
2 = 0.9986 is used to con-
vert SV Dcorr to [BPD]. (c) The measured
in vivo photosensitizer concentration using
the multi-fiber contact probe obtained flu-
orescence spectra versus ex vivo measured
BPD concentration. The line of best fit is
of the form y = 0.9821x with R2 = 0.9772.
The dashed line represents the line for
y = x.
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Figure 3.6: BPD fluorescence spectra collected with exci-
tation by the treatment light (690 nm). A long-pass filter
(cutoff at 715 nm) was used to eliminate the treatment light
signal.
3.3.3 Verification of in vivo BPD concentration
In order to verify the in vivo photosensitizer concentration measured using fluores-
cence spectroscopy, ex vivo experiments were performed on another set of tumors on
mice injected with BPD. Measurements of BPD levels in tissue were done based on
published ex vivo procedures [147–149]. After the correct incubation time (3 hours
for BPD), tumor tissue samples were excised and immediately frozen for later use.
At the time of measurement, samples were thawed to room temperature, weighed,
minced, and placed in a vial with the appropriate amount of tissue solubilizer, Solv-
able (Packard, Meriden, CT, USA). The samples were then heated at 50 ◦C in the
dark for 4 hours. After the solution was cooled, an equal volume of water was added,
and with thorough mixing, the solution was transferred to a cuvette to be measured.
The fluorescence of the solubilized samples was measured using a spectrofluorometer
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(FluoroMax-3, Jobin Yvon, Inc., Edison, NJ, USA) with an excitation wavelength of
435 nm. The concentration of BPD was calculated based on the increase in fluores-
cence signal resulting from the addition of a known amount of BPD to each sample
after its initial reading. The ex vivo measurements were compared to in vivo measure-
ments using the method described in section 3.3.1 and 3.3.2 for the same tumors (Fig.
3.2 (c) and 3.4 (c)). The good agreement between the two confirmed the accuracy of
the interstitial method used in vivo both pre- and post-PDT.
3.4 Treatment Delivery
Mice were administered with photosensitizer via the tail vein prior to treatment with
the appropriate drug-light interval (DLI) for the photosensitizer being used. For the
treatment, mice were anesthetized by inhalation of isoflurane in medical air (VetEquip
anesthesia machine, VetEquip, Livermore, CA, USA). For some studies, treatment
light was delivered interstitially with a fiber optic through a catheter inserted into
the tumor (see Fig. 3.2). Mice treated with this method of light delivery were
sacrificed one day following treatment, and the tumors were resected for pathology
and sectioning, as described in chapter 5. For those mice whose tumors needed to
be monitored over time (chapter 6), the catheters were not a viable option to deliver
light, as they would create damage to the surface of the skin, leaving the mouse prone
to infections and other tumor injury. These mice were treated with a broad beam of
light on the surface of the tumor to minimize non-PDT-related damage.
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3.5 Macroscopic Singlet Oxygen Model in vivo
The typical type II PDT process can be described by a set of kinetic equations,
described in detail in chapter 2. For the in vivo modeling scenario, an assumption is
made that the number of singlet oxygen acceptors present in the tissue is very large,
resulting in a large k72[A] term (k72[A]  k6 + k12([S0] + δ) + k9[Q]) and assuming
η = 0. Then, the relevant equations are simplified as the following:
d[S0]
dt
= − [
3O2]
[3O2] + β
ξσ([S0] + δ)φ[S0], (3.11)
d[3O2]
dt
= − [
3O2]
[3O2] + β
ξφ[S0]([S0] + δ) + g
(
1− [
3O2]
[3O2](t = 0)
)
, (3.12)
d[1O2]rx
dt
=
[3O2]
[3O2] + β
ξφ[S0], (3.13)
where the photosensitizer-specific parameters were determined for BPD in chapter
5 and validated in chapter 6. If the parameters are 10% over- or underestimated,
calculated [1O2]rx will deviate up to 12%. An increased σ estimates a smaller [
1O2]rx,
while an increased g or ξ estimates larger [1O2]rx.
The accumulated [1O2]rx that is used to kill cellular targets can be expressed as
[1O2]rx = −f
∫ t
0
d[A]
dt
dt = fk7
∫ t
0
[A][1O2]dt = fξ
∫ t
0
[3O2]
[3O2] + β
φ[S0]dt (3.14)
where f is the fraction of 1O2 interacting with [A] that effectively leads to tumor cell
death. For the pre-clinical studies done in this work, f has been set as 1.
For in vivo modeling, calculations were performed in Matlab with input values of
treatment conditions (fluence and fluence rate), the measured initial photosensitizer
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concentration, and depending on the study, the initial ground state oxygen concen-
tration. Results of these calculations are shown in detail in chapters 5 and 6 using a
mouse model.
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Chapter 4
Determination of In-Phantom
Photochemical Parameters
Most clinically relevant photosensitizers undergo type II processes in which the triplet
state transfers energy to ground-state oxygen to produce singlet oxygen [150], which is
the main photocytotoxic agent leading to cell death and therapeutic response [91,151].
Use of singlet oxygen concentration was investigated in this study. Direct measure-
ment of 1O2 by its near-infrared luminescence emission is technically challenging
in vivo due to the weakness of the signal and the short lifetime (∼30-180 ns) of
1O2 [50, 51]. Hence, a macroscopic singlet oxygen explicit dosimetry model has been
developed and studied in vivo and described in sections 3, 5, and 6. SOED was
compared in solutions to direct singlet oxygen luminescence dosimetry (SOLD). The
relevant photophysical parameters for the macroscopic model were verified by per-
forming explicit dosimetry of oxygen concentration and photosensitizer concentration
in phantoms. In performing a direct comparison between SOED- and SOLD-measured
1O2, the use of SOED in scenarios where direct luminescence detection is difficult is
validated. Furthermore, an analysis was performed to show that SOLD measured
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using a 523 nm pulsed laser (currently required by the availability of lasers with
suitable pulse length, repetition frequency, and energy) is well-correlated to singlet
oxygen generated by Photofrin by a CW 630 nm laser during PDT, by correcting for
the tissue optical properties at the two wavelengths.
4.1 Materials and Methods
4.1.1 SOED model in phantoms
From the kinetic equations summarized in section 2.1.4, the interactions of [3O2] and
[S0] in the phantom scenario where there is no added singlet oxygen quencher can be
described by the following equations
d[S0]
dt
= − (ξσ) [
3O2]
[3O2] + β
([S0] + δ)φ[S0]− η 1
[3O2] + β
φ[S0], (4.1)
d[3O2]
dt
= [−ξ + ξIIτ∆k6] [
3O2]
[3O2] + β
φ[S0] (4.2)
The definitions of the parameters are listed in table 2.2. ξ, σ, and δ were varied to
fit the measured ground state oxygen data. From the equation set and the measured
data, it is difficult to distinguish between type I and type II interactions, so only values
of ξ and σ were considered. The values of the parameters used for the calculation are
summarized in table 2.4 and described in section 4.2.2. For the in-phantom scenario
using Intralipid, the k72[A] term was calculated based on an assumed value of τ∆ using
τ−1∆ = k1([S0]+δ)+k6 +k72[A]. Without the addition of a quencher, the k9[Q] term is
set to 0. Here, the definition of σ is (σIξI +σIIξII)/ξ. Measured ground state oxygen
concentration and photosensitizer concentration were fit assuming no contributions
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from hypoxic interactions between the triplet state photosensitizer and the reactive
species acceptor, [A] in the solid lines in Fig. 4.2 and 4.3, for Photofrin and Rose
Bengal. The results show good agreement between measured data and calculated
values. The dashed line shows the best fit to the photosensitizer data including the η
term in Eq. (4.1). A dominant η term was used to fit the data, and then values of σ
and ξ were fit accordingly. Resulting values of ξ exceeded the acceptable calculated
range using the equation ξ = Φ∆ε/hν (where Φ∆ ≤ 1). Furthermore, in phantoms,
τ∆k6  1, so it is difficult to differentiate between type I and type II reactions.
Thus, for the photosensitizers investigated in-phantoms, hypoxic interactions should
be considered negligible since it cannot be made to fit the measured data.
τ∆ was taken to be 0.5 µs in studies with Intralipid, as the lipid emulsion acts as
an acceptor for reactions with singlet oxygen [152]. It is seen that the singlet oxygen
lifetime is reduced from the typical in-phantom value (3 µs) with the addition of
Intralipid, as seen in Fig. 4.1 [85]. Singlet oxygen luminescence counts were not seen
for phantoms with Intralipid concentrations of 0.2% in that study. For modeling of
the in-phantom studies presented in section 4.2.2, this reduction of τ∆ was considered
with a lifetime value that was undetectable from previous studies.
Chapter 4 Michele M. Kim 64
Figure 4.1: Singlet oxygen luminescence photon counts for
Rose Bengal (51 µM) phantoms with various amounts of In-
tralipid. With increasing amounts of Intralipid, the photon
counts obtained decreases, indicating a shorter singlet oxy-
gen lifetime (τ∆). Data with Intralipid 0% is fit with Eq.
(4.10).
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Figure 4.2: Measured (a) oxygen and (b) photosensitizer concentration data
is plotted with model calculations that include hypoxic interactions (η term
in Eq. 4.1). The symbols represent measured data at various concentrations
of Photofrin, and the lines show the calculated oxygen and photosensitizer
concentrations over a time of illumination. The solid lines shows the best
fit, and the dashed line shows the best fit for photosensitizer that includes
hypoxic interactions.
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Figure 4.3: Measured (a) oxygen and (b) photosensitizer concentration data
is plotted with model calculations that include hypoxic interactions (η term in
Eq. 4.1). The symbols represent measured data at various concentrations of
Rose Bengal, and the lines show the calculated oxygen and photosensitizer
concentrations over a time of illumination. The solid lines shows the best
fit, and the dashed line shows the best fit for photosensitizer that includes
hypoxic interactions.
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Assuming type II interactions, equation (4.1) can be rewritten as the following:
− d[S0]
dt
/(
φ[S0]
[3O2]
[3O2] + β
)
= ξσ([S0] + δ) (4.3)
The left-hand side of equation (4.3) versus [S0](t) gives the values of δ and σ. The
photobleaching rate (−d[S0]/dt) was determined at each time point with values of φ,
[3O2], [S0], and β for the calculation of the left-hand side of equation (4.3). A linear
fit to the data yields a value for the intercept and slope, and the intercept divided
by the slope gives the value of δ and the slope divided by ξ gives the value of σ.
Calculations were performed using Matlab 2014b (MathWorks, Natick, MA, USA).
Oxygen and photosensitizer measurements were performed and compared (Figs.
4.6 and 4.7) with model calculated values using the coupled differential equations
above in phantoms with a small amount of Intralipid (0.02% concentration).
To compare explicit dosimetry with direct dosimetry, instantaneous and cumu-
lative singlet oxygen concentration was calculated. Equation (2.23) can be written
as
[1O2] = ξτ∆
[3O2]
[3O2] + β
φ[S0]. (4.4)
The cumulative reacted singlet oxygen counts can be calculated from the integral of
Eq. (2.29)
[1O2]rx =
∫
ξ
[3O2]
[3O2] + β
φ[S0]dt. (4.5)
Comparisons where performed in phantom solutions with only the photosensitizer
and a solvent (MeOH or H2O), and the relevant parameters are summarized in table
2.4.
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Macroscopic model with oxygen quenching
In the biological scenario, 3O2 that is used to produce
2O2 is consumed and replen-
ished by blood flow (described by the g term). In experiments with a singlet oxygen
quencher, such as sodium azide (NaN3), singlet oxygen is not consumed rapidly and
returns to the lower energy state of ground state oxygen. Equation (2.12) and (2.16)
can be modified as follows:
d[S0]
dt
= −k0[S0]− k12[1O2]([S0] + δ)− k11[O –·2 ]([S0] + δ) + k2[T1][3O2] + k3[S1] + k4[T1]
(4.6)
d[3O2]
dt
= −S∆k2[T1][3O2]− SIk2[T1][3O2] + k6[1O2] + k9[Q][1O2] + Γ (4.7)
where k9 is the bimolecular rate of reaction of 1O2 with a quencher, [Q], and Γ is
the oxygen supply rate which describes diffusion of oxygen in vivo. In the phantom
scenario, [A] = 0 and Γ = 0. These can be simplified as before, solving for the
equilibrium state, to become
d[S0]
dt
= − (ξIIσII + ξIσI) [
3O2]
[3O2] + β
([S0] + δ)φ[S0]− η 1
[3O2] + β
φ[S0], (4.8)
d[3O2]
dt
= [− (ξII + ξI) + ξIIτ∆(k6 + k9[Q])] [
3O2]
[3O2] + β
φ[S0] (4.9)
Values of each photochemical parameter used is summarized in table 2.4. Some
parameters were taken as the reported literature value, such as k1. The value for
ξ was calculated for the in-phantom scenario and is described in table 2.4. Using
methods described later in section 4.2.1 and Fig. 4.5, the values for k6 and k9[Q] were
determined using singlet oxygen luminescence and lifetime measurements. Phantoms
with various concentrations of Photofrin and Rose Bengal with added amounts of
Chapter 4 Michele M. Kim 69
NaN3 were made and illuminated with a broad beam. Oxygen changes were monitored
over time, and the measured values were compared (Fig. 4.5) to the modeled values
using eqs. (4.8) and (4.9) for both Photofrin and Rose Bengal.
4.1.2 SOLD instrumentation
Singlet oxygen luminescence dosimetry (SOLD) was performed using a compact, fiber
optic near-infrared probe-based system [85,153]. The probe was coupled to a compact
InCaAs/InP single photon avalanche diode (SPAD) detector (Micro Photon Devices,
Bolzano, Italy). Samples were illuminated with a 523 nm wavelength pulsed laser
(QL-523-200-S, CrystaLaser, Reno, NV, USA) coupled into the delivery fiber via
a collimation package. The laser emits 10 ns duration pulses at a repetition rate
of 18.2 kHz with an average power of 200 mW. Patterned time gating was used to
limit the unwanted dark counts and eliminate the strong photosensitizer luminescence
background. The luminescence signal from singlet oxygen at 1270 nm was confirmed
through spectral filtering and lifetime fitting for Photofrin.
Figure 4.4 shows a photograph and schematic of the experimental setup. The
pulsed laser was coupled into the delivery fiber. The laser also outputs an electri-
cal signal that is sent to a programmable pulse pattern generator (PPG) (Agilent
81110A, Keysight Technologies, Inc., Santa Rosa, CA, USA). Each pulse generates
outputs on two separate channels, each with pulse shape designed to match the in-
tended input. The first output is a single pulse sent to the start channel of the time-
correlated single-photon counting (TCSPC) module (HydraHarp, PicoQuant GmbH,
Berlin, Germany), while the second is a pattern of pulses sent to the SPAD control
module. The SPAD is turned on for a preassigned time, only when the control mod-
ule receives a pulse from the PPG. The electrical signal from the laser to the PPG
triggers the release of two signals: one acts as the start signal for the photon counting
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module and the other triggers the SPAD gating.
Figure 4.4: Singlet oxygen luminescence dosimetry (SOLD) instru-
mentation set-up (a) on an optical bench; and (b) schematic diagram
of the experimental arrangement. PPG - pulse pattern generator;
SPAD - single photon avalanche diode; TCSPC - time-correlated
single-photon counting
The TCSPC module generates a timing histogram of photon counts versus time.
The background was removed by subtracting the histogram taken through a 1210 nm
filter from that through the 1270 nm filter. Equation (4.10) describes the [1O2] signal
as a function of time following a short illumination pulse.
[1O2](t) = NσA[S0]Φ∆
τ∆
τt − τ∆
(
e−t/τt − e−t/τ∆) (4.10)
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The cumulative SOLD singlet oxygen count can be calculated as the integral of equa-
tion (4.10) per τR [154].
∫ ∞
0
1
τR
[1O2](t)dt =
NσA[S0]Φ∆τ∆
τR
(4.11)
where N is the number of photons in the illumination pulse, σA is the photosensitizer
absorption cross-section (σA = (ε/NA) × 109), NA is Avogadro’s constant (6.022 ×
1023), ε is the extinction coefficient, and τR is the
1O2 phosphorescence lifetime (k
−1
6 ).
A fit of the background-subtracted histograms was performed to equation (4.10) (with
a y-axis offset as a free parameter to account for any change in the background level)
using Origin software with a Levenberg-Marquardt algorithm to iterate the parameter
values (see Fig. 4.1) [130].
4.1.3 Measurements in tissue-simulating phantoms
Explicit dosimetry of phantom studies was performed using tissue-simulating liquid
phantoms. Intralipid (Fresenius Kabi, Uppsala, Sweden) was added to solutions as
a scatterer. A broad beam was produced by a fiber with a microlens attachment
(Pioneer Optics Company, Bloomfield, CT, USA) onto cuvette phantoms. Oxygen
measurements were made with a bare-fiber OxyLite probe (Oxford Optronix, Oxford,
United Kingdom) on the side closest to beam entry in the middle of the beam field. In
the in vitro set-up, there is very little oxygen diffusion to the point of measurement.
Therefore, oxygen measurements were performed with interruption of the excitation
laser at 1-30 second intervals. Illumination light was briefly turned off during these
measurements, and multiple values were recorded for a single phantom. Oxygen
partial pressure was measured in mmHg and converted to µM by using a factor of α
= 1.3 [48,117].
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4.2 Results
4.2.1 SOED photophysical parameters
Photophysical parameter values for Photofrin were determined for in vitro macro-
scopic modeling from the literature as well as measurements to be used in the calcu-
lation of [1O2]rx. The values of the parameters are summarized in table 2.4.
Singlet oxygen lifetime was determined using the SOLD instrumentation for the
Photofrin and Rose Bengal phantoms and summarized in table 4.1. Lifetimes were
also determined for phantoms with varying concentrations of NaN3. Figure 4.5 shows
the plot of τ−1∆ versus concentration of NaN3 with their best linear fits for (a) Photofrin
(83 µM) and (b) Rose Bengal (50 µM). As NaN3 is a singlet oxygen quencher, the
line of best fit describes k9[Q] + k6 rather than k7[A].
Table 4.1: Measured singlet oxygen and photosensitizer
triplet state lifetimes (in µs) from fits to Eq. (4.10) for
Photofrin in methanol and Rose Bengal in water [85]
Photofrin Rose Bengal
in methanol in water
Triplet state lifetime, τt (µs) 0.43±0.03 2.1±0.2
Singlet oxygen lifetime, τ∆ (µs) 9.4±0.2 3.8±0.3
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Figure 4.5: Singlet oxygen lifetime (τ∆) changes due to quench-
ing with various concentration of sodium azide (NaN3) for (a)
Photofrin (83 µM) in MeOH and (b) Rose Bengal (50 µM) in
water. τ−1∆ = k12([S0] + δ) + k6 + k9[Q]. Symbols represent
measured data and the solid line is the best linear fit
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From this study, it was found that the value of k9[Q] for a NaN3 concentration of 5
mM is 1.17 × 106 s−1 for Photofrin and 1.15 × 105 s−1 for Rose Bengal. This value
is dependent on the concentration and efficiency of the singlet oxygen quencher that
is being investigated. For the purposes of in vivo modeling, it is assumed that any
singlet oxygen produced is biologically consumed in the process of cell destruction,
so there is no quenching effect. The value of k12([S0] + δ) + k6 was found to be
1.1× 105 s−1 for Photofrin and 2.7× 105 s−1 for Rose Bengal. Using the values of k12
and δ provided in table 2.4 along with the concentration of photosensitizer used (83
µM and 50 µM for Photofrin and Rose Bengal, respectively), the value of k6 can be
calculated by using k6 = intercept− k12([S0] + δ). For Photofrin, k6 = 3.8× 104 s−1
in methanol and for Rose Bengal, k6 = 2.7 × 105 s−1 in water. Using Photofrin in
Intralipid phantoms (see Fig. 4.1), the value of τ∆ was found to be 3.4 µs, resulting
in a calculated value of k6 = 2.2× 105 s−1.
4.2.2 SOED in phantom
Photofrin phantoms with Intralipid as optical scatterer and absorption due to both the
photosensitizer and water (or Intralipid) were used to measure the time dependence
of [3O2] and photosensitizer concentration, [S0], under CW 630 nm laser excitation.
[3O2](t) was measured using an oxygen phosphorescence probe and the photophysical
parameters summarized in table 2.4.
Figure 4.6a and b show the measured [3O2] and [S0] at just below the surface
(d = 0) versus time in an Intralipid phantom (with µ′s = 0.2 cm
−1) for three different
initial Photofrin concentrations (27, 50, 167 mM). The symbols are measured values
and the lines are SOED-calculated results. Figure 4.6c shows the photosensitizer pho-
tobleaching rate per PDT dose, −d[S0]
dt
1
[S0]φ[3O2]/([3O2]+β)
versus [S0]. The symbols are
calculated values using equation (4.3), and the line is the best linear fit. Figure 4.6d
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shows the expected SOED-calculated cumulative reacted singlet oxygen concentra-
tion, [1O2]rx, during illumination. The same is shown for Rose Bengal concentrations
of 16, 50, and 100 µM in Fig. 4.7.
In Fig. 4.6c and 4.7c, the linear fit to the data plotting −d[S0]
dt
1
[S0]φ[3O2]/([3O2]+β)
versus [S0] is shown as a red dashed line. The values found for the slope (m) and
intercept (b) can be used to calculate values of δ and σ. If the linear fit is given as
y = mx + b, then δ = b/m and σ = m/ξ. The value of ξ used for these phantom
studies is calculated using known values of extinction coefficient, Planck’s constant,
wavelength of interest, and the singlet oxygen quantum yield from literature. This is
described further in chapter 3 and, in particular, table 2.4. For Photofrin, the linear fit
shown in Fig. 4.6c has a slope of (6.9±0.5)×10−6 and an intercept of (1.8±0.3)×10−5,
resulting in calculated values of δ = 26±5 µM and σ = (6.6±5)×10−5 µM−1. For the
case of Rose Bengal, the linear fit shown in Fig. 4.7c has a slope of (1.6± 0.2)× 10−6
and an intercept of (3.9± 1.4)× 10−5, resulting in calculated values of δ = 25± 9 µM
and σ = (8.1± 1.2)× 10−6 µM−1.
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Figure 4.6: Comparison of measured and singlet oxygen explicit dosimetry
(SOED)-calculated values of (a) [3O2](t) and (b) [S0](t) at d = 0 for three initial
photosensitizer concentrations, [S0]0 = 27, 50, 167 µM. Measurements of ground-
state oxygen were made at 5-30 s intervals while photosensitizer spectra were
obtained every 10 s. The average initial [3O2]0 value was 160.4 µM. (c) The left-
hand side of equation (4.3) versus the Photofrin concentration, with the line of
best fit. (d) Calculated volume-averaged [1O2]rx over time. Eqs. (4.1) and (4.2)
were used for this set of data.
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Figure 4.7: Comparison of measured and singlet oxygen explicit dosimetry
(SOED)-calculated values of (a) [3O2](t) and (b) [S0](t) at d = 0 for three initial
photosensitizer concentrations, [S0]0 = 16, 50, 100 µM. Measurements of ground-
state oxygen were made at 5-30 s intervals while photosensitizer spectra were
obtained every 10 s. The average initial [3O2]0 value was 164.2 µM. (c) The left-
hand side of equation (4.3) versus the Rose Bengal concentration, with the line of
best fit. (d) Calculated volume-averaged [1O2]rx over time. Eqs. (4.1) and (4.2)
were used for this set of data.
In phantoms with NaN3, changes in [
3O2] were measured using the Oxylite phos-
phorescence based oxygen probe. Figure 4.8 shows a plot of measured [3O2]/[
3
O
2
]0 in
symbols for different concentrations of Photofrin and Rose Bengal. Solid lines show
the calculated changes in ground state oxygen using the modified equations to ac-
count for singlet oxygen quenching (eqs. (4.8) and (4.9)). A broad beam was used
to illuminate a cuvette with a fluence rate of 820 mW/cm2 at the surface. It is seen
that changes in oxygen are not as dramatic as those shown in Fig. 4.6 and 4.7 since
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the NaN3 quenching of singlet oxygen produced ground state oxygen.
Figure 4.8: Ground state oxygen relative to the initial
oxygen ([3O2]0) was measured (symbols)for phantoms
with NaN3 and photosensitizers (a) Photofrin (83, 333,
and 500 µM) and (b) Rose Bengal (16, 50, and 100
µM). Calculations are shown in solid lines. Eqs. (4.6)
and (4.7) were used for this set of data.
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4.2.3 SOED/SOLD comparison in solution
The singlet oxygen generated in Photofrin-containing solutions and Rose Bengal-
containing solutions was calculated using SOED and the results were compared to
SOLD-determined luminescence counts of 1O2. The latter was correlated with the
amount of 1O2 produced instantaneously and cumulatively. Instantaneous [
1O2] ac-
counts for the singlet oxygen generated for each pulse of laser excitation, while cumula-
tive [1O2]rx is the integral of all singlet oxygen produced during the entire illumination
time over the entire illumination volume. The agreement between the two methods
(SOED and SOLD) is shown in figure 4.9: (a) shows SOLD counts per accumulation
time (in seconds, t = 300 s before and after PDT) and (b) shows cumulative SOLD
counts over the entire treatment time of 900 s. Photofrin was dissolved in MeOH
solution and Rose Bengal was dissolved in water [130].
Figure 4.9: (a) Comparison of SOLD-obtained 1O2 counts (equation (4.10))
per accumulation time (in seconds) at 523 nm and SOED-calculated instanta-
neous [1O2] (equation (4.4)) for Photofrin concentrations in MeOH of 17, 50,
and 83 µM, and light fluence φ0 = 30 mW/cm
2. The initial oxygen concentra-
tion was measured as 175 ± 6 µM. (b) Comparison of SOLD cumulative 1O2
counts (equation (4.11)) and reacted singlet oxygen concentration ([1O2]rx)
calculated with SOED (equation (4.5)) for Photofrin concentration of 17, 50,
and 83 µM. PDT was performed with 523 nm light at φ0 = 30 mW/cm
2 for
900 s.
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Figure 4.10: (a) Comparison of SOLD-obtained 1O2 counts (equation (4.10))
per accumulation time (in seconds) at 523 nm and SOED-calculated instan-
taneous [1O2] (equation (4.4)) for Rose Bengal concentrations in water of
9.8, 19.7, 29.5, 39.3, and 49.1 µM, and light fluence φ0 = 30 mW/cm
2. The
initial oxygen concentration was measured as 178 ± 3 µM. (b) Comparison
of SOLD cumulative 1O2 counts (equation (4.11)) and reacted singlet oxygen
concentration ([1O2]rx) calculated with SOED (equation (4.5)) for Rose Ben-
gal concentrations of 9.8, 19.7, 29.5, 39.3, and 49.1 µM. PDT was performed
with 523 nm light at φ0 = 30 mW/cm
2 for 900 s.
4.3 Discussion
4.3.1 SOED and SOLD intercomparison
The SOED calculated [1O2] value in solution in Figure 4.8a corresponds to the vol-
umetric averaged instantaneous singlet oxygen concentration over a volume of 1 cm
depth and 1 cm2 area. SOED-calculated [1O2]rx in Figure 4.9b corresponded to the
volumetric average reacted singlet oxygen concentration of the same 1 cm3 volume.
In these solutions, the light fluence was calculated by introducing only the attenua-
tion that is due to the photosensitizer absorption, since no scatterer was added and
solutions were of pure Photofrin: φ = φ0 · e−µa×d, where φ0 is the light fluence rate
(mW/cm2) measured directly on the back of the front wall of the solution facing
the laser. Absorption coefficients (µa) were 0.15, 0.45, and 0.74 cm
−1 for Photofrin
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concentrations of 17, 50, and 83 µM, respectively, at 523 nm.
In order to experimentally determine the photophysical parameters of the spon-
taneous phosphorescence rate of 1O2 to
3O2 (k6) and the bimolecular reaction rate of
1O2 with the substrate (k7) in Photofrin phantoms, photosensitizer triplet-state and
singlet oxygen lifetime measurements were obtained using the SOLD system. Vary-
ing amounts of the singlet oxygen quencher, sodium azide (NaN3), were added to the
PhotofrinMeOH solutions. The resulting fits to obtain k6 and k7 are shown in Figure
4.5. For Photofrin with NaN3, k6 was found to be 1.14× 105s−1 (the intercept of the
line of best fit in Figure 4.5) and k7 was found to be 235 µM
−1s−1 (the slope of the
line of best fit in Figure 4.5). k7 is pH-dependent, but is in the range of the reported
value of 300400 µM−1s−1 for the quenching rate constant in water [155]. These values
were used to calculate τ∆ for the in vitro condition (without NaN3) and the in vivo
condition (taken from the literature for biological tissue [125]). Assuming that k7
for NaN3 is greater than or equal to that of in vivo conditions (assuming biological
tissue is less efficient than NaN3 in quenching
1O2), it can be estimated that in vivo
acceptor concentration [A] ≥ 107 (s−1)/235 mM−1s−1 = 42 mM. This value is much
higher than [A] = 0.83 mM in the literature [28], but we feel that it is more reason-
able since the singlet oxygen lifetime in vivo, τ∆, does not change for reacted singlet
oxygen concentrations [1O2]rx as high as 12 mM [27], indicating there are still plenty
of acceptors in vivo at this level.
The light fluence rate distribution in a semi-infinite medium as a function of
distance (d) was calculated by a Monte Carlo (MC) simulation [156] of a circular
parallel beam (diameter 0.8 cm, Figure 4.9a) and broad beam (diameter 16 cm,
Figure 4.11b) for absorption coefficient (µa) of 0.09, 0.18, and 0.58 cm
−1, and reduced
scattering coefficient (µ′s) of 0.2 cm
−1. The resulting φ/φ0 is shown in Figure 4.11
along with an exponential fit based on µa. For the tissue-simulating phantoms with
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Photofrin shown in Figure 4.6, φ0 is the measured local fluence rate at the front inner
surface of the phantom facing the laser and d is the depth from surface. At 630 nm,
µa = 0.09, 0.18, and 0.58 cm
−1 for Photofrin concentrations of 27, 50, and 167 mM,
respectively. It is clear that the function e−µa·d, while working well for the broad
beam, does not work very well for the 0.8 cm diameter beam at the deepest depths
investigated. As a result, MC-generated light fluence rate φ/φ0 was used directly for
the SOED calculations in phantom.
Figure 4.11: Monte Carlo (MC) simulation of fluence rate distribution by a
circular beam of radius (a) 0.4 cm and (b) 8 cm incident on a semi-infinite
liquid surface as a function of depth (d) for µa = 0.09, 0.18, and 0.58 cm
−1
and µ′s = 0.2 cm
−1. Fits of exponential forms are shown along with the MC
data. The exponential form of e−µa·d fits the simulation well up to a depth of
0.4 cm, while overestimating φ/φ0 at larger depths. Broad-beam simulations
agree with the simple exponential form up to a depth of 1.3 cm.
SOED calculations of singlet oxygen concentration are highly dependent on the
photophysical parameters used as input (table 2.4). In turn, these parameters depend
on the photosensitizer used, as well as the treatment environment. The necessary pa-
rameters for Photofrin-mediated PDT for in vitro studies were validated with explicit
measurements of the [3O2] and [S0]. In particular, the consumption rate of [S0] per
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PDT dose was used to determine a more accurate value of σ (slope/ξ) and δ (in-
tercept/slope) for the experimental setup used (Fig. 4.6 and 4.7 and Eq. (4.3)).
This was used to determine δ and σ using a method from reference [45] that is also
described in section 4.1.1. Photosensitizer concentration was measured over time
to determine the photobleaching rate (−d[S0]/dt) and [S0]. Along with the measured
[3O2], the photosensitizer photobleaching rate per PDT dose can be calculated and
plotted as in Fig. 4.6c. The slope and intercept were used to determine the values
δ = 26 ± 5µM and σ = (6.8 ± 5) × 10−5µM−1. The value of β was set to be 11.9
µM for this set of experiments [125]. Figure 4.6a and b show the SOED calculations
using equations (4.1) and (4.2), which agree with [S0](t) and [
3O2](t) measurements
at the surface (d = 0 cm) of the Intralipid phantom. Figures 4.6d and 4.7d show the
magnitude of SOED-calculated [1O2]rx for Photofrin and Rose Bengal to be in the
sub mM range.
It can be concluded from the intercomparison of SOED and SOLD in Photofrin
solutions (figure 4.9b) that the cumulative SOLD [1O2] counts, [SOLD], and SOED-
calculated [1O2]rx values track each other very well (R
2 = 0.98) for Photofrin, with a
conversion factor of the following form:
[1O2]rx(mM) =
(
2.16× 10−5)× [SOLD]− 11.8 (4.12)
The ratio of slopes between the two panels ((a) and (b)) in Fig. 4.9 is 9.6× 10−6
s, which is consistent with the value of τ∆ obtained (9.4 × 10−6 s). The reason
for the intercept is not known, and a linear fit without the intercept reduces the
correlation (R2 = 0.86). The good correlation of SOED-calculated [1O2] and [SOLD]
demonstrates that SOED can be utilized in scenarios where direct phosphorescence
measurement of 1O2 is difficult.
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4.3.2 Feasibility of using SOLD at 523 nm for predicting
[1O2]rx at 630 nm
Currently, the only available pulsed laser suitable for the SOLD application is at
523 nm (CrystaLaser, QL-523-200-S, CrystaLaser, Reno, NV, USA). As a result,
the effective tissue-sampling depth for [1O2] is not the same as that of the 630 nm
treatment light used clinically with Photofrin. Figure 4.12 shows the measured values
of µa and µ
′
s at various sites measured in vivo in patients, including the anterior chest
wall, apex of the heart (apex), posterior chest wall, diaphragm (diaph), serratus (ser),
anterior sulcus, posterior sulcus, pericardium (peri), and normal tissue (norm). This
data is from patients undergoing an institutional review board (IRB)-approved clinical
trial at the University of Pennsylvania. Details of which are included in chapter 7
Figure 4.12: Tissue (a) µa and (b) µ
′
s at 523 nm (hollow symbols) and 630
nm (filled symbols) measured in vivo in patients pleural cavities undergo-
ing radical pleurectomy and PDT for the treatment of malignant pleural
mesothelioma
Using an analytical fit [157] to MC simulations [158–161], the longitudinal dis-
tribution of φ in tissue with different optical properties was calculated. Figure 4.13
shows the ratio of φ and in-air fluence rate (φair) versus tumor depth for (a) 523 nm
and (b) 630 nm. The grey area shows the region of φ/φair with the upper and lower
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bounds of the tissue optical properties obtained in vivo as dark blue and light blue,
respectively. The dashed black lines show the calculated light fluence distribution
using the mean optical properties of µa = 5.52 cm
−1 and µ′s = 17.61 cm
−1 for 523
nm and µa = 0.58 cm
−1 and µ′s = 15.61 cm
−1 for 630 nm. As expected, the optical
penetration is much deeper with 630 nm than with 523 nm in vivo.
Figure 4.13: The ratio of φ and in-air fluence (φair) versus tumor depth for
(a) 523 nm and (b) 630 nm optically broad laser beams on an air-tissue
interface using an analytical formula that fits MC simulations using optical
properties obtained in vivo from patients undergoing treatment for MPM
The φ distributions were then used to calculate the reacted singlet oxygen con-
centration for the two wavelengths to study whether SOLD signals measured at 523
nm can be used to monitor [1O2]rx at 630 nm. PDT is currently performed at 630 nm
for patients undergoing Photofrin-mediated PDT in conjunction with radical pleurec-
tomy. Correlation between the calculated [1O2]rx for 630 nm and 523 nm is shown
in figure 4.14. µa ranges from 0.66 to 23.1 cm
−1 at 523 nm and 0.17 to 1.35 cm−1
at 630 nm, while µ′s ranges from 2.80 to 73.7 cm
−1 at 523 nm and 2.55 to 30.5 cm−1
at 630 nm (figure 4.12). To investigate the effects of different φ on the resulting
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calculated [1O2]rx, the SOED calculations were repeated for φ = 5, 25, 50, 75, and
150 mW/cm2. Different colors of the symbols represent different φ. The black solid
lines are the lines of best fits in figure 4.14. At 523 nm, the range of [1O2]rx changed
from 0-0.1, 0-0.63, and 0-5.6 mM for photosensitizer concentrations of 0.21, 2.1, and
21 µM, respectively, while the range of [1O2]rx at 630 nm changed from 0-0.24, 0-2.5,
and 0-20 mM, respectively, for the same photosensitizer concentrations.
The resulting correspondence for a range of photosensitizer concentrations (c) of
0.21, 2.1, and 21 µM (based on the average Photofin concentration obtained from
patient data) and light fluences of 10-120 J/cm2 [162] can be expressed as
[1O2]rx(630 nm) = a(c)[
1O2]rx(523 nm) + b(c, φ) (4.13)
where
a(c) = 0.05814c+ 1.922 (4.14)
and
b(c, φ) = (0.000618c− 0.000033)φ (4.15)
where c is the photosensitizer concentration (in µM) and φ is the light fluence (in
J/cm2). We thus conclude that the SOLD measurements performed at 523 nm can
be used to monitor the [1O2]rx at 630 nm if a conversion formula (such as that of Eq.
(4.13) - (4.15)) is used to convert the measured SOLD signal.
When SOLD signal from patients are used to determine the generation of singlet
oxygen, it is important to develop a tissue optical properties correction factor to
account for the absorption and scattering of luminescence by tissue, similar to the
optical properties correction factor needed for using fluorescence to determine the
photosensitizer concentration (described in section 3). This is beyond the scope of
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this study.
Figure 4.14: (a) [1O2]rx calculated at 630 nm and 523 nm for different to-
tal fluences (φ = 10, 60, 120 J/cm2 for mean Photofrin concentrations (c)
of (from left to right) 0.21, 2.1, and 21 µM. Absorption and scattering co-
efficients were obtained at the two wavelengths from figure 4.11. SOED
calculations of [1O2]rx were averaged over a 1 cm depth and 1 cm
3 volume
using the photophysical parameters for the in vivo conditions (listed in table
??); (b) Slope and intercept of the correlation of [1O2]rx at 630 nm and 523
nm as a function of fluence and photosensitizer concentration
4.4 Conclusions
Studies using Photofrin and Rose Bengal were performed to investigate explicit singlet
oxygen modeling in phantoms as well as the required in-phantom parameters. Use
of singlet oxygen luminescence detection enabled measurements changes in τ∆ with
the addition of NaN3. These results were able to be used to determine k6 and k9[Q].
Literature values were used for k1 and Φ∆ in the calculation of ξ. Absorption studies
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were used to determine the value of ε. Photosensitizer fluorescence was used to
measure relative changes in [S0] after the addition of a known amount to a phantom.
Light fluence was modeled as a broad beam with known fluence rate at the surface.
Direct singlet oxygen luminescence dosimetry (SOLD) measurements were com-
pared with singlet oxygen explicit dosimetry (SOED) calculations for phantoms using
Photofrin. Oxygen and photosensitizer concentration measurements were compared
with SOED predictions to validate the SOED model and to obtain the needed pho-
tophysical parameters (table 2.4, δ = 26 ± 5µM and σ = (6.8 ± 5) × 10−5µM−1).
Using lifetime measurements obtained with the SOLD system, photophysical param-
eters of k6 (2.2×104 s−1) and k9 (235µM−1s−1) were found for in vitro solutions with
NaN3. A linear relationship between SOLD singlet oxygen photon counts at 1270
nm and SOED-calculated reacted singlet oxygen (equation (4.12)) was established
for Photofrin for 523 nm light excitation. Based on our SOED calculations, a formula
(equations (4.13)-(4.15)) for converting cumulative SOLD signal measured at 523
nm to the corresponding [1O2]rx at 630 nm was established using optical properties
measured at the two wavelengths as a part of an ongoing clinical protocol.
These results indicate that, with suitable correction for the tissue optical proper-
ties at the two wavelengths, there is excellent correlation between the direct (SOLD)
and indirect (SOED) estimates of singlet oxygen generated during PDT. Since, at
the present time, the SOED approach is technically simpler and the instrumentation
is significantly less expensive, this validation supports the use of SOED in clinical
dosimetry. It should be noted, however, that the SOLD technique is intrinsically
more robust in that no simplifying assumptions are made as in SOED. Hence, care
must be taken in applying SOED to ensure that the treatment parameters lie within
the range of validity of these assumptions. Furthermore, the validation of SOED
must be carried out for each photosensitizer and set of clinical conditions. In the
Chapter 4 Michele M. Kim 89
future, developments such as a recent report of fiber optic-coupled SOLD techniques
based on novel superconducting nanowire single-photon detector technologies of direct
SOLD [153], may accelerate movement towards clinical utilization of SOLD alongside
SOED. For type I PDT where a reactive oxygen species (e.g. oxygen radicals) other
than singlet oxygen is the main cytotoxic agent, it is still possible to model the pho-
tophysical process using SOED, as described in section 2 and a recent review [34].
However, it still remains a challenge to find the value of the photophysical parameters
needed to describe the type I interactions for those photosensitizers.
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Chapter 5
Determination of in vivo
Photochemical Parameters
The macroscopic singlet oxygen model can be used for singlet oxygen explicit dosime-
try (SOED) as long as the relevant photochemical parameters are known. Determi-
nation of the in vivo photochemical parameters is critical for the use of SOED for
the photosensitizer of interest. A study was performed to optimize the values of the
photochemical parameters (ξ, σ, δ, β, and g) for in vivo benzoporphyrin monoacid
ring A (BPD)-mediated PDT with a 3 hour drug-light interval (DLI). Furthermore,
the singlet oxygen threshold dose ([1O2]rx,th) was determined to induce necrosis in a
radioactively induced fibroscarcoma (RIF) tumor in a murine model.
5.1 Theory and Methods
5.1.1 Macroscopic model for in vivo studies
The macroscopic singlet oxygen model was described previously in chapter 2 and in
section 3.5. To summarize, the photochemical reactions to describe the production
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and consumption of photosensitizer, oxygen, and singlet oxygen can be described by
the following equations:
d[S0]
dt
= − [
3O2]
[3O2] + β
ξσ([S0] + δ)φ[S0], (5.1)
d[3O2]
dt
= − [
3O2]
[3O2] + β
ξφ[S0]([S0] + δ) + g
(
1− [
3O2]
[3O2](t = 0)
)
, (5.2)
d[1O2]rx
dt
=
[3O2]
[3O2] + β
ξφ[S0], (5.3)
The parameters of ξ, σ, g, and threshold concentration of reacted singlet oxygen to
induce necrosis were determined in this study. The parameters β and δ were taken
from the literature that involved in vitro cell studies [53,125].
5.1.2 Treatment delivery
Mice were treated with linear source strength (LS), power released per length, of
12-150 mW/cm and total energy released per length of 24-135 J/cm. A 1 cm long
cylindrical diffusing fiber (CDF) light source was connected to an 8W, 690 nm diode
laser (B & W Tek Inc., Newark, DE, USA) via a SMA connector. Two catheters
were inserted parallel with a 3 mm separation into the mouse tumor (Fig. 3.2 (a)).
One catheter included the treatment light and was central to the tumor, and the
second catheter held the isotropic detector or a side-cut fiber for optical properties or
fluorescence measurements. Treatment conditions are summarized with the measured
data in table 5.1.
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5.1.3 RIF tumor necrosis measurement and analysis
The tumors were excised 24 hours after PDT and stored in formalin until time for
embedding and sectioning. Tumors were sectioned at 200 µm slices perpendicular
to the treatment linear source orientation and placed onto slides to be stained with
hematoxylin and eosin (H & E) to see the necrotic area. Slides were then scanned
digitally with a ScanScope microscope (Leica Microsystems Inc., Buffalo Grove, IL,
USA), and necrotic radii were obtained. Controls were included for each group of
animals studied, with the average necrotic radius among these controls (r0) being
1.6 mm. This was calculated by determining the necrotic area (Ac) on the digitally
scanned slide and using the formula Ac = pir
2. The PDT-induced necrosis for each
treated mouse was determined by rn = rt− r0, where rt is the measured raw necrosis
for treated mice. For all necrosis radii, a shrinkage factor (SF ) was included due
to the tumor shrinkage induced by preservation in formalin. This was determined
by measuring the tumor dimensions prior to formalin fixation and after at least 24
hours of fixation time. The standard error for each necrosis radius was determined
by propagating the uncertainty from each source of error. The standard deviation
of each individual mouse tumor necrosis radius as well as the uncertainty in radius
measurement due to the ellipsoidal shape of certain tumor sections was included
in this calculation. For ellipsoidal tumors, the radius was measured from the light
delivery source (central catheter) insertion point to the edge of the necrotic area at
various angles to determine the uncertainty due to this shape [120].
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Table 5.1: BPD-mediated Necrosis Study Treatment Conditions, Optical Properties,
Necrosis Radii
Treatment Conditions Optical Properites Necrosis Analysis
Group
LS a
(mW/cm)
Time
(s)
Energy b
(J/cm)
BPD Conc.
(µM)
µa
(cm−1)
µ′s
(cm−1)
Necrosis
Radius,
rt (mm)
Control
Radius,
r0 (mm)
PDT-Induced
Necrosis (mm)
(a) Experiment Group 1; each treatment group contains 3 mice
1 12 2000 24 0.90±0.14 0.8±0.1 8.0±0.5 2.8±0.7 1.6 1.2±0.7
2 12 3000 36 0.71±0.03 0.7±0.1 9.4±1.1 3.0±0.7 1.3 1.7±0.7
3 20 1600 32 0.49±0.07 0.7±0.1 8.0±0.5 1.9±0.7 1 0.9±0.7
4 30 1020 30.6 0.98±0.02 0.9±0.1 7.9±1 3.4±0.7 1.3 2.1±0.7
5 75 660 49.5 0.59±0.13 0.8±0.1 10.3±0.7 2.6±0.4 1.7 0.9±0.4
6 75 1800 135 0.47±0.10 0.6±0.1 12.5±1 3.2±0.2 1 2.2±0.2
7 150 420 63 0.99±0.03 0.8±0.1 9.9±0.6 2.9±0.6 1.3 1.6±0.6
(b) Experiment Group 2 from 2013 [119]; individual ungrouped mice were used
8 12 4000 48 0.43 0.7 6.5 2.5 1.3 1.2
9 12 6000 72 0.17 0.7 11.2 3.1 2.3 0.8
10 20 3000 60 0.17 0.7 13.5 2.4 2.3 0.1
11 20 4000 80 0.32 0.7 15.2 3 1.3 1.7
12 30 1980 59.4 0.42 0.6 10.8 2 0.8 1.2
13 30 4500 135 0.35 0.5 14.3 1.4 0.8 0.6
14 75 300 22.5 0.25 0.7 12.2 2.6 2.3 0.4
15 150 180 27 0.17 0.5 9.8 2.8 2.3 0.5
16 150 660 99 0.17 0.8 9.4 2 2.3 0
a Linear source strength
b Total energy delivered per unit length
5.1.4 Macroscopic singlet oxygen model to fit necrosis
The equations for the macroscopic singlet oxygen model first described in chapter 2
and specified for in vivo environments in Eq. (5.1)-(5.3) were used in the calculation
of reacted singlet oxygen to fit the necrotic radius and to determine the in vivo
photochemical parameters. For a given value of φ, spatially resolved light fluence
rate profiles can be constructed using the diffusion equation
µaφ∇ ·
(
1
3µ′s
∇φ
)
= S (5.4)
where φ is the light fluence rate, S is the source term, and µa and µ
′
s are the abosorp-
tion and scattering coefficients, respectively. For a given value of φ, spatially resolved
light fluence rate profiles can be constructed using equation (5.4), which were then
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used in the calculation of the PDT kinetic equations. For this study, a 1 cm CDF
was used as the treatment source. From the simulation results, it can be seen in Fig.
5.3 that the light fluence rate distribution within a 5 mm radial distance with respect
to the center of the linear source does not show significant differences for the case of
experimentally varying optical properties.
In order to fit the necrotic radius, a fitting quantity called “apparent singlet oxygen
threshold concentration” ([1O2]rx,sd) was introduced. An initial estimate for each
photochemical parameter (g, ξ, and σ) as well as the singlet oxygen threshold dose
([1O2]rx,sh) is used to calculate [
1O2]rx for each treatment group described in table
5.1. The differential evolution algorithm adjusts the photochemical parameters of g,
ξ, and σ to match the calculated [1O2]rx at the necrosis radius to match the assigned
[1O2]rx,sd. Values of σ and β were kept constant according to values obtained from
the literature throughout the fitting process to avoid convergence issues from having
too many free-floating parameters [44,54,125]. Furthermore, the calculated [1O2]rx is
less sensitive to these quantities than other model parameters [44]. The initial tissue
oxygen concentration was set as 40 µM [48]. After calculating the time series solution
for [1O2]rx, the value at the radius of necrosis was determined and compared to the
[1O2]rx,sd by minimizing the standard deviation according to the following objective
function:
f =
√√√√∑Ni ∣∣∣1− [1O2]rx(ri)[1O2]rx,sd ∣∣∣2
(N(N − 1) (5.5)
Here, N is the total number of groups or individual mice, and ri is the measured radius
of necrosis for group/mouse number i. Multi-variable optimization using the func-
tional minimization function fminsearch.m from Matlab (Mathworks, Natick, MA)
was implemented.
Error margins for the fitted parameters were determined by propagating the sys-
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Figure 5.1: (a) Fluence rate
(in mW/cm2) per linear source
strength (LS, in mW/cm) in
RIF tumors tissue for various
optical properties measured in
mice. Calculations were made
with a linear source model. (b)
The fluence rate relative to the
mean fluence rate for all mea-
sured optical properties. The
maximum deviation at 3 mm
away from the light source is
around 20% for the first 7 treat-
ment groups with 3 mice each,
indicating that variations in op-
tical properties account for less
than 20% of the experimental
error with consistent measure-
ments.
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tematic and random error from the experiment through the fitting process. To deter-
mine the variation in the resulting parameters that were fit, over 500 combinations of
initial input parameters were chosen to start the fitting. The initial estimated param-
eters ranged from σ = (0.5− 10)× 10−5µM−1, ξ = (10− 100)× 10−3 cm2mW−1s−1,
g = 0.5−2.0µMs−1, and [1O2]rx,sd = 0.5−2.0mM . In each iteration, only one param-
eter was changed within the range presented while the others were set to standard
initial estimates (σ = 5×10−5µM−1, ξ = 85×10−3 cm2mW−1s−1, g = 0.7µMs−1, and
[1O2]rx,sd = 0.7mM). Each round of optimization minimized the objective function
equation (5.5) and output parameters were collected and analyzed for their maxi-
mum deviations. Final values determined from the best optimization of the objective
function are presented along with their minimum and maximum ranges in table 5.2.
Using the macroscopic model, [1O2]rx and PDT dose were calculated and compared
to PDT-induced necrosis. [1O2]rx and PDT dose at 3 mm from the CDF was used as
a dose metric, where 3 mm was chosen since it happened to be the distance used in
the measurements between the two catheters. [1O2]rx and PDT dose at the necrosis
radius were also calculated as second dose metrics. These values are summarized in
table 5.3.
Necrosis radii, along with their standard uncertainties are presented in table 5.1.
The error includes the sum of squares of variations in radius measured between mice
treated with the same condition as well as the systematic error of necrosis. Some
of the tumor sections obtained exhibited an ellipsoidal shape due to the treatment
and sectioning. The variation in necrosis due to the ellipsoidal shape was taken into
account as systematic error. Standard deviation of each calculated value of fluence,
PDT dose, and [1O2]rx are also presented in table 5.3. For the most part, 3 mice were
used in each treatment group.
All fitting and simulation were performed using Matlab R2014b on an iMac OSX
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version 10.10.5 (processor 2.9 GHz Intel Core i5, 16 GB memory). The calculation
times were in seconds for the rate equations and in minutes for the spatially coupled
differential equations.
5.2 Results
The photochemical parameters found for explicit dosimetry modeling in vivo for BPD-
mediated PDT are summarized in table 5.2. Initial fitting was performed with the
estimate for these parameters in ranges found for other in vitro and in vivo studies
of other photosensitizers. These parameters were further validated using an outcome
modeling study described in chapter 6.
The concentration of BPD in tumors was acquired interstitially. The method
was verified with an ex vivo method described in section 3.3.3. The results of the
comparison are shown in figure 3.4. Each data point represents the average value of
three separate measurements made in the same tumor using both interstitial and ex
vivo methods. The best linear fit obtained when comparing the two was y = 0.98x
with R2 = 0.98 (black solid line). The dashed line represents a line with a slope of 1,
which would be the case if both measurements were in perfect agreement. However,
the results from the comparison show that the fluorescence correction for interstitial
measurements is fairly accurate.
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Table 5.2: In vivo photochemical parameters obtained for BPD [120]
Photochemical Parameter Initial Value a Fit Value b
ε (cm−1 µM−1) 0.0783
δ (µM) 33 [53]
β (µM) 11.9 [125]
σ (µM−1) (0.5− 10)× 10−5 (1.8± 3)× 10−5
ξ (cm2mW−1s−1) (10− 100)× 10−3 (55± 40)× 10−3
g (µM s−1) 0.5-2.0 1.7± 0.7
[1O2]rx,sh (mM) 0.5-2.0 0.67± 0.13
[3O2]0 (µM) 40
c[48]
a The initial guess of parameters were assigned randomly within
the presented ranges
b The obtained values by the macroscopic model with their overall
error. Each value is presented as the mean ± standard deviation
c The initial ground state oxygen concentration was kept constant
for all mice using a value from Ref. [48]
The distribution of φ in tumor tissue was calculated using the diffusion equation
and the linear light source characteristics. Measured optical properties in tumors were
used as input parameters to see the effect of varying µa and µ
′
s on the light fluence
distribution. Figure 5.1 shows the drop of φ/LS along the tumor depth. With varying
measured µa and µ
′
s, the deviation of φ/LS inside tumors at depths up to 3 mm was
within the deviation of the measured µa and µ
′
s (indicated by the grey region). The
mean measured optical properties were µa = 0.7± 0.1 cm−1 and µ′s = 11± 2.4 cm−1.
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Figure 5.2: (a) [1O2]rx profile versus
radius for mice calculated using the sin-
glet oxygen explicit dosimetry model
and the photochemical parameters in
table 5.2. Data points 1-7 were ob-
tained by averaging a group of 3 mice
with the same treatment conditions
while data points 8-16 were individ-
ual mice. The bold dashed black line
indicates [1O2]rx,sh determined by this
study (0.67 mM), and the grey region
indicates the range. (b) The PDT-
induced necrosis radius that is calcu-
lated by the model versus the measured
PDT-induced necrosis radius. The
dashed line indicates a perfect cor-
respondence between calculated and
measured data (y = x). The solid line
is a linear fit to the data, y = 1.085x
with R2 = 0.8384. (c) PDT-induced
necrosis radius versus PDT dose calcu-
lated at the necrosis radius. The solid
line shows a linear fit to the data us-
ing functional form y = 0.1708x with
R2 = 0.127. The grey area shows the
upper ad lower bounds of the fit with a
95% confidence interval
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Figure 5.3: PDT-induced necrosis ver-
sus (a) PDT dose at 3 mm, (b) pho-
tobleaching ratio, and (c) [1O2]rx at
3 mm. PDT dose was calculated
for those groups of mice where there
was a PDT-effect due to treatment.
Photobleaching ratio was calculated
by 1 − [SV D]post/[SV D]pre for those
groups of mice where pre- and post-
PDT BPD fluorescence components
were measured. [1O2]rx was calculated
for all treated groups of mice. The solid
lines show the best fits to the data us-
ing functional forms (a) y = 0.1802x
with R2 = 0.147, (b) y = 2.28x with
R2 = 0.436, and (c) y = 8.43/(1 +
exp(−(x−0.92)/0.16)) with R2 = 0.96.
The grey area shows the upper and
lower bounds of the fits with a 95% con-
fidence interval.
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Figure 5.2 shows PDT-induced necrosis radius versus the [1O2]rx at the necrosis
radius. The legend indicates each treatment condition. Figure 5.2 (b) shows the
model predicted PDT-induced necrosis versus the measured PDT-induced necrosis.
The good correlation is an indicator of the accuracy of the optimization fit. Table 5.2
summarizes the photochemical parameters obtained from the fitting routine as well
as their initial values for the model. The best fit estimated values (along with their
standard deviation) of σ = (1.8±3)×10−5µM−1, ξ = (55±40)×10−3cm2mW−1s−1,
g = 1.7±0.7µMs−1, and [1O2]rx,sh = 0.67±0.13mM . The values for β and δ were held
constant at 33 µM and 11.9 µM, respectively. The grey region in Fig. 5.2 (a) shows
the range for the singlet oxygen threshold concentration, [1O2]rx,sh. The PDT dose
was calculated at the necrosis radius and compared with the PDT-induced necrosis
radius in Fig. 5.2 (c). The grey region indicates the upper and lower bounds of the
fit with a 95% confidence interval. The best fit to the data was y = 0.1708x with
R2 = 0.127, indicating that PDT dose at the necrosis radius is not well-correlated
with the necrotic outcome.
Figure 5.3 (a) shows the PDT dose at 2 mm versus PDT-induced necrosis radius.
The solid line represents the best fit to the data using a functional form of y = 1802x
with a goodness of fit of R2 = 0.147. Figure 5.3 (b) shows the photobleaching
ratio versus PDT-induced necrosis radius. Photobleaching ratio was calculated as
1 − ([SV D]post/[SV D]pre), where [SV D]pre and [SV D]post are the measured BPD
fluorescence components pre- and post-PDT. While there is a positive correlation
with PDT-induced necrosis as indicated by the linear fit of y = 2.28x, it is not a good
fit of the data since the goodness of fit R2 = 0.436. Fig. 5.3 (c) shows the [1O2]rx at
a depth of 3 mm versus PDT-induced necrosis. The solid line is the best fit to the
data y = 8.43/(1 + exp(−(x− 0.92)/0.16)) with a goodness of fit of R2 = 0.96. The
grey regions indicate the upper and lower bounds of the fit with a 95% confidence
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interval.
5.3 Discussion
PDT promises to be an effective treatment modality for diseases. However, clinical
application of PDT has been hindered due to the complicated dosimetry [44, 163].
BPD-mediated PDT has been shown to correlate well with calculated 1O2 as shown
in this study. A DLI of 3 hours was used for this study. By this time, the drug has
systemically extravasated into the tumor interstitial and cellular components [164].
With a shorter DLI, vascular-targeted PDT can be achieved [121,164].
Currently, the common approach in clinical PDT dosimetry is based on the pho-
tosensitizer concentration that is administered to the patient and the amount of light
delivered to the treatment site. This method does not account for many of the com-
plexities that arise with PDT. If the treatment site is hypoxic, or becomes hypoxic
through the course of the treatment, the expected 1O2 produced will be higher than
what is produced and treatment will be less effective [163, 165]. As seen in the data
from table 5.3, the photosensitizer uptake is very heterogeneous even though the ad-
ministered dose is the same. The variation in photosensitizer concentration in the
treatment tissue from site to site within the same individual (intra-tumor variation)
and from individual to individual (inter-tumor variation) results in varied PDT treat-
ment response [44, 163, 166]. Optical properties of the treatment tissue affect the
penetration of light into the target area and are tissue-type dependent [18]. Further-
more, optical properties can be affected by the tissue and blood oxygenation, which
is a key component in PDT [18,22,28]. All of these factors are dynamically changing
during PDT, making accurate clinical dosimetry a challenge.
Singlet oxygen explicit dosimetry is of particular interest as it involves measure-
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ment of the key components involved in PDT and modeling 1O2, the major cytotoxic
agent in type II PDT. Pre-clinical studies were performed using a murine model to
determine the range of relevant photochemical parameters needed for BPD-mediated
PDT explicit dosimetry. A range of source strengths and exposure times were per-
formed on mice with RIF tumors to generate varying amounts of 1O2 and induce
necrosis. [1O2]rx were calculated using the macroscopic model using the information
obtained from pre-PDT measurements regarding the tumor tissue optical properties
(µa and µ
′
s) and the photosensitizer concentration. The distribution of φ was also
calculated using the diffusion approximation for a linear source. Photosensitizer con-
centration was measured with interstitial fluorescence spectra, and the method was
validated by comparing the in vivo and ex vivo measurements on separate mice.
Measured optical properties were used to calculate φ distribution in the tumor
tissue using the light source characteristics and the diffusion equation. The first
7 treatment groups included 3 mice per treatment condition. The deviation in φ at
depths up to 3 mm varied 20% indicating that variations in optical properties account
for less than 20% of the experimental error with consistent, long-term measurements
with the same experimental set-up (Fig. 5.1 (b)). Some of the measurements in indi-
vidual mice made in an earlier experiment with a different batch of mice (experiment
group 2 in table 5.1 and 5.3 (b)) shows larger deviations of φ (up to 40%), which
contain additional measurement uncertainties.
Figure 5.2 shows the most important results of this study. The threshold dose
model only works to an extent if the threshold concentration for [1O2]rx is allowed a
range as shown by the grey shaded area in Fig. 5.2 (a). Those that do not achieve the
threshold singlet oxygen dose (indicated by the dashed black line and its uncertainty
as indicated by the grey area) do not exhibit any PDT-induced necrosis (data points
9, 10, 14, 15, and 16). The other points that achieve the threshold dose delineate
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the upper and lower bounds of uncertainty for [1O2]rx,sh. By plotting the measured
PDT-induced necrosis radius against the model-predicted values (the values from
each [1O2]rx profile curve that intersect the [
1O2]rx,sh dashed line) in Fig. 5.2 (b), the
goodness of the macroscopic model in predicting the necrosis radius can be evaluated.
A good correlation indicates a good fit. The dashed line indicates a perfect correlation
and the fit to the data yields y = 1.085x with R2 = 0.838. The grey region indicates
the 95% confidence interval of the fit. Figure 5.2 (d) shows that unlike [1O2]rx,
PDT dose at the necrosis depth is a very poor predictor for the necrosis radius, with
R2 = 0.127.
The calculated [1O2]rx was fit to the in vivo BPD-mediated necrosis radius so
that the photochemical parameters g, ξ, and σ could be determined along with the
[1O2]rx,sh. The uncertainty for the resulting photochemical parameters (g, ξ, σ) was
quite large based on the fitting algorithm and incorporating experimental uncertain-
ties.
The parameters obtained for BPD (ξ = 55 × 10−3 cm2mW−1s−1, σ = 1.8 ×
10−5µM−1, and g = 1.7µM s−1) were compared to those obtained for HPPH (ξ =
70 × 10−3 cm2mW−1s−1, σ = 1 × 10−5µM−1 [117], and g = 1.5µM s−1), Photofrin
(ξ = (2.1 − 3.7) × 10−3 cm2mW−1s−1 and σ = 7.6 × 10−5µM−1) [44], mTHPC
(ξ = 30 × 10−3 cm2mW−1s−1 and σ = 3.0 × 10−5µM−1) [124], and ALA-PpIX
(ξ = 3.7 × 10−3 cm2mW−1s−1 and σ = 9.0 × 10−5µM−1) [167]. The value of ξ
for BPD was found to be larger than that of other photosensitizers except HPPH,
which corresponds to the proportionality of ξ with the absorption coefficient and
the larger absorption coefficient of BPD. The fit value of σ was found to be smaller
than those of other photosensitizers, but in the same range as that of HPPH. The
[1O2]rx,sh was found to be 0.67± 0.13 mM, which is similar to the reported value for
that of Photofrin ([1O2]rx,sh = 0.7 ± 0.3 mM) [44]. The values are presented with
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their standard deviations.
Figure 5.3 compares three dosimetric quantities PDT dose, photobleaching ratio,
and [1O2]rx versus PDT-induced necrosis. The grey area shows the upper and lower
bounds of the fits with the 95% confidence level. It is clear that [1O2] is the best
dosimetric indicator compared to PDT dose and photobleaching ratio, as defined by
1− [SV D]post/[SV D]pre, the [SV D]pre and [SV D]post were determined from the BPD
fluorescence components before and after PDT. THe solid lines in the figure represent
the best fit to the data. Their goodness of fit R2 = 0.96, 0.436, and 0.147 for [1O2]rx,
photobleaching ratio, and PDT dose, respectively. The reason PDT dose is not a good
indicator may be due to ignoring the oxygen consumption during PDT. The reason
that photobleaching ratio is not a very good indicator may be associated to the fact
that [S0] concentration in vivo (0.2 - 1 µM) is much lower than the value of δ = 33µM
used for BPD. [1O2]rx was calculated using the macroscopic model and incorporating
information regarding the spatial distribution of φ based on measured tissue optical
properties and the photosensitizer concentration in tissue. For this study, the initial
ground state oxygen concentration ([3O2]0) was fixed to 40 µM. However, this could
be further improved by performing direct [3O2] measurements directly for each mouse.
For the practical application of SOED in clinical PDT, it is not generally necessary
to determine the tissue optical properties in order to calculate [1O2]rx. [
1O2]rx can be
calculated directly using the measured φ and photosensitizer concentration. The other
unknowns for a specific photosensitizer are the photochemical parameters, which can
be found in the literature for most commonly used photosensitizers [34].
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5.4 Conclusion
An explicit dosimetry model for BPD-mediated PDT was investigated on mice bearing
RIF tumors. Since direct measurement of 1O2 concentration is difficult in vivo, SOED
can be useful as a measure of PDT dosimetry The photochemical parameters needed
for the macroscopic modeling of 1O2 were found. The threshold dose of singlet oxygen
to induce necrosis in the tumor was determined by correlating the calculated [1O2]rx
and the tumor necrosis induced by PDT. Correlation of PDT-induced necrosis with
photobleaching ratio, PDT dose, and [1O2]rx was compared. It showed that [
1O2]rx
serves as a better dosimetric quantity than photobleaching ratio or PDT dose in
predicting the treatment outcome. This study is important in understanding the
effect of 1O2-based dosimetry for BPD-mediated PDT as well as determining the
range of photochemical parameters required for SOED. A further study was necessary
to investigate the correlation between SOED calculated [1O2]rx to a more meaningful
PDT treatment efficacy, such as local tumor control rather than necrosis. This is
described in the following chapter 6. However, this was the first study of its kind to
find relevant in vivo photochemical parameters for BPD-mediated PDT.
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Chapter 6
In vivo Outcome Study
Utilizing the macroscopic model, the effectiveness of reacted singlet oxygen concentra-
tion ([1O2]rx) as a dosimetric quantity to predict outcome for BPD-mediated PDT. In
addition, a few other dose metrics were evaluated in this study, including total light
fluence, photobleaching ratio, and PDT dose, in their ability to predict PDT out-
come. For each PDT treatment group, explicit measurements of BPD concentration
in tumor and tissue optical properties were performed pre- and post-treatment. Mice
bearing radiation-induced fibrosarcoma (RIF) tumors were treated with BPD-PDT
and a range of in-air fluences (30 to 350 J/cm2) and in-air fluence rates (50 to 150
mW/cm2). For a subset of mice, real-time in vivo measurements of BPD concentra-
tion and tissue oxygenation level ([3O2]) throughout PDT were taken to optimize the
photosensitizer-specific PDT photochemical parameters (ξ, σ, and g), reduce their un-
certainty from the necrosis study described in chapter 5, and calculate [1O2]rx. These
photochemical parameters were used to calculate [1O2]rx for each PDT treatment
group. Other dose metrics, such as photobleaching ratio and PDT dose, were deter-
mined either directly using explicit measurements pre- and post-PDT or calculated
using the time dependence of BPD concentration based on the macroscopic model and
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the definition of PDT dose. This study is the first, to our knowledge, to investigate
the threshold value of [1O2]rx and the relationship between various dose metrics and
cure index (CI) at 14 days in an in vivo mouse model for BPD-mediated PDT. The
results of this study with additional real-time measurements of BPD concentration
and [3O2] provide reduced uncertainties for the photochemical parameters determined
for BPD-mediated PDT, as well as a validation that our macroscopic model can ac-
curately predict the oxygen consumption for BPD-mediated PDT, making it feasible
to determine [1O2]rx without oxygen measurements.
6.1 Materials and Methods
6.1.1 Photodynamic therapy treatment
An optical fiber with a microlens attachment was coupled with a 690 nm diode laser
with a maximum output power of 8 W (B&WTek Inc., Newark, Delaware, USA) to
produce a collimated beam with a diameter of 1 cm on the surface of the tumor,
as shown in Fig. 6.1 (a). The surface illumination of the tumor is non-invasive,
compared to the interstitial treatment of chapter 5, which is necessary to monitor
the tumor volume after treatment for 2 weeks. Mice were treated with in-air fluence
rates (φair) of 50 to 150 mW/cm
2 and total in-air fluences from 30 to 350 J/cm2 at
690 nm to induce different PDT outcomes and assess the reciprocity between BPD
concentration and light fluence. The “in-air fluence rate” is defined as the calculated
irradiance determined by laser power divided by the treatment area. The “in-air
fluence” was calculated by multiplying the “in-air fluence rate” by the treatment time.
All mice were injected with 1 mg/kg BPD via tail vein injection at 3 hours prior to
light illumination. RIF tumor-bearing mice with (i) no BPD and no light excitation
and mice with (ii) no BPD but the highest light fluence (φair = 150 mW/cm
2 and
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2333 second exposure) were used as controls (n = 5).
Figure 6.1: Experimental set-up with the (a) collimate beam treat-
ment of RIF tumors on mouse shoulder and (b) the multi-fiber con-
tact spectroscopy probe
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6.1.2 Tissue oxygen concentration and photosensitizer con-
centration measurements
Real-time in vivo BPD concentration and tissue oxygen concentration over the course
of treatment (80 mW/cm2, 2000 s exposure time) was also determined for a subset
of four mice using characteristic fluorescence spectra obtain at 30 to 300 s time inter-
vals with excitation by the treatment light. SVD fitting was used to determine the
BPD concentration. Measured data are shown in Fig. 6.2 (a) with symbols. The in
vivo tissue oxygen partial pressure, pO2 was measured during PDT treatment using
a phosphorescence-based bare fiber-type 3O2 probe (OxyLite Pro with NX-BF/O/E,
Oxford Optronix, Oxford, United Kingdom). Measurements are presented for each 30
s interval during treatment. 3O2 concentration ([
3O2]) was calculated by multiplying
the measured pO2 with
3O2 solubility in tissue, which is 1.295 µM/mmHg [48]. Mea-
sured [3O2] was used to refine the photochemical parameters determined in chapter 5.
for the singlet oxygen explicit dosimetry model used to calculate [1O2]rx, and obtained
values are summarized in table 7.1. Individually measured [3O2](t) for each mouse
were fit with the model-calculated values. Measured data are shown as symbols and
calculated fits are shown with lines in Fig. 6.2 (b).
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Figure 6.2: Real-time in vivo measurements of (a) BPD concentration
([BPD]) at the tumor surface and (b) [3O2] concentration at a 3 mm
depth measured for four mice over the course of PDT light delivery (80
mW/cm2, 160 J/cm2). The open symbols represent measured data and
the solid curves represent the model-calculated [BPD] and [3O2] using
eqs. (3.11) and (3.12) and the photochemical parameters listed in table
6.2. The black ’x’ symbols and dashed black line represents the mean
data and fit to data, respectively. The PDT parameters used to model
the mean data are summarized in table 7.1
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6.1.3 Tumor regrowth rate analysis
Tumor volumes were tracked daily after PDT. Width (a) and length (b) were measured
with slide calipers, and tumor volumes (V ) were calculated using V = pi × a2 × b/6
[168]. Tumor volumes were tracked for 15 days and the tumor regrowth factor (k)
was calculated by an exponential fit to the data with the form f(d) = ekd to the
measured volume over days (d). CI was calculated for each treatment group by
CI = 1− k
kctr
(6.1)
where k is the tumor regrowth factor for each group and kctr is the regrowth factor
for the control group, which has no injection of BPD or illumination of light.
Figure 6.3: Tumor volumes over days after PDT
treatment. Solid lines are the exponential fit to
the data with a functional form of ekd, where d is
days after PDT treatment. The resulting tumor
regrowth rates, k, and uncertainty, δk, are listed in
table 6.3
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6.1.4 Monte Carlo simulation of φ distribution in tumors
The diffusion theory is not valid for the simulation of φ in tissue when the lateral
dimension of the beam geometry becomes comparable to the mean-free-path of the
photons or when the region of interest is near the air-tissue interface [157,169]. Based
on a previous study by Ong et al. [157], an empirical six-parameter fitting equation
was used to fit the Monte Carlo (MC) calculated light fluence rate data for a 1 cm
diameter field with µa = 0.52 to 0.80 cm
−1 and µ′s = 7.9 to 14.1 cm
−1. The equation
is of the following form:
φ/φair = INV ×
(
1− b× e−λ1d) (C2e−λ2d + C3e−λ3d) , (6.2)
where the parameters λ1, λ2, λ3, b, C2, and C3 are functions of µa and µ
′
s and described
elsewhere [157]. For µa = 0.5 cm
−1 and µ′s = 10 cm
−1, λ1 = 17.1, λ2 = 4.88, λ3 = 0,
b = 0.3579, C2 = 5.207, and C3 = 0. INV = [SSD/(SSD + d)]
2, where the source-
to-surface distance SSD = 9.34 cm based on the measurement of light fluence rate
in water for the same collimated beam as a function of depth and fit to the inverse-
square law formula. The inverse-square law factor was added to the MC simulation
results, which is suitable for parallel beams to account for the divergence of the
collimated beam from the microlens. The mean tissue optical properties were found
to be µ¯a = 0.69 ± 0.12 cm−1 and µ¯′s = 11 ± 3 cm−1 for RIF tumors at 690 nm, and
the maximum error for using the mean optical properties is ±15%, as seen in chapter
5.
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6.2 Results
6.2.1 Parameter verification
BPD-mediated PDT with different in-air fluences, different φair, and different ex-
posure times was performed in mouse models bearing RIF tumors. Tissue optical
properties, photosensitizer concentration, and tissue oxygenation were measured to
calculate photobleaching percentage, PDT dose, and [1O2]rx. Table 6.3 summarizes
all of the treatment conditions, as well as the measured and calculated quantities
using the photochemical parameters summarized in table 7.1.
Table 6.1: Photochemical parameters for BPD based on those determined in chapter
5. The standard deviation for each parameter is reduced [126]
Photochemical
Parameter Definition Value
ε (cm−1 µM−1) Photosensitizer extinction coefficient 0.0783
δ (µM) Low-concentration correction 33
β (µM) Oxygen quenching threshold concen-
tration
11.9
σ (µM−1) Specific photobleaching ratio (1.8± 0.3)× 10−5
ξ (cm2mW−1s−1) Specific oxygen consumption rate (55± 15)× 10−3
g (µM s−1) Macroscopic maximum oxygen supply
rate
1.7± 0.4
[1O2]rx,sh (mM) Singlet oxygen threshold dose for tu-
mor regrowth
0.99± 0.12
[3O2]0 (µM) Initial oxygen concentration 40
Four mice, summarized in table 6.2, were used to monitor the photosensitizer
concentration and [3O2] throughout the treatment using φair = 80 mW/cm
2 and
total fluence of 160 J/cm2. The measured results (open symbols) were compared to
calculated values (solid lines) in Fig. 6.2 to validate the photochemical parameters
used in the calculation of [1O2]rx. R
2 values are provided to evaluate their fits. The
photochemical parameters found from individual fits of [3O2](t) are summarized in
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table 6.2. The mean data was fit using the photochemical parameters summarized in
table 7.1.
Table 6.2: PDT parameters obtain for four mice treated with an in-air fluence of
160 J/cm2 and in-air fluence rate of φair = 80 mW/cm
2 using individual fitting to
[3O2](t) and [S0](t) simultaneously (Fig. 6.2). The other photochemical parameters
(δ = 33µM and β11.9µM)are kept the same as in table 7.1
Mouse [BPD]0 (µM) ξ (cm
2 mW−1 s−1) σ (µM−1) g (µM s−1) [1O2]rxa(mM) [1O2]rxb(mM)
1 0.76± 0.10 (60± 8)× 10−3 (1.8± 0.3)× 10−3 1.6± 0.4 1.23± 0.24 1.21± 0.40
2 0.87± 0.19 (60± 10)× 10−3 (1.5± 0.4)× 10−3 1.5± 0.4 1.64± 0.31 1.37± 0.17
3 0.58± 0.16 (50± 10)× 10−3 (1.5± 0.4)× 10−3 1.3± 0.3 1.05± 0.33 0.93± 0.13
4 0.80± 0.19 (50± 7)× 10−3 (1.5± 0.3)× 10−3 1.7± 0.4 1.44± 0.28 1.26± 0.21
a Calculated [1O2]rx using individually fit PDT photochemical parameters and [
3O2]0 = 50µM
b Calculated [1O2]rx using the mean PDT photochemical parameters from table 7.1
6.2.2 Explicit dosimetry and treatment outcome evaluation
Measured tumor volume over 14 days after treatment for each treatment group is
shown in Fig. 6.3. Compared to control mice, all treatment conditions had significant
control of the tumor regrowth after PDT. CI was calculated for each treatment
group using Eq. (6.1). PDT using 150 J/cm2 with 75 mW/cm2 was a more effective
treatment than with 100 mW/cm2. Each tumor volume was normalized to the mean
initial volume, so that they are equal on day 0 (treatment date) before fitting for the
tumor regrowth rate.
BPD concentration was measured both before and after PDT treatment. Mea-
sured [BPD] was compared to model-calculated values for all the treatment condi-
tions and is shown in Fig. 6.4 (a). The symbols represent the measured values, and
the solid lines are model-calculated photosensitizer concentration during treatment.
Figure 6.4 (b) shows the spatial distribution of reacted singlet oxygen in the RIF tu-
mor model. The symbols indicate [1O2]rx at a 3 mm tumor depth for each treatment
condition. The depth of 3 mm was chosen as it encompasses the initial tumor size
of all treatment tumors. Previous publications also calculated [1O2]rx at 3 mm, and
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results of this study can be compared to those directly.
Several dose metrics were evaluated for predicting the treatment outcome. Figure
6.5 shows the correlation of CI (tumor control) versus in-air fluence, photobleaching
ratio (%), PDT dose at 3 mm depth, and [1O2]rx at 3 mm depth. The mean of k and
kctr for all mice in each treatment group (number of mice per group is shown in table
6.3) was used to determine CI using Eq. (6.1). Photobleaching was determined by the
ratio of BPD SV Dcorr measured immediately following treatment ([SV Dcorr]post) to
the BPD concentration measured prior to treatment ([SV Dcorr]pre) and calculating
1 − ([SV Dcorr]post/[SV Dcorr]pre). PDT dose is defined by the time integral of the
product of the φ at a 3 mm tumor depth and the local BPD concentration. Figures 6.5
(a)-(d) show the correlation of CI to fluence, photobleaching percentage, PDT dose,
and mean [1O2]rx along with their line of best-fit. The lines of best-fit (shown with
solid lines) are CI = (3.309 × 10−3)x, CI = (1.118 × 10−3e0.06731x, CI = 1.052/(1 +
1014.4e−0.08172x), and CI = 1.08/(1 + 3490e−8.301x) with R2 = 0.6260, 0.6274, 0.9360,
and 0.9850 for fluence, photobleaching percentage, PDT dose, and [1O2]rx at 3 mm,
respectively [126].
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Figure 6.4: (a) The temporal changes of BPD concentration versus fluence at 3 mm
depth for the treatment conditions. The lines represent the calculated changes of
photosensitizer concentration during treatment. The symbols show the measured
BPD concentration pre- and post-PDT. Initial drug concentrations for the calcu-
lation were matched to measured values. (b) The spatial distribution of reacted
singlet oxygen ([1O2]rx) in the RIF tumors calculated for different treatment con-
ditions. [1O2]rx at 3 mm tumor depth is shown by the symbols. R
2 values for each
calculation are shown in the legend.
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Figure 6.5: CI plotted against (a) fluence at a 3 mm tumor depth, (b)
measured photosensitizer photobleaching (%), (c) calculated PDT
dose at 3 mm depth, and (d) mean reacted singlet oxygen at 3 mm
depth ([1O2]rx) calculated using the parameters summarized in table
7.1. The solid lines show the best-fit to the data with functional
forms CI = (3.309 × 10−3)x, CI = (1.118 × 10−3e0.06731x, CI =
1.052/(1 + 1014.4e−0.08172x), and CI = 1.08/(1 + 3490e−8.301x) with
R2 = 0.6260, 0.6274, 0.9360, and 0.9850 for (a), (b), (c), and (d),
respectively. The grey region indicates the upper and lower bounds
of the fit with 95% confidence level.
6.2.3 Long term local tumor control
Local tumor control for a more long-term treatment endpoint was investigated for a
group of mice. Treatment was delivered with the same collimated beam and admin-
istration of BPD as before. Explicit dosimetry was used to calculate reacted singlet
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oxygen ([1O2]rx). The dose metrics of light fluence, photobleaching ratio, and PDT
dose were compared to reacted singlet oxygen to evaluate their effectiveness in cor-
relating with long term tumor control. Kaplan-Meier survival analyses were done for
long-term local tumor control rate (LCR) for an endpoint of tumor volume ≤ 100
mm3. Tumors were monitored for up to 90 days. The treated mice are summarized
in table 6.4.
Table 6.4: Summary of treated mice for long term tumor control. De-
livered fluence rate (φair), treatment time, initial BPD concentration
([BPD]0), photobleaching ratio (Pb.), PDT dose, and calculated reacted
singlet oxygen ([1O2]rx) are summarized with the tumor response to the
treatment at the end of the 90 day monitoring period.
Mouse φair Time [BPD]0 Pb. PDT Dose [
1O2]rx Survival
No. (mW/cm2) (s) (µM) (%) (µM J/cm2) (mM) (90 Days)
1 75 4000 0.43 65.7 54.8 0.72 Regrowth
2 75 4000 0.57 89.7 73.4 0.95 Regrowth
3 75 4000 0.64 82.5 80.4 1.07 Regrowth
4 75 4000 0.58 92.0 75.2 0.97 Regrowth
5 75 4000 0.54 89.9 69.8 0.91 Regrowth
6 75 4000 0.52 90.9 66.4 0.86 Regrowth
7 75 4000 0.42 60.3 53.7 0.70 Regrowth
8 75 4000 0.30 84.9 37.6 0.50 Regrowth
9 75 4000 0.47 88.1 59.8 0.78 Regrowth
10 75 4000 0.60 91.3 77.4 1.00 Regrowth
11 75 4000 0.49 88.4 62.6 0.82 Regrowth
12 75 4000 0.38 83.3 48.4 0.64 Regrowth
13 75 4000 0.31 93.4 39.7 0.52 Regrowth
14 75 4000 0.48 93.1 61.5 0.80 Regrowth
15 75 4000 0.56 89.8 72.2 0.94 Regrowth
16 75 4000 0.25 46.1 32.2 0.43 Regrowth
17 75 4000 0.25 78.3 31.0 0.41 Regrowth
18 75 4000 0.34 56.9 43.3 0.57 Regrowth
19 75 4000 0.31 78.4 39.0 0.51 Regrowth
20 75 4000 0.76 92.7 98.8 1.26 No Tumor
21 75 3600 0.73 92.6 89.0 1.21 No Tumor
22 75 5400 0.69 91.9 93.5 1.15 No Tumor
23 75 3600 0.75 91.8 92.1 1.24 No Tumor
24 75 3600 0.46 84.5 54.9 0.76 Regrowth
25 75 3600 0.44 82.6 52.6 0.73 Regrowth
26 75 3600 0.30 56.9 36.2 0.48 Regrowth
27 75 3600 0.69 91.7 84.5 1.15 No Tumor
28 75 3600 0.67 90.4 81.1 1.10 No Tumor
29 75 3600 0.72 90.8 87.9 1.19 No Tumor
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30 75 3600 0.64 89.0 78.5 1.10 No Tumor
Comparing dose metrics, it is seen that singlet oxygen does the best of predicting
LCR. Furthermore, the [1O2]rx dose required to have LCR for 90 days with BPD-
mediated PDT is 1.1 mM [170]. Figure 6.6 shows the survival curves that compares
the dose metrics. A correlation of the delivered light fluence, BPD photobleaching
ratio, and PDT dose with LCR showed that less than 25% of the tumors exhibit a
complete response at 90 days to the treatment with a light fluence greater than 270
J/cm2. Photobleaching ratio and PDT dose were also not sufficient in correlating
with tumors that responded with a complete response. However calculated [1O2]rx >
1.1 mM was able to predict long term complete tumor control.
Figure 6.6: Survival curves based on (a) in-air delivered light fluence, (b)
BPD photobleaching ratio, (c) PDT dose, and (d) calculated [1O2]rx. Tu-
mor volumes less than 100 mm3 and control at 90 days were considered as
treatment end points.
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6.3 Discussion
As shown in Fig. 6.2, the photochemical parameters σ, ξ, and g were validated by
measuring [BPD] changes and [3O2] during the PDT treatment for individual mice
and applying the parameters to the explicit dosimetry model. Based on a previous
study, the parameters of σ, ξ, and g werefound to be (1.8 ± 0.3) × 10−5 µM−1,
(55 ± 15) × 10−3 cm2mW−1s−1, and 1.7 ± 0.4 µM−1, respectively. The standard
deviation of each parameters is reduced based on the fitting of [S0] and [
3O2] as
shown in Fig. 6.2, which is a more robust data set for deriving the photochemical
parameters. Each individually measured [3O2] in Fig. 6.2 was fitted to validate
the photochemical parameters as shown in table 6.2. RMSE between measured and
calculated values of [3O2] was used as a measure of good fit.
To asses the effect of photochemical parameters, the values of calculated reacted
singlet oxygen concentration using the individually obtained photochemical param-
eters for each mouse (from table 6.2) were compared to [1O2]rx calculated using the
phtochemical parameters from the necrosis-based study in chapter 5 and table 7.1.
For the same mouse, [1O2]rx calculated using the two sets of photochemical parameters
agree with each other within a maximum uncertainty of 20% and a standard deviation
of 8%. The good agreement between measurement and caluclation of photosensitizer
concentration and oxygen concentration provided a validation of the photochemical
parameters determined previously and allowed for reduction in the uncertainty of each
parameter. For BPD, the comparisons between the measured and calculated [3O2]
for a subset of four mice show that the macroscopic model can accurately predict
[3O2] for the mice studied with R
2 values ranging from 0.70 to 0.90. The agreement
between measured and calculated [3O2] makes it unnecessary to measure the oxy-
gen concentration directly during PDT. One complication of the comparison between
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measurement and calculation for in vivo oxygen concentration is the uncertainty of
the depth at which oxygen concentration was measured, which lies at around 3 mm.
To illustrate this effect, spatial and temporal variations of [3O2] are shown for various
φair (20, 50, 75, and 150 mW/cm
2) in Fig. 6.7. The temporal changes of [3O2] at
1, 3, and 5 mm with [BPD] = 0.57 µM (the mean value of BPD concentration for
all mice studied) are shown in Fig. 6.7 (a)-(c). Figure 6.7 (d)-(f) show the temporal
changed of [3O2] at 1, 3, and 5 mm with [BPD] = 0.87 µM. Initial [
3O2] of 40 µM
and the photochemical parameters in table 7.1 were used for the calculations. As
the depth increases from 1 to 5 mm, the minimum value of [3O2] increases, while
the rate of [3O2] recovery due to photobleaching (for 50 to 2000 s) deceases. Higher
initial [BPD] will cause a larger drop of [3O2], depending on the light fluence rate.
Lower light fluence rates will have less [3O2] consumption during PDT. The optimized
depth for the best agreement between model and measurement is found to be 3 mm,
corresponding to the placement of the oxygen probe during PDT.
Chapter 6 Michele M. Kim 125
Figure 6.7: Temporal dependence of [3O2](t) calculated for various φair (20, 50,
75, and 150 mW/cm2) at depths of 1, 3, and 5 mm in the tumor for two ini-
tial BPD concentrations, (a)-(c) [BPD] = 0.57 µM and (d)-(f) [BPD] = 0.87
µM. Photochemical parameters in table 7.1 are used for [3O2] are used for the
calculations.
Compared to control mice, all treated mice with total fluence larger than 30 J/cm2
had significant control of the tumor regrowth after PDT (see Fig. 6.3). However,
mice with tumors of about the same size, administered with the same BPD dose,
and treated with identical fluence exhibited different survival and tumor control as
φair was changed. In the group of mice treated to 150 J/cm
2, CI increased as the
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source strength was lowered from 100 to 75 mW/cm2. This is in agreement with prior
reports of increased therapeutic response with a reduced φair by expanding the radius
of 1O2 formation around a tumor capillary in a multicell tumor spheroid model [23].
Figure 6.4 (a) compares the measured pre- and post-PDT BPD concentration
versus calculated [BPD] during treatment for each treatment condition using the
photochemical parameters summarized in table 7.1. The good agreement (for mean
[S0], R
2 = 0.88) between measured [BPD] pre- and post-PDT further validates the
photochemical parameters used for the modeling. Figure 6.4 (b) shows the spatial
distribution of [1O2]rx for each treatment condition. The value of [
1O2]rx at 3 mm is
shown with symbols. While the comparison of CI versus [1O2]rx was done using these
values at 3 mm, the value of [1O2]rx is almost a constant for depths between 1 and 4
mm for most of the PDT treatment groups, indicating that the correlation between
[1O2]rx and CI in Fig. 6.5 (d) should be equally valid for any depth between 1 and
4 mm.
Fluence, photosensitizer photobleaching ratio, PDT dose, and [1O2]rx at 3 mm
were compared as dosimetric quantities to estimate the outcome of BPD-mediated
PDT for RIF tumors on a mouse model. The outcome was evaluated by the calcu-
lation of CI. No tumor regrowth up to 15 days after the treatment resulted in a CI
of 1. The goodness of fit and the corresponding upper and lower bounds of the fits
(grey area) to each of the dosimetric quantities are shown in Fig. 6.5. As seen in
Fig. 6.5 (a), while fluence correlates linearly with the PDT outcome, it exhibits large
uncertainties as defined by the large bounds of the grey area, as well as by the low
value of R2 = 0.67. As evident by the lower value of R2 = 0.63 and a relatively large
bound of grey area in Fig. 6.5 (b), the BPD photobleaching ratio is not a better dosi-
metric quantity for predicting the PDT outcome as compared to fluence. The BPD
concentration (∼0.2 to 0.8 µM) as used clinically is much lower than the value of δ
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(=33 µM), and this may be a reason for the poor correlation of the photobleaching
ratio and CI. In photobleaching-based implicit dosimetry, a much more sophisticated
model than simple bleaching fraction is used, and the result of this study does not
mean that other methodologies of photobleaching-based implicit dosimetry will not
be applicable for PDT dosimetry. As shown in Fig. 6.5 (c), PDT dose allows for re-
duced subject variation and improved predictive efficacy as compared to fluence and
photobleaching. PDT dose showed a better correlation with CI with a higher value
of R2 = 0.97 and a narrower band of grey area as it accounts for both light fluence
and tissue [BPD] levels. However, PDT dose over-estimates [1O2]rx in the presence
of hypoxia as it does not account for the oxygen dependence of 1O2 quantum yield.
The goodness of fit R2 = 0.99 and the narrowest grey area in Fig. 6.5 (d) shows that
the mean [1O2]rx correlates best with CI. [
1O2]rx accounts for the key quantities of
light fluence, photosensitizer concentration, and tissue oxygen level.
Based on the findings of this study, PDT dose and [1O2]rx exhibit threshold dose
behavior as they can be fit by a sigmoid function of the form S(x) = 1/[1+e−(x−x0)/w0 ],
where x0 = 58 µM J/cm
2 with uncertainty w0 = 12 µM J/cm
2 and x0 = 0.98 mM with
uncertainty w0 = 0.12 mM for PDT dose and [
1O2]rx, respectively. For PDT dose,
x0 can be converted to the absorbed dose by BPD by multiplying by the extinction
coefficient (ε = 0.0783µM−1cm−1), resulting in 4.5 J/cm3, which corresponds to (16±
4) × 1018 photons/cm3 (by dividing by the energy per photon hc/λ = 2.88 × 10−19
J for λ = 690 nm). The PDT dose threshold for BPD is in agreement with those
reported for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) (19 × 1018
photons/cm3) [171]. The mean [1O2]rx threshold concentration of x0 = 0.98 ± 0.12
mM is similar to that which is published for HPPH (1.00 mM) [171]. The definition of
the threshold dose for both PDT dose and [1O2]rx is the value for when CI = 0.5 [126].
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6.4 Conclusion
The response of mouse RIF tumors to PDT depends on the tissue oxygenation, photo-
sensitizer uptake, total energy delivered, and the φ at which the treatment is delivered.
An accurate dosimetry quantity for the evaluation of the treatment outcome should
account for all of these parameters. This study evaluated the efficacy and outcomes
of different PDT treatments and how fluence, BPD photobleaching, PDT dose, and
[1O2]rx compare as dosimetric quantities. The correlation between CI and [
1O2]rx
suggests that [1O2]rx at 3 mm is the best quantity to redict the treatment outcome
for a clinically relevant tumor regrowth endpoint. PDT dose is the second most effec-
tive dosimetry quantity when compared to fluence or photosensitizer photobleaching,
but is worse than [1O2]rx as it does not account for the consumption of [
3O2] for
different φ. For BPD in RIF tumors, the measurements show consistent temoral de-
pendence of in vivo oxygen concentration during PDT that can be well modeled by
the macroscopic model, implying that it is not necessary to make [3O2] measurements
during PDT to obtain [1O2]rx as well as by using model-calculated values. This study
validated the model and photochemical parameters for BPD-mediated PDT for an
endpoint that is clinically relevant.
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Chapter 7
IR Navigation System
Pleural photodynamic therapy (PDT) is performed intraoperatively for the treatment
of microscopic disease in patients with malignant pleural mesothelioma. Accurate de-
livery of light fluence is critical to PDT efficiency. As a standard of care, light fluence
is delivered to the prescribed fluence using 8 isotropic detectors in pre-determined
discrete locations inside the pleural cavity that is filled with a dilute Intralipid solu-
tion. An optical infrared (IR) navigation system was used during light delivery to
monitor the position of the light source within the treatment cavity. The light source
is tracked using a modified and improved treatment delivery wand with reflective
passive markers that are seen by the infrared camera-based navigation system. This
information was used to calculate the light fluence, incorporating a constant scattered
light fluence and using a dual correction method. Calculation methods were exten-
sively compared for 8 detector locations and 6 patient case studies. The light fluence
uniformity was also quantified by representing the unraveled three-dimensional ge-
ometry on a two-dimensional plane. Calculated light fluence at the end of treatment
delivery was compared to measured values from isotropic detectors. Using a constant
scattered dose for all detector locations along with a dual correction method, the
130
agreement between calculated and measured values for each detector was less than
15%. Primary light fluence alone does not fully account for the light delivered in-
side the cavity. This is useful in determining the light fluence delivered to areas of
the pleural cavity between detector locations, and can prove to improve treatment
delivery with implementation in real-time in the surgical setting.
7.1 Pleural Photodynamic Therapy
PDT typically uses light in the near infrared region, which will penetrate only several
millimeters into tissue. For that reason, PDT is utilized for the treatment of regions
that are easily accessible, such as the skin or oral cavities. In the treatment of pleu-
ral malignant mesothelioma, treatment involves radical pleurectomy. This surgical
opening of the pleural cavity allows for intraoperative delivery of the treatment light.
Radical pleurectomy and surgical debulking of the macroscopic tumor leaves behind
microscopic tumor cells that can develop into larger tumors. PDT is used to treat
the microscopic disease after the debulking. It has been seen that with the addition
of PDT, patients see prolonged survival despite recurrence [13].
As a part of a Phase II/III clinical trial at the Hospital of the University of Penn-
sylvania, patients were enrolled in a randomized trial to under surgical resection or
surgical resection with interoperative PDT. Photofrin was used as the photosensitiz-
ing agent and was intravenously administered to the patient 24 hours prior to surgery
at a concentration of 2 mg per kg of body weight. 630 nm wavelength laser light
was delivered by a Laser Scope dye and KTP-YAG laser system (630 XP, Laser-
scope, Inc., San Jose, CA, USA). PDT was delivered to a prescribed 60 J/cm2, which
was measured by 8 isotropic detectors (Medlight SA, Ecublens, Switzerland) placed in
pre-determined locations within the pleural cavity: apex, posterior chest wall (PCW),
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anterior chest wall (ACW), posterior sulcus (PS), anterior sulcus (AS), posterior me-
diastinum (PM), pericardium (Peri), diaphragm (Diaph). The current standard of
treatment involves treatment to the prescribed light fluence at each of the isotropic
detectors.
7.2 Optical Infrared (IR) Navigation System
A commercial IR navigation system (Polaris, NDI, Waterloo, Canada) was used for
tracking the light delivery during pleural PDT [172–175]. The camera consists of a
pair of cameras that measure the light reflection from a modulated laser source (with
a wavelength of 850 nm). The stero-cameras typically track 3-4 passive reflective
markers with known geometry in real-time at a rate of 20-60 Hz). The reflective
markers track the position of a point at the end of a rigid wand. The wand used to
track treatment, however, was modified to have 3 faces with 3 passive markers so that
position data could be collected at more angles around the wand. The position of
the point is given by the 3D Cartesian coordinates (x, y, and z) and the orientation
(Q0, Q1, Q2, Q3). With the IR navigation system, position of the light source being
used to deliver laser light inside the pleural cavity is continuously tracked, and raw
position data is used to determine the cavity contour. The accuracy of the system is
∼0.5 mm in 3D, and the maximum detection volume for the extended system ∼205
× 186 × 147 cm3, which is optical for use during treatment of the pleural cavity for
the patient population studied. The IR camera is positioned above the patient from
the ceiling prior to treatment.
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7.2.1 Modified treatment delivery wand
During pleural PDT, light is delivered through a bare fiber connected to the laser
source that is enclosed in a modified endotracheal (ET) tube (Fig. 7.1). Previous
versions of the treatment light delivery system included a rigid metal rod that clipped
onto the ET tube. The passive reflective markers were calibrated so that the position
information obtained by the camera was that of the tip of the metal rod. There
would be a shift between the location that the camera tracks and the location of
the fiber tip inside the balloon. The shift would have to be determined and applied
throughout the set of data obtained. An updated treatment delivery wand was created
so that the passive reflective spheres would track the location of the fiber tip directly
with an expected shift in x, y, and z of 0 mm each. Prior to sterilization, the
wand was calibrated so that the markers tracked the position of the fiber tip. The
calibrated wand was equipped with an ET tube to be filled with Intralipid to facilitate
light scattering. The calibration consistency was evaluated by determining the shift
between the calibrated point to the fiber point after treatment and is summarized in
table 7.1.
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Figure 7.1: (a) Modified treatment delivery wand. Magnification shows the
tip of the treatment wand, which is the tip of the bare fiber used to deliver
laser light. The wand is calibrated so that the passive markers (9) are tracking
the tip of the light source, eliminating the need for a separate calibration
calculation to determine the light source position. (b) Image of the IR camera
in use during pleural PDT. The camera is positioned above the patient body.
Table 7.1: Light source point shift from calibration point
Case No. Shift x (mm) Shift y (mm) Shift z (mm) Average
008 0.88±0.72 0.98±0.12 -0.52±0.42 0.45±0.84
012 1.27±0.11 -0.17±0.04 -0.46±0.26 0.21±0.93
014 0.70±0.42 0.80±0.78 -0.62±0.45 0.29±0.79
016 -0.28±0.13 -0.92±0.19 -0.53±0.35 -0.58±0.32
017 1.20±0.43 0.51±0.24 -0.75±0.23 0.32±0.99
018 1.64±0.17 0.46±0.27 -0.48±0.35 0.54±1.06
020 -0.68±0.19 0.44±0.20 -0.89±0.24 -0.37±0.72
Average 0.68±0.85 0.30±0.65 -0.61±0.16
Prior to the development of the modified treatment delivery wand, there was
a fixed shift between the calibrated tip of the metal rod that was attached to the
reflective spheres and the tip of the fiber optic laser source inside the inflated balloon
of the ET tube. The shift in x, y, and z needed to be determined for each assembly of
the wand. The unassembled wand required sterilization prior to use in the operating
room. The shift was determined by using a device that held one isotropic detector.
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The location of that isotropic detector was determined using a different tracking
wand. The treatment delivery wand was then used to determine the fluence at 8
different positions. Using the information of light fluence, distance, and calculated
values of fluence (using Eq. (7.1)), the shift between the actual light source position
and the treatment wand tip was determined. In the surgical setting, this would be
time consuming and occasionally, the ET tube would have to be replaced mid-surgery.
In this instance, the shift may not be determined, or would have to be determined in
the laboratory setting after surgery is complete.
An updated light source positioning tool was developed, which used 8 detectors
in fixed locations inside an acrylic ring device (Fig. 7.2). Detectors were placed both
near and far from the central opening on two layers. The location of the ring was
determined with a separate wand, and the treatment wand would be placed inside the
ring for one measurement (compared to 8). While this was an improvement to the
first generation light source locator, the new modified treatment wand with calibration
directly to the light source fiber eliminates the need for an extra measurement prior
to surgery and reduces uncertainty in shift determination.
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Figure 7.2: Light source position rela-
tive to the calibrated metal tracking wand
tip was determined using a tool with 8
isotropic detectors. Light fluence at 8
known positions was optimized to find the
shift in x, y, and z.
With the acrylic ring device, it was critical to determine the location of the 8 isotropic
detectors inside the ring relative to the reference to the ring body. Each isotropic
detector needed to be calibrated prior to use and connected to the dosimetry system
in the operating room setting. The modified wand saved much-valuable time in
the operating room and requires less pre-surgery set-up. Furthermore, the wand
was lighter and less cumbersome without the metal rod, creating a better treatment
delivery experience for the physician delivering the light while maintaining the rigid
geometry required for accurate positioning.
7.2.2 Pleural cavity geometry reconstruction
The pleural geometry was determined using position data obtained inside the pleural
cavity. A more detained description of the algorithm to reconstruct the cavity contour
can be found elsewhere [172]. Briefly, the Cartesian coordinates of the contour were
converted to spherical coordinates. For each defined grid, the boundary was found by
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selecting data points from the largest radial distance. These points were interpolated
to find surface information. At the time of surgery, a standard coordinate was deter-
mined by recording a position with a wand parallel to the patient and the reflective
sphere end of the wand towards the head of the patient. The obtained pleural cavity
contour was oriented to have the apex location at the top aligned with the z-axis.
Figure 7.3 shows the geometry reconstructed from treatment data with the locations
of the 8 isotropic detectors. Using the standard coordinate, all treated geometries
can be oriented the same way for intercomparison.
Figure 7.3: (a) Schematic of detector locations (8) used for each pleural PDT
patient. (b) Detector positions inside a patient cavity contour determined
from raw data.
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7.2.3 Light fluence calculations
Using the position data obtained throughout the treatment using the optical IR navi-
gation tracking system, the position of the light source is known as well as the surface
of the pleural cavity geometry that is being treated. The light fluence to each point on
the cavity is a sum of the primary (direct) component and the scattered component
of the light [172]. The primary component of the light fluence rate (φprimary) can be
calculated by
φprimary =
S
4pir2
(7.1)
where S is the source power and r is the distance from the point light source to
the point of interest on the pleural cavity surface. To improve agreement between
the measured light fluence from the isotropic detectors and the calculated values,
a constant scattered light contribution was considered in the calculation. During
treatment, the pleural cavity is filled with a dilute solution of Intralipid (0.1% lipid
content) to facilitate scattering. To account for the general scattering in the pleural
cavity, the light fluence rate (φscatter) can be calculated by
φscatter =
S
4pir2
+ b (7.2)
where b is the constant scattered light fluence rate that is added for every calculation
point. Total light fluence is calculated as the time integral of the light fluence rate
(φ), which is a function of r and time, t. The agreement between measured and
calculated light fluence, a dual correction method was applied to the light fluence
rate. The method involves a time-dependent multiplication correction factor (CF (t))
that is applied to the entire calculated light fluence rate. A value of CF is applied to
match the measured light fluence rate every 30 seconds, and another CF is applied
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every 150 seconds to match the total cumulative light fluence at the detector location
with the largest sum fluence over the past 30 seconds. A correction is applied only if
the difference is more than 5%. This second correction ensures that the total fluence
is in agreement. The time intervals for the correction factor was chosen from trial
and error. With the addition of the scattered light fluence, the light fluence rate can
be calculated by
φ(r, t) =
(
S
4pir(t)2
+ b
)
· CF (t) (7.3)
The value of CF is determined for one of the eight detectors that has the largest sum
fluence at the time interval of interest and is applied to the entire volume, as well as
the locations of the other detectors.
For an integrating-sphere-like cavity, such as the pleural cavity, the scattered light
fluence rate inside the sphere can be calculated according to [138]
b =
4S
As
· Rd
1−Rd (7.4)
where As is the surface area of the cavity, and Rd is the diffuse reflectance of the
scattering wall surface. This is assuming that the area is a sphere and the infinite
number of reflections is uniform. Setting equations (7.2) and (7.4) equal to each other,
Rd/(1 − Rd) was calculated for each patient case and summarized in table 7.9 The
relationship between Rd and tissue optical properties can be found in Ong et al. [157].
7.2.4 Anisotropy modeling
The treatment light is delivered through a polished bare-tip optical fiber that is inside
of a modified endotracheal (ET) tube filled with Intralipid. The ET tube balloon is
filled with scattering fluid but still exhibits anisotropy around the perimeter. This
anisotropy was measured, modeled, and applied in the calculation for light fluence at
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detector locations.
Figure 7.4: (a) Balloon illuminated with low light to illustrate
the anisotropy (b) Set-up to measure angular anisotropy with an
isotropic detector (c) Angle definition for the anisotropy function
Using an isotropic detector, the anisotropy of the light being emitted from the
balloon was measured on an angular platform (shown in Fig. 7.4b). Assuming az-
imuthal symmetry about the wand, the measurements taken at 5◦ intervals were fit
to a polynomial of order 2 (Eq. (7.5)). As seen in Fig. 7.4a, the least attenuated light
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results from the capped end of the balloon (defined as θ = 180◦), which is oriented
closest to the polished face of the bare fiber. The anisotropy function was fit to the
following form
A(θ) = p1θ
2 + p2θ + p3 (7.5)
where θ is described as the angle from the axis of the wand, as shown in figure 7.4c.
The fit model is shown in figure 7.5 with two sets of measured data. The parameters
for the model were found to be p1 = 2.764× 10−5, p2 = 0.01027, and p3 = 0.03685.
Figure 7.5: Treatment wand balloon anisotropy. Relative light flu-
ence measurements (circles) were obtained every 5◦. Assuming az-
imuthal symmetry, an anisotropy function (solid red line) was fitted
according to equation (7.5). The solid black line represents the func-
tion A(θ) without the anisotropic model (constant)
To verify the model, a treatment was done on a chest phantom of known geometry.
Four isotropic detectors were placed in the chest cavity and treated to 10 J/cm2.
The measured fluence values were compared with the calculations using the position
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from the navigation tracking system. Since there was no scattering media inside the
treatment cavity, only the primary component of light was considered for calculations
(Eq. (7.1)). The anisotropy function was applied by multiplying it with the calculated
primary light component.
The navigation system provides the treatment delivery point source location in
Cartesian coordinates along with rotation quaternions (Q1, Q2, Q3, Q4) [172]. The
raw coordinates (R = (x, y, z)) obtained are relative to the camera (camera coordi-
nates) and can be converted to the wand coordinate system, described in Fig. 7.4c
(R′ = (x′, y′, z′)). The coordinate transformation is performed by
R′ = M−1R (7.6)
where the rotation matrix, M , is given by
M =

Q1Q1 +Q2Q2 2(Q2Q3 −Q1Q4) 2(Q2Q4 +Q1Q3)−Q3Q3 −Q4Q4
2(Q2Q3 +Q1Q4)
Q1Q1 −Q2Q2 2(Q3Q4 −Q1Q2)+Q3Q3 −Q4Q4
2(Q2Q4 −Q1Q3) 2(Q3Q4 +Q1Q1) Q1Q1 −Q2Q2−Q3Q3 +Q4Q4
 (7.7)
From the wand coordinates, the angle of the balloon that is closest to the treatment
surface can be found by the following
θ = arctan
(√
x′2 + y′2
z′
)
(7.8)
The angle is then used in the anisotropy function A(θ), and applied to the light fluence
calculations.
In a phantom with no scatterer, only primary light component was calculated and
compared with and without application of A(θ). Four detectors in a chest phantom
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compared and the results are shown in Fig. 7.6. With the balloon anisotropy function,
the fluence data is better matched; however, the larger variation after a long treatment
time is not taken into account. Any attenuation of the light from the wand itself was
not considered for this study.
Figure 7.6: Measured fluence (red lines) compared to calculated fluence using
primary light calculations only (blue lines) versus those incorporating balloon
anisotropy (green lines). Four detectors were placed inside a open chest
phantom and treated.
A large factor affecting the modeling of the balloon anisotropy is variations in the
ET tube balloons. Each balloon has its own unique shape and anisotropy. Further
studies would have to be done with numerous different treatment wands and better
angular resolution as well as measurements from various distances from the balloon
center. However, this initial study shows one improvement in light fluence calculations
Chapter 7 Michele M. Kim 143
using the IR navigation system.
7.2.5 Light fluence dosimetry in lung shaped cavities
Scattered fluence dosimetry was investigated in phantoms to simulate the clinical
treatment environment. Lung shaped cavities with different dimensions surrounded
by turbid media with varying optical properties were used to simulate the intracav-
ity lung geometry. Equations (3.5) and (3.6) were used to calculate scattered light.
Distances from the point source to each detector position were measured and ver-
ified from a CT scan of the phantom. In-air fluence measurements with the same
geometry were used to determine the primary component (φprimary) of the light and
subtracted from the total measurement (φtotal). The measured scattered light compo-
nent (φscattered) is determined by subtracting the primary from the total light fluence:
φscattered = φtotal − φprimary. This was then compared to the calculated values. The
surface area (SA) was determined using (i) the volumetric average of the phantom
and the (ii) the CT-determined surface area. Optical phantoms were prepared by
using Intralipid and ink as scattered and absorbing media, respectively. The optical
properties of the surrounding media were measured using a two-catheter method de-
scribed in section 3.1.3. Measurements were made with two point source locations –
centered in the phantom and 1.5 cm lowered.
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Figure 7.7: (a) Schematic of pleural cavity simulating phantom.
Isotropic detectors were placed around the phantom at different
positions relative to the isotropic point source. (b) Photograph of
the experimental set up. The phantom was submerged in a tissue-
simulating optical phantom. The optical properties of the surround-
ing phantom were measured using the two-cathether system, shown
on the right.
The measured and calculated scattered dose in the pleural cavity simulating phan-
tom agreed best using the CT surface area (ii) and equation (3.5). The measured
values are summarized for the centered and off-center point source positions in table
7.2 as φscattered/s, where s is the source power. Data is shown with a fixed µ′s = 6.7
cm−1 in the surrounding media and varying µa for each of the 3 detector locations.
Calculated values are shown in table 7.3. The percent error between mean measured
scattered dose and each calculated value is summarized in parenthesis.
Table 7.2: φscattered/s in phantoms with µ
′
s = 6.7 cm
−1
```````````````Detector
µa (cm
−1) 0.088 0.34 0.83
(Rd = 0.567) (Rd = 0.355) (Rd = 0.220)
Centered Point Source
0◦ Location 0.0465 0.0177 0.0090
45◦ Location 0.0420 0.0190 0.0085
90◦ Location 0.0456 0.0218 0.0104
Off-Center Point Source (1.5 cm down)
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0◦ Location 0.0416 0.0176 0.0094
45◦ Location 0.0428 0.0164 0.0110
90◦ Location 0.0410 0.0244 0.0088
Mean ± Std. 0.0433 0.0195 0.0095± 0.0023 ± 0.0030 ± 0.0010
Table 7.3: Calculated φscattered/s with µ
′
s = 6.7 cm
−1 (% error between cal-
culated and measured mean)
hhhhhhhhhhhhhhhhCalculation Method
µa (cm
−1) 0.088 0.34 0.83
(Rd = 0.567) (Rd = 0.355) (Rd = 0.220)
Eq. (3.5) with SA(i)
0.0414 0.0174 0.0089
(-4.37%) (-10.79%) (-6.27%)
Eq. (3.5) with SA(ii)
0.0465 0.0195 0.0100
(7.45%) (0.24%) (5.32%)
Eq. (3.6) with SA(i)
0.0533 0.0213 0.0097
(23.15%) (9.40%) (1.88%)
Eq. (3.6) with SA(ii)
0.0599 0.0240 0.0109
(38.37%) (22.92%) (14.47%)
MC Simulation
0.0366 0.0206 0.0117
(-15.50%) (5.81%) (23.16%)
The measurements in an ellipsoid phantom agreed best to the calculated values
of φscattered/s using Eq. (3.5) and the actual surface area obtained from the CT scan
of the phantom (ii) with percent errors less than 10%. MC simulated results are
comparable to Eq. (3.6) using the CT-based surface area. Equation (3.5) is derived
from diffuse reflectance in an integrating sphere.
7.3 Extrapolation of Detector Locations
For each pleural PDT treatment, the physician must provide the location of the 8
isotropic detectors that are sutured into the pleural cavity by pointing a separate
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calibrated wand tip to each detector and recording the position coordinates. While
this is an accurate method of determining the detector locations instantly in the
clinical setting, sometimes it is not possible to obtain them due to time constraints
in the operating room or missed field of view from the camera to the wand. In
some scenarios, the detector locations were given, but the coordinate system for the
treatment data was changed due to removal or blockage of the global reference to the
patient bed. A post-processing procedure was developed and applied to extrapolate
the locations of the detectors to compare with the measured detector positions. With
the development of this method, the data acquisition process in the operating room
can be streamlined.
During the course of treatment, it is rare that multiple detectors are being illumi-
nated by the treatment light since the cavity is fairly large (average volume of ∼6.5L).
For each of the measured cumulative fluence data for each detector, time points where
there are “features” were determined. These are described as areas where the treat-
ment wand is close to a detector and is illuminating that area specifically. Those
regions are characterized by their fast increase in cumulative fluence or high fluence
rates and are illustrated for patient case 020 at the apex detector in Fig. 7.8.
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Figure 7.8: Measured cumulative fluence is shown for pa-
tient case 020 at the apex detector with regions highlighted
in red that display “features.” These features were used to
determine the time stamps that are indicative of the treat-
ment wand location being near that particular detector.
Using the features for each detector, the times at which the treatment wand was
near the detector were found. Times when the treatment light was illuminating the
detector were times that show increases in fluence. The locations of the treatment
wand for those times were plotted, and the center of mass was used as the extrap-
olated detector location. These are shown as an ‘×’ symbol next to the measured
detector locations in solid circles in Fig. 7.9. A summary of the shifts between the
extrapolated and measured detector locations for each patient case is in table 7.4.
For case number 016, there is no reported shift between the extrapolated detector lo-
cation and the measured detector location because there is no data for the measured
detector location. In the operating room, if it is proving to be difficult to locate a
detector using the IR navigation system, it is possible that the physician will skip
that step to minimize the patient’s time on the operating table. However, using these
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methods, it is possible to extrapolate the location of the detector and calculate the
fluence to be compared to the detector-measured fluence.
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Figure 7.9: Treatment wand locations for times when the detectors were
being illuminated are plotted in 3D for each detector for patient case 020.
The center of mass was used as the extrapolated detector location, shown as
an ’x,’ and the measured detector location is shown as a solid circle.
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Table 7.4: Shifts between measured and extrapolated detector locations
summarized for each patient. Shifts are described in units of cm.
Detector ∆x (cm) ∆y (cm) ∆z (cm) d (cm)
Case 012
Diaph -2.87 2.20 -2.77 4.56
PS -0.91 1.98 -2.11 3.03
AS 2.10 1.90 -3.19 4.26
PM 0.92 1.12 -1.84 2.34
PCW 1.98 2.09 -1.40 3.20
ACW 2.17 -1.93 -0.98 3.07
Peri -2.86 -2.47 2.18 4.36
Apex 0.97 0.06 3.69 3.82
Average 0.19±2.13 0.62±1.88 -0.80±2.44 3.58±0.79
Case 014
Diaph 1.97 -1.28 -4.62 5.18
PS 1.54 2.11 -3.19 4.12
AS 1.77 1.65 3.21 4.02
PM 1.10 0.99 1.28 1.95
PCW -1.07 2.89 -2.32 3.86
ACW -0.98 -0.67 -1.97 2.30
Peri -2.50 -2.01 -1.69 3.62
Apex -1.11 -1.48 3.88 4.30
Average 0.090±1.70 0.28±1.86 -0.68±3.09 3.67±1.06
Case 016
Diaph 3.86 -1.18 -4.17 5.81
PS 1.39 2.11 3.27 4.13
AS 1.86 2.11 -3.19 4.26
PM -1.58 1.09 -4.10 4.53
PCW -1.57 2.17 -1.01 2.87
ACW 0.98 -0.99 3.86 4.10
Peri – – – –
Apex – – – –
Average 0.82±2.11 0.89±1.58 -0.89±3.64 4.28±0.94
Case 017
Diaph 1.39 -4.20 -1.87 4.80
PS 1.29 1.40 -3.20 3.72
AS 1.13 1.18 -1.78 2.42
PM 2.11 -1.73 -1.98 3.37
Chapter 7 Michele M. Kim 151
PCW 1.09 -0.98 2.09 2.56
ACW 1.33 2.32 -1.20 2.93
Peri 1.72 1.38 -1.78 2.84
Apex 0.91 1.11 2.43 2.83
Average 1.37±0.38 0.06±2.19 -0.91±2.04 3.18±0.78
Case 018
Diaph 0.99 -1.19 -2.11 2.61
PS 1.19 -0.92 -1.30 1.98
AS -1.11 4.18 -4.76 6.43
PM 0.91 1.18 -1.41 2.06
PCW -1.88 1.30 -0.92 2.46
ACW 2.76 -3.20 1.92 4.64
Peri -2.40 1.20 -1.29 2.97
Apex 1.08 -4.53 2.42 5.24
Average 0.19±1.78 -0.24±2.79 -0.40±2.44 3.55±1.67
Case 020
Diaph 0.01 -0.27 -1.17 1.20
PS 0.37 0.07 -2.21 2.20
AS 0.90 -0.93 -1.52 1.99
PM 0.01 1.28 -0.92 1.57
PCW -0.32 0.90 -0.74 1.20
ACW 0.05 -0.28 -0.43 0.52
Peri -1.02 -1.50 -0.29 1.84
Apex 0.09 -0.52 1.75 1.82
Average 0.010±0.55 -0.16±0.91 -0.40±1.31 1.54±0.55
For patient case 020, the detector locations were able to be determined to an accu-
racy of under 2 cm, however, this is not always possible for each case. Depending on
the geometry of the pleural cavity of the patient and the location of the infrared cam-
era on the day of surgery, some of the detectors may be illuminated without providing
any information of the treatment wand location. For those cases, the position data
of the wand cannot be used to determine the wand location. The accuracy of this
method can be greatly increased with more efficient data collection of the treatment
wand location.
For earlier cases (case numbers 012-017), the data obtained from extrapolated
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isotropic detector locations is not as accurate as those of later cases (case numbers
018-020). Camera placement is critical prior to surgery and a well-placed camera
will be able to collect more treatment light position information during treatment.
This process was improved over time with experience and knowledge about patient
placement.
The cumulative fluence at the end of treatment was calculated using the extrap-
olated detector positions compared to the measured fluence from the isotropic de-
tectors. Table 7.5 shows that by using the primary component in addition to the
scattering component of light (Eq. (7.2)), the measured and calculated fluence agree
to within 21%. With the addition of the dual correction factor (Eq. (7.3)), the
agreement is improved to be within 15%.
Table 7.5: Percent error from measured light fluence at the end of treatment with
calculated light fluence using the (a) primary and scattering component (Eq. (7.2))
and (b) primary and scattering component with CF (Eq. (7.3)) using extrapolated
detector positions
(a) Primary and Scattering Component
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 21.0% 12.7% 11.7% 9.6% 9.7% 9.1% 16.7% 16.3%
13.3%
± 4.3%
014 17.0% 10.0% 8.3% 6.7% 11.4% 7.1% 8.2% 13.0%
10.2%
± 3.5%
016 16.6% 7.7% 8.1% 8.2% 6.3% 10.2% 18.6 16.9
11.6%
± 4.9%
017 15.1% 8.1% 8.9% 12.9% 7.8% 10.6% 12.9% 14.5%
11.4%
± 2.9%
018 10.7% 8.8% 15.6% 6.9% 9.8% 9.5% 8.7% 10.6%
10.1%
± 2.5%
020 8.6% 6.5% 6.4% 7.2% 9.0% 1.7% 6.6% 9.6%
7.0%
± 2.4%
Avg.
14.8% 9.0% 9.8% 8.6% 9.0% 8.0% 12.0% 13.5%
±4.5% ±2.2% ±3.3% ±2.4% ±1.8% ±3.3% ±4.9% ±3.0%
(b) Primary and Scattering Component with Dual Correction (CF )
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 13.8% 9.1% 8.2% 7.3% 7.3% 8.6% 13.7% 12.9%
10.5%
± 3.5%
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014 10.4% 9.7% 8.3% 6.6% 10.5% 8.2% 7.4% 11.6%
9.1%
± 1.7%
016 13.0% 4.7% 5.4% 6.1% 6.3% 9.9% 12.9 14.0
9.0%
± 3.8%
017 10.6% 5.7% 2.7% 11.0% 6.4% 9.6% 10.0% 13.4%
8.7%
± 3.5%
018 6.1% 8.2% 7.8% 3.8% 4.3% 10.9% 10.6% 7.3%
7.4%
± 2.6%
020 6.0% 3.3% 3.3% 0.7% 6.2% 3.0% 0.1% 3.0%
4.5%
± 5.0%
Avg.
10.5% 6.8% 6.0% 5.9% 6.7% 8.4% 9.1% 10.4%
±4.1% ±2.6% ±2.5% ±3.5% ±2.1% ±2.8% ±4.9% ±4.3%
It can be seen from both table 7.4 and 7.5 that certain detector locations are
more accurately extrapolated than others. The general trend is that detectors in the
extremities of the pleural cavity including the diaphragm, anterior sulcus, and apex,
show larger errors between measured and extrapolated locations. More specifically,
the detector located at the diaphragm shows a larger negative shift in the z direction,
indicating that the extrapolated detector location is above the measured detector
location. During treatment, it is more likely that the treatment balloon does not
fully reach the detector area while it is being illuminated, resulting in a collection of
position points above the actual detector and an extrapolated position with a large z
shift. Similarly, the apex detector located at the top of the pleural cavity has a larger
positive shift in the z direction, consistent with the treatment wand being below the
actual detector location during light delivery.
Table 7.6: Shifts between measured and extrapolated detector locations
averaged across patient cases for each site. Shifts are described in units
of cm.
Detector ∆x¯ (cm) ∆y¯ (cm) ∆z¯ (cm) d¯ (cm)
Diaph 0.89±2.24 -0.99±2.06 -2.79±1.36 4.03±1.75
PS 0.81±0.94 1.13±1.27 -1.46±2.42 3.20±0.95
AS 1.11±1.18 1.68±1.65 -1.87±2.75 3.90±1.58
PM 0.58±1.25 0.65±1.17 -1.49±1.74 2.64±1.11
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PCW -0.30±1.54 1.39±1.36 -0.71±1.49 2.69±0.89
ACW 1.05±1.37 -0.79±1.85 0.20±2.23 2.93±1.45
Peri -1.41±1.89 -0.68±1.83 -0.57±1.65 3.13±0.94
Apex 0.39±0.93 -1.07±2.14 2.83±0.91 3.60±1.32
Shifts in x, y, and z directions for each extrapolated detector location compared
to the measured detector location were averaged across the patient cases studied and
summarized in table 7.6. The shift in the extrapolated detector locations for the
diaphragm and apex positions show a systematic shift with standard deviations that
are smaller. These average shifts were applied to the extrapolated positions and light
fluence was calculated and compared in table 7.7. The extrapolated position for the
diaphragm detector was shifted in the z direction by -2.79 cm, and the extrapolated
position for the apex detector was shifted in the z direction by 2.83 cm. With these
new extrapolated positions, the calculated fluence at the end of treatment better
matched the measured fluence, as seen in table 7.7. With the adjusted extrapolated
diaphragm and apex detector locations, both calculation methods have improved
agreement with measured fluence. Using the primary and scattered components of
light, the fluence agrees to within 15% for both diaphragm and apex detectors. The
addition of the dual correction factor improves the agreement to within 13%. For
cases where there is no measured detector location, this method of extrapolating the
detector location from the treatment data can be used.
Table 7.7: Percent error from measured light fluence at the end of treat-
ment with calculated light fluence using the (a) primary and scattering
component (Eq. (7.2)) and (b) primary and scattering component with
CF (Eq. (7.3)) using extrapolated detector positions with average shift
for detectors
(a) Primary and Scatter-
ing Component
(b) Primary and Scatter-
ing with Dual Correction
Case No. Diaph Apex Diaph Apex
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012 10.6% 9.3% 4.1% 7.7%
014 14.8% 10.1% 8.1% 9.5%
016 13.9% 12.9% 11.7% 12.4%
017 7.6% 10.9% 7.1% 7.3%
018 8.9% 9.7% 5.9% 6.2%
020 3.7% 6.0% 4.7% 1.3%
Average 9.9%±4.1% 9.8%±2.3% 6.9%±2.8% 7.4%±3.7%
7.4 Clinical Photofrin Pleural PDT Results
The position of the light source being used to deliver light during pleural PDT was
tracked throughout the treatment and used to acquire the pleural cavity geometry
and calculate the light fluence distribution. Calculation methods were improved from
using just the primary (direct) light component to adding a constant scattered light
component. The calculation method was further improved by implementing a time-
dependent dual correction factor (CF ). Evaluation of the light fluence calculation
was done by comparing the calculated light fluence at the locations of the 8 isotropic
detectors with the measured light dose.
The improved light delivery wand was evaluated for consistency before and after
treatment. Calibration of the wand tip location is done prior to sterilization. The
design of the wand involves assembly of the reflective spheres immediately before
treatment. To ensure that the optical IR tracking system is tracking the fiber tip
after assembly, the shift between the calibrated point and the light source fiber tip
point was determined after treatment. The results are summarized in table ??. The
maximum shift was 1.64±0.17 mm, which is less than the 2 mm measurement uncer-
tainty from the device. This ensures that the modified treatment delivery wand is an
improvement from having to determine and apply a 3 mm shift from the laser source
position to the tracking device point position. This eliminates a potential uncertainty
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from implementation in the clinical setting, where the shift may not be able to be
determined at every case.
Using only the primary light component, the calculated light fluence is consistently
lower than the measured dose for all 8 detector locations, as seen in figure 7.10. For
the case shown in Fig. 7.10 (case 020), the maximum percent error from the measured
light dose at the end of treatment using Eq. (7.1) at each detector location is 67.5% at
the Apex location. For 6 patient case studies, the average deviation for all detectors
was 51.6% ± 5.6%. From the data, it is clear that φprimary is not fully accounting
for the light fluence that is delivered. The percent error from measurements using
φprimary is summarized for each detector location and each patient case in table 2 (a).
The mean values for each detector across all patient cases as well as the mean values
for each patient case across all detectors are shown with their standard deviations.
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Figure 7.10: Measured (red solid line) light fluence data over
the course of treatment along with calculated (blue ’x’) light
fluence using the primary component (Eq. (7.1)) plotted for
8 detector locations: (a) apex (b) anterior chest wall (ACW)
(c) posterior chest wall (PCW) (d) anterior sulcus (AS) (e)
posterior sulcus (PS) (f) posterior mediastinum (PM) (g)
pericardium (Peri) (h) diaphragm (diaph)
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Table 7.8: Percent error from measured light fluence at the end of treatment with
calculated light fluence using the (a) primary component (Eq. (7.1)), only the (b)
primary component with CF, the (c) primary and scattering component (Eq. (7.2)),
and the (d) primary and scattering component with CF (Eq. (7.3))
(a) Primary Component Only
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 39.8% 56.4% 57.2% 58.5% 51.0% 56.6% 29.2% 45.8%
49.3%
± 10.4%
014 52.9% 46.9% 63.9% 42.4% 46.5% 67.6% 51.8% 50.0%
52.7%
± 8.7%
016 50.0% 47.4% 52.4% 58.3% 41.2% 56.5% – –
51.0%
± 6.3%
017 39.4% 49.3% 63.4% 44.5% 28.2% 39.6% 29.2% 45.7%
42.4%
± 11.3%
018 43.2% 52.8% 62.1% 52.1% 45.4% 63.0% 58.9% 61.4%
54.9%
± 7.7%
020 52.2% 63.6% 58.7% 59.0% 53.2% 58.0% 60.6% 67.5%
59.1%
± 5.0%
Avg.
46.2% 52.7% 59.6% 52.5% 44.2% 56.9% 45.9% 54.1%
±6.2% ±6.4% ±4.4% ±7.5% ±9.0% ±9.5% ±15.7% ±9.9%
(b) Primary and Scattering Component
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 13.8% 7.4% 10.1% 10.2% 5.4% 8.3% 15.8% 1.3%
9.1%
± 4.6%
014 1.0% 6.3% 3.0% 3.7% 9.0% 3.2% 1.2% 15.1%
5.3%
± 4.8%
016 2.5% 1.7% 5.9% 4.2% 15.4% 13.9% – –
7.3%
± 5.9%
017 12.9% 8.7% 6.7% 14.9% 6.6% 14.7% 13.7% 13.1%
11.4%
± 3.5%
018 13.6% 5.7% 9.0% 4.2% 9.2% 9.4% 6.5% 8.9%
8.3%
± 2.9%
020 3.1% 8.3% 3.5% 2.5% 1.6% 2.4% 6.1% 13.1%
5.0%
± 3.7%
Avg.
7.8% 6.4% 6.4% 6.6% 7.9% 8.7% 8.7% 10.1%
±6.2% ±2.6% ±2.9% ±4.9% ±4.6% ±5.2% ±6.0% ±95.4%
(c) Primary Component with Dual Correction (CF )
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 20.5% 21.6% 10.1% 26.3% 16.7% 13.3% 0.8% 1.3%
13.8%
± 9.3%
014 1.0% 6.3% 35.0% 3.7% 9.0% 32.1% 1.2% 15.1%
12.9%
± 13.5%
016 2.5% 18.1% 22.5% 4.2% 15.4% 19.3% – –
13.7%
± 8.3%
017 15.2% 8.3% 23.5% 17.6% 6.6% 13.5% 19.7% 15.0%
14.9%
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± 5.6%
018 13.6% 3.8% 9.0% 18.6% 7.2% 18.6% 5.6% 0.4%
9.6%
± 6.7%
020 24.3% 8.9% 6.4% 24.3% 47.1% 6.9% 17.3% 4.4%
17.5%
± 14.4%
Avg.
12.9% 11.2% 17.8% 15.8% 17.0% 17.3% 8.9% 7.2%
±9.4% ±7.1% ±11.1% ±9.7% ±15.3% ±8.5% ±9.0% ±7.3%
(d) Primary and Scattering Component with Dual Correction (CF )
Case No. Diaph PS AS PM PCW ACW Peri Apex Avg.
012 8.6% 1.2% 4.3% 5.4% 5.1% 5.4% 10.2% 2.9%
5.4%
± 2.9%
014 4.5% 9.0% 7.5% 7.9% 3.5% 4.3% 5.5% 9.0%
6.4%
± 2.2%
016 1.9% 2.8% 5.3% 3.1% 9.8% 8.2% – –
5.2%
± 3.2%
017 8.9% 3.8% 1.7% 8.3% 4.3% 11.2% 9.8% 3.5%
6.5%
± 3.5%
018 4.0% 2.3% 8.1% 0.8% 3.4% 7.1% 11.2% 6.6%
5.4%
± 3.4%
020 6.2% 4.7% 1.0% 6.4% 12.4% 2.3% 1.6% 0.4%
4.7%
± 4.9%
Avg.
5.7% 4.0% 4.6% 5.3% 6.9% 6.4% 7.7% 4.5%
±2.8% ±2.8% ±2.9% ±2.9% ±4.8% ±3.1% ±4.0% ±3.4%
Agreement between the calculated light fluence and measured values are further
improved with the addition of a constant scattered light dose. Figure 7.11 shows the
data for case 020 with calculations using Eq. (7.2). It is seen that for all of the
detectors, a constant value for b (in this case, b = 7 mW/cm2) improved the percent
deviation. The maximum deviation for case 020 was seen at the Apex location at
13.1%. The average deviation for all detectors and case studies is 7.7% ± 2.4%, and
the data is summarized in table 7.8 (b).
With the use of the dual correction factor to the calculation with φprimary, the
agreement is improved slightly and summarized in table 7.8 (c). For case 020, the
maximum deviation is 47.1% from the PCS detector location. The average deviation
for all detectors and case studies for this calculation method is 13.7% ± 2.6%. While
this method of calculation improves the agreement, the CF is large.
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Implementation of the dual correction method to the calculation with both pri-
mary and scattered light components improved the agreement between measured and
calculated final light fluence the most. The comparison is shown in Fig. 7.12. The
maximum percent error for case 020 was reduced to 12.4% at the PCW location. The
average across all detectors and patient cases was 5.6% ± 0.7%. The deviations are
summarized in table 7.8 (d).
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Figure 7.11: Measured (red solid line) light fluence data
over the course of treatment along with calculated (blue
’x’) light fluence using the primary component with a fixed
constant scattering component (Eq. (7.2)) plotted for 8
detector locations: (a) apex (b) anterior chest wall (ACW)
(c) posterior chest wall (PCW) (d) anterior sulcus (AS) (e)
posterior sulcus (PS) (f) posterior mediastinum (PM) (g)
pericardium (Peri) (h) diaphragm (diaph)
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Figure 7.12: Measured (red solid line) light fluence data over
the course of treatment along with calculated (blue ’x’) light
fluence using the primary component with a fixed constant
scattering component and dual correction factor (Eq. (7.3))
plotted for 8 detector locations: (a) apex (b) anterior chest
wall (ACW) (c) posterior chest wall (PCW) (d) anterior sul-
cus (AS) (e) posterior sulcus (PS) (f) posterior mediastinum
(PM) (g) pericardium (Peri) (h) diaphragm (diaph)
Chapter 7 Michele M. Kim 163
For most cases, larger deviations were seen in the diaphragm, posterior/anterior
sulcus, or the apex locations detectors. This may be improved with greater data
acquisition at those locations. Due to the cavity geometry and the IR camera location,
certain extreme angles or far locations from the center may have less efficient data
collection rates. Furthermore, any blockage of the optical path from the reflective
spheres to the IR camera will result in loss of position data, which will affect the
calculations as well.
Table 7.9: Summary of the pleural cavity surface area, vol-
ume, diffuse reflectance (Rd), and scattering component (b)
for each study. Rd was calculated using Eq. (7.4)
Case No.
Area Volume b S Rd
1−Rd Rd(cm2) (cm3) (mW/cm2) (mW)
012 886 2742 7.5 6300 0.264 0.209
014 1710 8192 7.5 6500 0.493 0.330
016 1158 6095 7.5 6500 0.334 0.250
017 1447 7618 6.5 6500 0.362 0.266
018 1766 8103 7.5 6890 0.481 0.325
020 1262 6308 7.0 6500 0.340 0.254
Average
1372 6510 7.3 6531 0.379 0.272
±337 ±2050 ±0.4 ±193 ±0.090 ±0.047
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Figure 7.13: Fluence distribution map for a representative
patient (Case No. 020). The 3D geometry is unwrapped
and displayed on a 2D surface plot with the locations of the
isotropic detector locations indicated by × symbols
The uniformity of the treatment delivery was evaluated for all patients. The
3D pleural cavity geometry was unwrapped along the x- and y-axes so that the
apex detector location was located at the top of the 2D representation. Figure 7.13
shows the fluence distribution at the end of treatment for case 020 along with labeled
detector locations. The profile of light fluence along the z-axis for each horizontal
angle is plotted in Fig. 7.14. The mean is shown as a black solid line, the standard
deviation is indicated by the grey shaded area, and the dashed line represents the
prescribed light fluence of 60 J/cm2. Most of the cavity excluding the extremities
reached the prescribed dose. Large peaks are seen for certain horizontal angles. This
is due to the surgical opening and position data that is obtained for movement in and
out of the surgical cavity. This region is extrapolated from the data and indicated by
the dashed vertical lines in Fig. 7.14. In future studies, the surgical opening will be
delineated by the physician so that any position data outside of the treatment cavity
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can be properly eliminated.
Figure 7.14: Fluence distribution along the z-axis (depth) for each angular
location. The mean is shown in a solid black line, and the grey area indicates
the standard deviation. Uniformity is calculated as percent variation and
summarized for each patient in table 2, excluding the region corresponding
to the surgical opening, outlined by the dotted lines. (a)-(f) indicate case
numbers 012, 014, 016, 017, 018, and 020, respectively.
The uniformity is quantified as standard deviation from the mean in table 3 for
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each case. The standard deviation was calculated as the standard deviation of the
mean profile (black line) from the prescribed light fluence (60 J/cm2). The variation
of standard deviation is the standard deviation of the grey region. Across all patients,
the uniformity was on average 9.5% with a variation of the standard deviation 17.7%.
Table 7.10: Summary of uniformity across all horizontal
angles for profiles shown in Fig. 7.14
Case No.
Standard Deviation Variation of Std. Deviation
(% Difference) (% Difference)
012 3.6% 10.5%
014 6.3% 9.7%
016 14.3% 29.1%
017 9.2% 20.6%
018 13.5% 22.9%
020 9.8% 13.3%
Average 9.5% ± 4.1% 17.7% ± 7.8%
7.5 Conclusions
In this chapter, the light modeling aspect of explicit dosimetry was investigated in
depth for a clinical treatment setting. Initial measurements of scattering was per-
formed in ellipsoid shaped phantoms to model scattering in the pleural cavity, which
is an improvement from scattering measurements in spherical cavities.
As a standard of care for pleural PDT at the University of Pennsylvania, the light
fluence is monitored using 8 isotropic detectors at pre-determined discrete locations.
This method does not account for light dose delivered at locations between the de-
tectors and can result in “hot spots” of light fluence when treatment is delivered
to the detectors, rather than the entire cavity. A previously developed optical IR
navigation system to monitor the light source position during the treatment is im-
Chapter 7 Michele M. Kim 167
proved in this study. Use of the treatment wand position data in conjunction with
measured dosimetry data was investigated to consider the possibility of not having to
have the physician point to each isotropic detector inside the pleural cavity. For cases
with effective position data collection, the detector location could be extrapolated to
within 2 cm of the measured location. While this is promising initial data, further
improvements will need to be made to increase the data collection efficiency during
treatment in the operating room.
The position of the 8 isotropic detectors may not always be measured in the op-
erating room setting. Therefore, a method to extract detector locations from the
treatment light wand position data during light illumination was developed and in-
vestigated for 6 patient cases. Comparison was done between measured and extracted
detector locations, as well as between calculated fluence at the extrapolated detector
location and the measured fluence. Fluence was found to be in agreement to within
15% using the extrapolated detector locations, showing promise for use in cases where
no detector locations were measured.
Calculation of the light fluence and comparison to measured values is analyzed
in depth for each detector for 6 patient cases. Light fluence calculated both the
primary component and scattered component of light agrees to within 15% of the
measured values. The uniformity of the treatment delivered is also quantified. Using
this technology and calculation method, uniform light dose delivery can be aided
visually with the fluence distribution map to avoid under-treatment of areas between
isotropic detectors.
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Chapter 8
Conclusions and Future Work
The project aims of this work was to fully investigate explicit dosimetry modeling
in vivo and in phantoms for photodynamic therapy. Prior to this work, explicit
dosimetry was developed only for in vivo in a limited model. This work incorpo-
rated measurements of light fluence, photosensitizer concentration, and ground state
oxygen concentration to determine reacted singlet oxygen concentration with various
treatment scenarios.
The required photochemical parameters for macroscopic singlet oxygen modeling
in vivo for BPD-mediated PDT was determined with this study and validated with
an outcome-evaluation mouse model, which was the first study of its kind. Measured
BPD concentration using fluorescence spectra both interstitially and on the surface
of the tumor were validated with an ex vivo method. The optical property-based
correction of the fluorescence signal was also investigated for the two measurement
geometries.
Explicit dosimetry of phantom studies was also investigated in detail, with mod-
ifications to the prior in vivo model to account for singlet oxygen quenching. These
studies further validate the use of explicit modeling and can provide insight into pre-
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viously unknown photochemical parameters, such as with the photosensitizer Rose
Bengal. Future work with new photosensitizers can be performed in phantoms to esti-
mate the photochemical parameters before moving on to the more resource-intensive
in vivo studies.
The explicit singlet oxygen dosimetry model was compared to the gold-standard
method of direct singlet oxygen measurements using singlet oxygen luminescence.
This further validated the model by showing that calculated values and measured
values in a phantom tracked each other. Further work will be needed to validate the
model and direct measurements in vivo and to accurately determine the absolute con-
centration of total reacted singlet oxygen produced while measuring the luminescence
counts. This validates the use of explicit dosimetry for the many scenarios where
direct measurements are not feasible.
Another important aspect of this work involved improvements to the navigation-
based light dosimetry used in the treatment of the pleural cavity in patients with
mesothelioma. Scattered light fluence for ellipsoid cavities for various optical proper-
ties were measured and compared to a new model. Improvements were made to the
light delivery wand as well as the calculation methods. Treatment wand location data
was also investigated to extrapolate the isotropic detector locations. With efficient
data collection, the extrapolated isotropic detector locations can be found within 2
cm of the measured locations. These isotropic detector locations are important in
comparing the calculated light fluence dose on the surface of the cavity with those
that are measured continuously in the pre-determined discrete locations. Future work
can improve the method to extrapolate the detector locations as well as improve the
efficiency of treatment wand position data collection. Currently, the infrared camera
placement is dependent on the user and can vary case to case.
Further developments for a fast, real-time light fluence dosimetry model for the
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patient treatment scenario remains to be completed. Once this is accomplished,
real-time singlet oxygen calculations can be performed in combination with real-time
spectroscopy. This knowledge can be used to implement a patient-specific PDT light
fluence that is focused on production of the reactive oxygen species to improve overall
PDT efficacy.
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Appendix A
Chlorophyll Products
The typical mouse diet in the laboratory setting has chlorophyll. It was found that
the emission peak for chlorophyll is in the same range as the emission peaks for
common photosensitizers, such as BPD and HPPH. A study was performed to deter-
mine the decay of this signal after a mouse is put on an alfalfa-free (chlorophyll-free)
diet (Harlan Laboratories Inc., Indianapolis, Indiana, USA), so that photosensitizer
fluorescence spectra can be collected accurately.
Fluorescence spectra are collected during treatment and used to measure the pho-
tosensitizer concentration for use in PDT explicit dosimetry. The characteristic emis-
sion peaks of the photosensitizer are fit using known basis spectra. These spectra
can be complicated by the presence of chlorophyll and its digestion products. The
emission peak for chlorophyll is in the same range as the emission peaks for common
photosensitizers, such as BPD and HPPH. Chlorophyll is present in most common
laboratory mouse diets [176]. By switching mice to an alfalfa-free diet (thus eliminat-
ing chlorophyll), the undesired peak can be eliminated, and characteristic peaks in
fluorescence can be attributed to the photosensitizer of interest. In this study, mice
were observed for 9 days following a dietary change to see the decay of the chlorophyll
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fluorescence over time. No photosensitizer was administered to these mice while be-
ing monitored. Figure A.1 shows representative fluorescence spectra for a mouse on
a standard diet analyzed with an HPPH basis. While there is no HPPH present in
this mouse, it is seen that the emission peak of chlorophyll is very similar to that of
HPPH. Using this method of fitting data, mice without any photosensitizer could mis-
takenly be fit with the photosensitizer basis and found to have a large concentration
of photosensitizer.
Figure A.1: Fluorescence spectra of a mouse on a standard diet
analyzed with an HPPH basis. The emission peak of chlorophyll is
very similar to the emission peak of HPPH and is fit as such, which
is incorrect.
A small, custom-made multi-fiber contact probe (Fig. A.2) similar to that dis-
cussed in chapter 2 was used to measure the fluorescence spectra on mouse tumors
as well as the footpad. This probe has smaller source-detector separations, making it
possible to detect fluorescence signal from both the shoulder region and the footpad.
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Figure A.2: (a) Multi-fiber contact probe. 6 fibers are collected at
one end with two source fibers (white light and 405 nm light) and
4 detector fibers are at different source-detector separations. (b)
Schematic diagram of the fiber arrangement on the probe face.
The chlorophyll product signal observed on the first day varied among mice by as
much as a factor of 5. This is consistent with previous observations that this emission
is variable among animals and over time. In all mice observed in this study, the
chlorophyll product component was reduced to less than 3% of the autofluorescence by
the 4th day. The time course of the reduction in chlorophyll product emission is shown
in figure A.3. These results indicate that fluorescence spectroscopy measurements will
be free of chlorophyll product contamination after 4 days on a chlorophyll-free diet.
It is noted that this is on the short end of the time scale previously reported [177].
Chapter A Michele M. Kim 174
Figure A.3: Chlorophyll signal normalized by autofluorescence ob-
served over 9 days for 25 different mice. The red line indicates 5%
of a typical HPPH signal.
The chlorophyll component of the fluorescence spectra had a peak ∼675 nm,
which has significant overlap with the spectra of commonly used photosensitizers.
This chlorophyll signal could be mistaken for photosensitizer, thus affecting the dose
calculations. The red line in Fig. A.3 indicates the point where typical HPPH sig-
nal is 5% of the maximum value. This indicates that chlorophyll signal may decay
quickly with the modified diet; however, the desired measurements (such as HPPH)
could still be affected by the presence of chlorophyll. To evaluate the effect of chloro-
phyll photoproduct contamination on a typical HPPH measurement, we looked at the
spectra of chlorophyll (mice without any other injected photosensitizer) and analyzed
them with the basis spectra of HPPH (a commonly used photosensitizer for PDT).
Since the emission peaks are very close to each other, chlorophyll spectra could be
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mistakenly analyzed as HPPH spectra, indicating a false presence of sensitizer in the
tumor.
For all of the in vivo studies performed in this work, mice were provided with the
alternative, chlorophyll-free diet for at least 5 days prior to photosensitizer adminis-
tration and fluorescence measurement. Standard laboratory diets were provided upon
the completion of PDT treatment if mice were being monitored over time.
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Appendix B
P3 Approximation in an Infinite
Medium
B.1 Light Transport and Optical Properties
The amount of light that reaches the targeted tissue accounts for the treatment effi-
cacy in PDT. Light transport in biological matter is characterized by the absorption
and scattering of photons. These qualities are characterized by the optical proper-
ties of that tissue, namely, the absorption coefficient (µa) and the reduced scattering
coefficient (µ′s).
B.1.1 Diffusion Approximation for Light Transport
Light propagation can be described by a series of equations and boundary conditions
called the diffusion theory of light transport. The radiative transport equation can be
solved using several different approximation. The diffusion approximation was used
as a solution to the radiative transport equation. The radiance, L(~r, sˆ), is defined as
the power per unit area per unit solid angle in direction sˆ at position ~r and can be
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described by the time-independent Boltzmann equation [178,179].
1
c
∂L (r, sˆ, t)
∂t
= −∇ ·L (r, sˆ, t) sˆ− µtL (r, sˆ, t) + µs
∫
4pi
L (r, sˆ, t) f (sˆ, sˆ′) dΩ′ + S (r, sˆ, t)
(B.1)
S(~r, sˆ) represents the source term, and the f(sˆ, sˆ′) is the scattering phase function
which describes the probability that a photon incident in direction sˆ′ will be scattered
into direction sˆ. The right side of equation (B.1) describes the gradient in radiance
distribution (first term), the decrease of L(~r, sˆ) by absorption and photons that are
scattered away from direction sˆ (second term), and the increase of radiance by photons
scattered into sˆ (third term) and by the light source S(~r, sˆ) (the remaining terms).
The source term S(~r, sˆ) is represented in many ways depending on the light source
used. For planar geometries, the light can be a wide beam with collimated incidence
(often referred to as a pencil beam or a wide beam with diffuse incidence). If the
source is an isotropic point source, it can be described as S0δ(r), and the solution
to equation (B.1) is a Green’s function, and the solution for any other source can be
obtained by a convolution of the source and Green’s function.
The scattering phase function f(sˆ, sˆ′) is assumed to depend only on the deflection
angle, θ, between sˆ and sˆ′. f(sˆ, sˆ′) becomes a complicated function in biological
media owing to the high particle density and inhomogeneity of tissue. An accepted
approximation for f(sˆ, sˆ′) is the Henyey-Greenstein phase function [180,181].
fHG(cos θ) =
(
1
4pi
)
1− g2
(1 + g2 − 2g cos θ)3/2 (B.2)
where g is the scattering anisotropy given by
g =
∫
4pi
f(sˆ, sˆ′)dΩ. (B.3)
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This quantity, g, is equal to the average of the scattering cos θ. The scattering
anisotropy ranges from -1 to 1, corresponding to backward and forward scattering,
respectively. If g = 0, then there is no preference for forward or backward scattering.
In tissue, g is estimated to be in the range of 0.7-0.9 but is commonly taken to be
equal to 0.9 [181,182].
At the boundary of two different media (L1 and L2) with different indicies of
refraction, the boundary condition can be specified by following the reflection and
transmission attributed to Fresnel’s law [183]:
L1(sˆ)sˆ · nˆ = RFresnel(sˆ)L1(sˆ)sˆ · (−nˆ) + TFresnel(sˆ)L2(sˆ)sˆ · nˆ
L2(sˆ)sˆ · nˆ = RFresnel(sˆ)L2(sˆ)sˆ · (−nˆ) + TFresnel(sˆ)L1(sˆ)sˆ · nˆ′ (B.4)
where nˆ is the normal direction of the boundary, sˆ is the direction of the irradiance
under consideration, and RFresnel and TFresnel = 1− RFresnel are the reflectance and
transmission coefficients according to Fresnel’s Law [184].
Equation (B.1) can be solved analytically in idealized one-dimensional geome-
tries, but these are not applicable in calculating the light distribution in relevant
experimental situations [178]. The spherical harmonic approximation can be used to
simply the solution by expanding the radiance and source terms as a series of spheri-
cal harmonics and the scattering phase functions as a series of Legendre polynomials.
The most common approximations are the first-order (P1) and the third-order (P3)
approximations [181,182,185]
L (~r, sˆ) =
N∑
l=0
l∑
m=−1
√
2l + 1
4pi
φlmYlm(sˆ) (B.5)
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S (~r, sˆ) =
N∑
l=0
l∑
m=−1
√
2l + 1
4pi
σlmYlm(sˆ) (B.6)
f (sˆ, sˆ′) =
N∑
l=0
2l + 1
4pi
glPl (sˆ · sˆ′) (B.7)
In general, Ylm(θ, φ) can be written as
Ylm(θ, φ) =
√
2l + 1
4pi
(l −m)!
(l +m)!
Plm(cos θ)e
imφ (B.8)
where the associated Legendre function, Plm(x), with positive or negative values of
m = −l, . . . , l is given by the following formula
Plm(x) =
(−1)m
2ll!
(1− x2)m/2 d
l+m
dxl+m
(x2 − 1)l. (B.9)
The Legendre polynomials, Pl are given by Rodrigues’ formula, Pl(x) =
1
2ll!
dl
dxl
(x2−1)l.
By expanding the radiance, phase function, and source terms of the transport equation
(eq. (B.1)) in spherical harmonics and evaluating the integral over the solid angle
using the orthogonality relations for spherical harmonics,
∫
Ylm(θ, φ)Yl′,m′(θ, φ)dΩ = δ(l − l′)δ(m−m′) (B.10)
the transport equation can be rewritten as [186]
∑
l,m
[
1
c
∂φl,m
∂t
+ µ
(l)
t φl,m − ql,m
]
Yl,m(sˆ) +∇ · (φl,mYl,m(sˆ)sˆ) = 0 (B.11)
where µ
(l)
t = µs(1−gl)+µa/gl (note that µ(0)t = µa) is the coefficient for the lth moment
of the normalized phase function. For the Henyey-Greenstein phase function, gl = g
l,
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where g is the average cosine of the scattering angle [181]. The PN approximation is
obtained by truncating the expansions in equations (B.5) - (B.7) at l = N , where N
is the order of approximation. The resulting set of coupled differential equations can
be solved to determine the corresponding moments of the radiance.
The P1 approximation, also known as the diffusion approximation, has been widely
used to model photon transport in tissue. With this approximation, only l = 0, 1 is
considered, and the radiance can be written as [182,183]
L(~r, sˆ, t) =
1
4pi
φ(~r, t) +
3
4pi
J(~r, t) · sˆ, (B.12)
where the fluence rate is given by φ(~r) =
∫
4pi
L(~r, sˆ, t)dΩ and has units of mW/cm2,
and the photon flux (or current density) is given by J(~r, t) =
∫
4pi
L(~r, sˆ, t)sˆdΩ and
has units of mW/cm2.
The source term can be written as [182,183]
S(~r, sˆ, t)
1
4pi
S0(~r, t) +
3
4pi
S1(~r, t) · sˆ, (B.13)
where S0(~r, t) and S1(~r, t) are the monopole (isotropic) and dipole moments of the
source, respectively. By inserting equations (B.12) and (B.13) into equation (B.1)
and integrating over sˆ, we can get [183]
1
c
∂
∂t
φ(~r, t) + µaφ(~r, t) +∇ · J(~r, t) = S0(~r, t). (B.14)
By inserting equations (B.12) and (B.13) into equation (B.1) and multiplying by
sˆ and then integrating over sˆ, we can get [183]
1
c
∂
∂t
J(~r, t) + (µ′s + µa)J(~r, t) +
1
3
∇ · φ(~r, t) = S1(~r, t). (B.15)
Chapter B Michele M. Kim 181
By decoupling equations (B.14) and (B.15) for φ(~r, t), the P1 equation can be obtained
[183]
−D∇2φ(~r, t) + µaφ(~r, t) + 1
c
· ∂φ(~r, t)
∂t
+
3D
c
[
µa
∂φ(~r, t)
∂t
+
1
c
∂2φ(~r, t)
∂t2
]
= S0(~r, t) +
3D
c
∂S0
∂t
− 3D∇ · S1(~r, t), (B.16)
where the diffuse coefficient is D = 1
3(µa+µ′s)
, and the reduced scattering coefficient
is given by µ′s = (1 − g)µs. The standard photon diffusion equation for the P1
approximation is obtained when certain terms are dropped from equation (B.16).
The dipole moment term of the source can be dropped when assuming an isotropic
source. Collimated sources are treated as isotropic sources displaced one mean free
path into the scattering medium from the collimated source, thus supporting this
assumption. The last term on the left-hand side of the equation is dropped as well.
In the frequency domain, the time dependence of the source is taken as e−iωt. When
the intensity of the source is sinusoidally modulated, the photon fluence becomes
φ(~r)e−iωt. The time derivative can be replaced by −iω and the rest of the term can be
ignored when 3Dω/c2  1 [183]. This is equivalent to cµ′s/ω  1, which means that
the scattering frequency (cµ′s) must be much larger than the modulation frequency
(ω). Given these assumptions, the photon diffusion equation can be rewritten as the
following
−D∇2φ(~r, t) + µaφ(~r, t) + 1
c
∂φ(~r, t)
∂t
= S0(~r, t). (B.17)
The even-order approximations do not significantly change the degree of anisotropy
in the radiance that is modeled, and inconsistencies arise at the boundaries with the
solutions [181, 186, 187]. Therefore, the odd-order approximations are widely used.
This approximation is good when the albedo, a = µs/(µs + µa), is close to 1, the
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phase function is not too anisotropic, and the source-detector separation is large
when compared to 1/(µs(a− g1)) [186].
In the tissue-non-scattering medium interface, the boundary condition consistent
with the P1 approximation is obtained by integrating equation (B.4) over all angles
Ω over 2pi [186]
φ(~r)− 2ADnˆ · ∇φ = 0, (B.18)
where nˆ is the normal direction of the boundary, D is the diffusion coefficient, and
A is a dimensionless internal reflection coefficient that accounts for the reflectance
and transmission because of the mismatch of the indicies of refraction between the
two media (A = 1 for a matching interface and A = 2.95 for an air-tissue interface)
[181]. In the scattering-scattering medium boundary with mismatching indices of
refraction, the boundary condition consistent with P1 approximation can be expressed
as discontinuous fluence rate, φ1/φ2 = (n1/n2)
2, and continuous flux, D1nˆ · ∇φ1 =
D2nˆ · ∇φ2 [188].
For a point source in an infinite homogeneous medium, the source term becomes
S0(~r) = S0δ(~r), where ~r is the position at which fluence rate is measured and the
position of the source is at 0, the origin. The steady-state solution of the fluence rate
becomes [181,189].
φ(~r) =
S0
4piDr
exp(µeffr), (B.19)
where r is the distance to the point source and µeff =
√
3µa · (µa + µ′s).
The P3 approximation is often necessary in regions of high tissue absorption of
proximity to the light source position. For the P3 approximation, moments greater
than l = 3 are ignored, so φl,m = 0 for l > 3 in equation (B.11). Equations (B.5) -
(B.7) simplify to for a point source in steady-state condition since only the m = 0
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term needs to be considered because of spherical symmetry.
L(~r, sˆ) =
3∑
l=0
2l + 1
4pi
φl(r)Pl(~r, sˆ) (B.20)
S(~r, sˆ) =
3∑
l=0
2l + 1
4pi
ql(r)Pl(~r, sˆ) (B.21)
f(sˆ, sˆ′) =
3∑
l=0
2l + 1
4pi
gl(r)Pl(sˆ, sˆ
′) (B.22)
Inserting these into equation (B.1) and ignoring the time-dependent term resulted in
(B.11) with m = 0 only. Multiplying the resulting equation by Pl and integrating
over all solid angles yields the following equation set for φl in an infinite homogeneous
medium [181,190,191].
1
2l + 1
·
{[
(l + 1)
∂φl+1
∂r
+ l
∂φl−1
∂r
]
+
1
r
[(l + 1)(l + 2)φl+1(r)− l(l − 1)φl−1(r)]
}
+ µ
(l)
t φl(r) = ql (B.23)
Here, l = 0, 1, 2, 3, and the orthogonality properties of the Legendre polynomials
were used:
∫
Pl(x)Pl′(x)dx =
2
2l+1
δ(l − l′). This equation set yields 4 coupled dif-
ferential equations (φ−1 = φ0 = 0). The right hand side of equation (B.23) has the
moments of the source distribution. We can assume that the source is an isotropic
point source such that ql = 0 for l > 0, if we are a few scattering lengths from
the source. For an infinite medium, the solution of equation (B.23) for φ0, the light
fluence rate, has been solved by Hull and foster for an isotropic point source at the
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origin q0 = δ(r) as [181]
φ0(r) =
[−C−(ν−)2
2pi
]
exp(−ν−r)
(−ν−r) +
[−C+(ν+)2
2pi
]
exp(−ν+r)
(−ν+r) , (B.23)
where
C− =
ν−3(3µaµ
(1)
t − ν+2)
6µ2aµ
(1)
t (ν
−2 − ν+2)
C+ =
ν−3(3µaµ
(1)
t − ν−2)
6µ2aµ
(1)
t (ν
+2 − ν−2)
ν± =
(
β ±√β2 − γ
18
)1/2
β = 27µaµ
(1)
t + 28µaµ
(3)
t + 35µ
(2)
t µ
(3)
t
γ = 3780µaµ
(1)
t µ
(2)
t µ
(3)
t
Unlike the analytical solution for the P1 approximation, the analytical solution for
the P3 approximation includes two exponential terms: one rapidly decaying term with
an attenuation coefficient ν− and another slower decaying term with an attenuation
coefficient ν+ that is corresponding to the solution for the P1 approximation. Under
the condition that β  γ and µ(l)t  µ1t , l = 2, 3, one has µ+ = µeff and C+ =
µeff/2µa so that the second term takes the same form as equation (B.1.1), as the
first term disappears since ν− = 0 under this condition. For this reason, the second
term in equation (B.1.1) is also called the asymptotic solution of P3 approximation
according to Hull and Foster [181].
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